Methods for manufacturing allogeneic car t cells

The method enhances allogeneic CAR-T cell production by enriching, activating, and transducing CD4+ and CD8+ T cells, improving manufacturing efficiency and therapeutic efficacy while reducing graft rejection and graft vs. host disease.

WO2026241504A1PCT designated stage Publication Date: 2026-11-19CARGO THERAPEUTICS INC +9
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028164
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current manufacturing processes for allogeneic CAR-T cells face challenges such as graft rejection, low graft persistence, and graft vs. host disease, with lengthy turnaround times and low manufacturing success rates, hindering the widespread application of high-quality, GMP-grade CAR-T cell therapies for treating hematologic malignancies.

Method used

A method involving the enrichment, activation, transduction, and expansion of CD4+ and CD8+ T cells using specific recombinant polynucleotides and cytokines, followed by cryopreservation of CD3/TCR-negative allogeneic CAR-expressing immune cells, to enhance therapeutic efficacy and manufacturing efficiency.

Benefits of technology

The method improves the production of high-quality, GMP-grade CAR-T cells, reducing turnaround times and increasing manufacturing success rates, thereby addressing graft rejection and graft vs. host disease issues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028164_19112026_PF_FP_ABST
    Figure US2026028164_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to methods of making a population of allogeneic CAR-expressing immune cells that provide several improvements over existing manufacturing methods, thereby enabling production of a robust supply of clinically useful CAR T-cell therapies.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 063384-525001WOMETHODS FOR MANUFACTURING ALLOGENEIC CAR T CELLSCROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application claims priority to U. S. Provisional Patent Application Serial No. 63 / 807,259, filed on May 16, 2025. The contents of the above-referenced application is herein expressly incorporated by reference in its entirety, including any drawings.FIELD

[0002] The present disclosure relates generally to the fields of immune-oncology and cell therapy and more particularly relates to improved methods of making and / or manufacturing a population of allogeneic chimeric antigen receptor (CAR)-expressing immune cells. The disclosure provides populations of allogeneic CAR-expressing immune cells made and / or manufactured by the improved methods, and pharmaceutical compositions comprising the same. The disclosure also describes methods for treating a health condition in a subject in need thereof.BACKGROUND

[0003] Allogeneic CAR-T cell (chimeric antigen receptor T cell) therapies have been used for the treatment of hematologic malignancies including leukemias and lymphomas and for patients having such diseases who have relapsed after receiving chemotherapy. Despite advances made by commercially available CAR-T cell therapies, there remain key challenges for the use of allogeneic immunotherapies, including graft rejection, low graft persistence, and conditions such as graft vs. host disease (GvHD). Therefore, there remains an urgent medical need for improved allogeneic CAR-T immunotherapies.

[0004] Production of high-quality, GMP-grade CAR-T cells is an essential prerequisite for the wide application of this technology. Successful manufacturing of such high-quality CAR T-cell products for clinical applications has been challenging and costly, with common pitfalls including lengthy turnaround times and unacceptably low manufacturing success rates.

[0005] Current manufacturing processes for CAR-T cells have various drawbacks and so there is a pressing need to develop better and more efficient manufacturing processes for large-scale production of CAR-T cells with improved therapeutic activities.Attorney Docket No.: 063384-525001WOSUMMARY

[0006] The present disclosure relates generally to, inter alia, improved methods of making and / or manufacturing a population of allogeneic chimeric antigen receptor (CAR)-expressing allogeneic immune cells. Also provided are populations of CAR-expressing allogeneic immune cells made and / or manufactured by the improved methods, as well as pharmaceutical compositions comprising a population of C AR-expressing allogeneic immune cells of the disclosure. The disclosure also provides methods for treating a health condition in a subject in need thereof by administering the pharmaceutical compositions of the disclosure.

[0007] In one aspect of the disclosure, provided herein is a method of manufacturing a population of CAR-expressing immune cells, the method comprising: (a) obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject; (b) processing the initial population of cells comprising immune cells; on day 0; (c) enriching the population of cells comprising immune cells for CD4+ and CD8+ T cells to generate an enriched population of cells comprising immune cells; (d) culturing the enriched population of cells in a volume of a medium comprising an activation agent to generate an enriched and activated population of cells comprising immune cells; (e) transducing the enriched and activated population of cells comprising immune cells with one recombinant polynucleotide encoding three CARs and one recombinant polynucleotide encoding a universal allogeneic expression cassette comprising (i) a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surface of an immune cell and optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58, thereby generating an enriched, activated, and transduced population of cells comprising allogeneic CAR- expressing immune cells; (f) expanding the enriched, activated, and transduced population of cells comprising allogeneic CAR-expressing immune cells in media to yield an expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells; (g) harvesting the expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells on or after Day 6 after the culturing in step (d); (h) depleting CD3 / TCR+ immune cells from the harvested population of cells; and (i) formulating the harvested population of enriched, activated,Attorney Docket No.: 063384-525001WOtransduced and CD3 / TCR+ depleted cells comprising allogeneic CAR-expressing immune cells for cryopreservation and administration to patients.

[0008] In some embodiments, the liquid sample is a cryopreserved sample. In some embodiments, the cryopreserved sample is thawed prior to step (b) to generate a thawed population of cells comprising immune cells.

[0009] In some embodiments, the liquid sample including an initial population of cells comprises a leukapheresis product.

[0010] In some embodiments, the processing step (b) comprises diluting the liquid sample comprising the initial population of cells with media to generate a diluted population of cells comprising immune cells. In some embodiments, the media comprises Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0011] In some embodiments, the processing step (b) further comprises a step of washing and concentrating the diluted population of cells in media to generate a washed and concentrated population of cells. In some embodiments, the washing comprises phosphate buffered saline (PBS) and ethylenediaminetetraacetic acid (EDTA)(PBS / EDTA) + 0.5% (w / v) human serum albumin (HSA). In some embodiments, the processing is performed on a Rotea CounterflowTM Centrifugation System.

[0012] In some embodiments, the enriching step (c) comprises positive selection of CD4+ and CD8+ T cells.

[0013] In some embodiments, the enriching step (c) comprises negative selection of CD4+ and CD8+ T cells. In some embodiments, the positive selection comprises mixing the diluted or thawed and diluted population of cells with magnetic beads derivatized with CD4-specific binding agents and CD8-specific binding agents, washing, and eluting to generate the enriched population of cells. In some embodiments, the positive selection is performed on a Miltenyi Prodigy®.

[0014] In some embodiments, the negative selection comprises mixing the diluted, washed, and concentrated population of cells with anti-CD14, anti-CD16, anti-CD19, anti-CD20, anti-CD36, anti-CD56, anti-CD123, and anti-CD235ab (anti-glycophorin A / glycophorin B) antibodies to generate the enriched population of cells. In some embodiments, the negative selection is performed on an Akadeum Alerion™.Attorney Docket No.: 063384-525001WO

[0015] In some embodiments, the culturing of the enriched population of cells comprises seeding between at least 30×106cells and at least 300×106cells from the enriched population of cells in a vessel. In some embodiments, the vessel is a G-Rex® vessel.

[0016] In some embodiments, the enriched population of cells is cultured in a volume of media comprising modified T Cell Culture Medium. In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL- 15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0017] In some embodiments, the activation reagent comprises agonists of CD3 and CD28. In some embodiments, the activation reagent comprising CD3 and CD28 agonists comprises the T cell TransActTM reagent. In some embodiments, the activation reagent comprising CD3 and CD28 agonists comprises CTS™ Detachable Dynabeads™ CD3 / CD28.

[0018] In some embodiments, the one recombinant polynucleotide encoding three CARs comprises a first lentiviral expression vector and the one recombinant polynucleotide encoding a universal allogeneic expression cassette comprises a second lentiviral expression vector.

[0019] In some embodiments, the lentiviral expression vector(s) is / are manufactured using a suspension cell culture method.

[0020] In some embodiments, the transduction in step (e) is performed on Day 1.

[0021] The method of any one of claims 1 to 27, wherein the transduction in step (e) is performed 22-26 hours after culturing of the enriched and activated population of cells comprising immune cells on Day 0.

[0022] In some embodiments, the amount of vector used to transduce the enriched population of cells comprising immune cells in step (e) is determined based on the infectious titer of the first and second lentiviral vectors and the number of cells used to culture the enriched population of cells comprising immune cells such that the transduction is performed with a multiplicity of infection (MOI) of 1.7 for the first lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs and an MOI of 2.5 for the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette.

[0023] In some embodiments, the transduction is performed with an MOI of at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1.0, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at leastAttorney Docket No.: 063384-525001WO2.0, at least 2.1, at least 2.2, at least 2.3, at least 2.4, at least 2.5, at least 2.6, at least 2.7, at least 2.8, at least 2.9, at least 3.0, at least 3.5, at least 4.0, at least 4.5, at least 5.0, at least 5.5, at least 6.0, at least 6.5, at least 7.0, at least 7.5, at least 8.0, at least 8.5, at least 9.0, at least 9.5, or at least 10.0 for each vector.

[0024] In some embodiments, the transduction is a co-transduction.

[0025] In some embodiments, the transduction is a serial transduction.

[0026] In some embodiments, the first lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs and the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette are thawed, diluted into modified T Cell Culture Medium, and added to the enriched population of cells comprising immune cells.

[0027] In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0028] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 2.5 mL.

[0029] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 5 mL.

[0030] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 7 mL.

[0031] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 10 mL.

[0032] In some embodiments, the expanding step comprises culturing the enriched, activated, and transduced population of cells in modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

[0033] In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0034] In some embodiments, the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 6.

[0035] In some embodiments, the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 7.Attorney Docket No.: 063384-525001WO

[0036] In some embodiments, the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 8.

[0037] In some embodiments, the harvested cells are washed and concentrated prior to the depleting step (h). In some embodiments, the washing and concentrating of the harvested cells is performed on a CTS™ Rotea™ Counterflow Centrifugation System.

[0038] In some embodiments, the harvested cells are concentrated into Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0039] In some embodiments, the harvested cells are concentrated into Phosphate Buffered Saline (PBS) + 1 mM Ethylenediaminetetraacetic acid (EDTA) + 0.5% Human Serum Albumin (HSA).

[0040] In some embodiments, depleting CD3 / TCR+ immune cells comprises mixing the harvested population of cells with magnetic beads derivatized with CD3-specific binding agents. In some embodiments, the magnetic beads derivatized with CD3-specific binding agents comprise CliniMACS® CD3 Reagent.

[0041] In some embodiments, the depleting step is performed on a CliniMACS® Plus.

[0042] In some embodiments, depleting CD3 / TCR+ immune cells comprises bubble assisted cell separation. In some embodiments, the bubble assisted cell separation comprises the Alerion™ Microbubble Cell Separation System.

[0043] In some embodiments, the formulation step is automated.

[0044] In some embodiments, the formulation step is manual.

[0045] In some embodiments, the harvested population of cells including CAR-expressing immune cells comprises allogeneic CAR-expressing immune cells that are CD3 / TCR negative.

[0046] In some embodiments, the harvested population of cells including allogeneic CAR-expressing immune cells comprises allogeneic T cells expressing a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and a third molecule capable of reducing CD58 expression on the surface of an immune cell.

[0047] In some embodiments, the recombinant polynucleotide encoding three CARs encodes a CD19-specific CAR, a CD20-specific CAR, and a CD22-specific CAR.Attorney Docket No.: 063384-525001WO

[0048] In some embodiments, the recombinant polynucleotide encoding three CARs comprises a polynucleotide sequence encoding the CD19-specific CAR, a polynucleotide sequence encoding the CD20-specific CAR, and a polynucleotide sequence encoding the CD22-specific CAR, wherein each CAR-encoding polynucleotide sequence is separated from the other CAR-encoding polynucleotide sequences by a sequence encoding a viral ribosome skipping peptide selected from the group consisting of a P2A peptide, a T2A peptide, an E2 A peptide, and an F2A peptide.

[0049] In some embodiments, the recombinant polynucleotide encoding three CARs comprises from 5’ to 3’, a sequence encoding the CD22-specific CAR; a sequence encoding a viral P2A ribosome skipping peptide; a sequence encoding the CD19-specific CAR; a sequence encoding a viral T2A ribosome skipping peptide; and a sequence encoding the CD20-specific CAR.

[0050] In some embodiments, the CD22-specific CAR comprises a CD22-specific binding domain, a transmembrane domain, and an intracellular domain.

[0051] In some embodiments, the CD22-specific CAR comprises a CD22-specific binding domain, a spacer, a hinge domain, a transmembrane domain, a peptide linker, and an intracellular domain.

[0052] In some embodiments, the CD22-specific binding domain comprises an antibody that binds CD22 or an antigen-binding fragment thereof.

[0053] In some embodiments, the CD22-specific binding domain comprises an antibody that binds human CD22.

[0054] In some embodiments, the CD22-specific binding domain comprises an antigenbinding fragment of an antibody that binds human CD22.

[0055] In some embodiments, the antigen-binding fragment of an antibody that binds human CD22 is a single chain variable fragment (scFv) that binds CD22.

[0056] In some embodiments, the scFv that binds CD22 has the sequence of QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPG KAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIK (SEQ ID NO: 1).

[0057] In some embodiments, the scFv that binds CD22 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 1.Attorney Docket No.: 063384-525001WO

[0058] In some embodiments, the CD22-specific CAR comprises a CD8a hinge domain comprising the sequence of TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 23) and a CD8a transmembrane domain comprising the sequence of IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 24) and optionally a peptide linker having the sequence of LYC.

[0059] In some embodiments, the CD22-specific CAR comprises a CD8a hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 23 and a CD8a transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 24.

[0060] In some embodiments, the CD8a transmembrane domain further comprises a spacer having the sequence of LYC.

[0061] In some embodiments, the CD22-specific CAR comprises an intracellular domain comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.

[0062] In some embodiments, the primary T cell activating domain comprising an ITAM comprises a CD3ζ intracellular signaling domain.

[0063] In some embodiments, the CD3ζ intracellular signaling domain comprises the sequence ofRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGL YNELQKDKM AE A YSEIGMKGERRRGKGI IDGLYQGLST ATKDTYD ALHM Q AL PPR (SEQ ID NO: 26).

[0064] In some embodiments, the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

[0065] In some embodiments, the costimulatory signaling domain comprises a 4-1BB / CD137 signaling domain.

[0066] In some embodiments, the 4-1BB / CD137 signaling domain comprises the sequence of KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 25).

[0067] In some embodiments, the 4-1BB / CD137 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 25.Attorney Docket No.: 063384-525001WO

[0068] In some embodiments, the CD22-specific CAR comprises the sequence of QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 29).

[0069] In some embodiments, the CD22-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 29.

[0070] In some embodiments, the CD22-specific CAR comprises the sequence of MLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAW NWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPED TAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVT ITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQ AEDFATYYCQQSYSIPQTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFM RPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 30).

[0071] In some embodiments, the CD22-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 30.

[0072] In some embodiments, the CD19-specific CAR comprises a CD19-specific binding domain, a transmembrane domain, and an intracellular domain.

[0073] In some embodiments, the CD19-specific CAR comprises a CD19-specific binding domain, a hinge domain, a transmembrane domain, a spacer, and an intracellular domain.

[0074] In some embodiments, the CD19-specific binding domain comprises an antibody that binds CD 19 or an antigen-binding fragment thereof.

[0075] In some embodiments, the CD19-specific binding domain comprises an antibody that binds human CD19.Attorney Docket No.: 063384-525001WO

[0076] In some embodiments, the CD19-specific binding domain comprises an antigen¬ binding fragment of an antibody that binds human CD 19.

[0077] In some embodiments, the antigen-binding fragment of an antibody that binds human CD19 is a single chain variable fragment (scFv) that binds CD19.

[0078] In some embodiments, the scFv capable of binding CD 19 has the sequence of EVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDS YTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSS SNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDE ADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 34).

[0079] In some embodiments, the scFv capable of binding CD19 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 34.

[0080] In some embodiments, the CD19-specific CAR comprises a CD28 hinge domain comprising the sequence of IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43) and a CD28 transmembrane domain comprising the sequence of FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).

[0081] In some embodiments, the CD19-specific CAR comprises a CD28 hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 43 and a CD28 transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 44.

[0082] In some embodiments, the CD19-specific CAR comprises an intracellular domain further comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.

[0083] In some embodiments, the primary T cell activating domain comprising an ITAM comprises a CD3ζ intracellular signaling domain.

[0084] In some embodiments, the CD3ζ intracellular signaling domain comprises the sequence of RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26).Attorney Docket No.: 063384-525001WO

[0085] In some embodiments, the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

[0086] In some embodiments, the costimulatory signaling domain comprises a CD28 signaling domain.

[0087] In some embodiments, the CD28 signaling domain comprises the sequence of RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 45).

[0088] In some embodiments, the CD28 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 45.

[0089] In some embodiments, the CD19-specific CAR comprises the sequence of EVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSS SNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMYPPPYLDNEKSNGTIIHVKGKHLCPS PLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLY QGLSTATKDTYDALHMQALPPR (SEQ ID NO: 47).

[0090] In some embodiments, the CD19-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 47.

[0091] In some embodiments, the CD19-specific CAR comprises the sequence ofMALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDT AMYYCARPGDILTGWAMDVWGQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSV LTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMYPPP YLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQ GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 48).Attorney Docket No.: 063384-525001WO

[0092] In some embodiments, the CD19-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 48.

[0093] In some embodiments, the CD20-specific CAR comprises a CD20-specific binding domain, a transmembrane domain, and an intracellular domain.

[0094] In some embodiments, the CD20-specific binding domain comprises an antibody that binds CD20 or an antigen-binding fragment thereof.

[0095] In some embodiments, the CD20-specific binding domain comprises an antibody that binds human CD20.

[0096] In some embodiments, the CD20-specific binding domain comprises an antigen¬ binding fragment of an antibody that binds human CD20.

[0097] In some embodiments, the antigen-binding fragment of an antibody that binds human CD20 is a single chain variable fragment (scFv) that binds CD20.

[0098] In some embodiments, the scFv capable of binding CD20 has the sequence of DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPG KGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA RKSYYGSGSPDVFDIWGQGTMVTVSS (SEQ ID NO: 50).

[0099] In some embodiments, the scFv capable of binding CD20 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 50.

[0100] In some embodiments, the CD20-specific CAR comprises a CD28 hinge domain comprising the sequence of IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43) and a CD28 transmembrane domain comprising the sequence of FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).

[0101] In some embodiments, the CD20-specific CAR comprises a CD28 hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 43 and a CD28 transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 44.

[0102] In some embodiments, the CD20-specific CAR comprises an intracellular domain further comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.Attorney Docket No.: 063384-525001WO

[0103] In some embodiments, the primary T cell activating domain comprising an ITAM comprises a CD3(^ intracellular signaling domain.

[0104] In some embodiments, the CD3(^ intracellular signaling domain comprises the sequence ofRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGEDDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26).

[0105] In some embodiments, the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

[0106] In some embodiments, the costimulatory signaling domain comprises a CD2 signaling domain.

[0107] In some embodiments, the CD2 signaling domain comprises the sequence ofKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAP SHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN(SEQ ID NO: 59).

[0108] In some embodiments, the CD2 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 59.

[0109] In some embodiments, the CD20-specific CAR comprises the sequence of MLLLVTSLLLCELPHPAFLLIPDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKN YLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYC QQYYSFYQTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKN SLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYL DNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEELETRAIIRVATEERGRKPHQIPASTPQNPATSQFIPPPPPGHRSQAPSH RPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 64).

[0110] In some embodiments, the CD20-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 64.Attorney Docket No.: 063384-525001WO

[0111] In some embodiments, the CD20-specific CAR comprises the sequence of DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGWRPGGSLRLSCTASGFTFGDYGMSWVRQAPG KGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA RKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPL FPGPSKPFWVLWVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEELETRAHRVAT EERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPS GTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLY NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGITDGLYQGLSTATKDTYDALFIMQALPPR (SEQ ID NO: 62).

[0112] In some embodiments, the CD20-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 62.

[0113] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises at least one or more of an exogenous promoter, a post-transcriptional response element (PRE), and a polyadenylation signal sequence.

[0114] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is tricistronic.

[0115] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is bicistronic.

[0116] In some embodiments, the first molecule of the universal allogeneic expression cassette comprises a dominant negative mutant TCR-CD3 complex component capable of binding an unmutated or wild-type TCR-CD3 complex component. In some embodiments, the dominant negative mutant TCR-CD3 complex component is a dominant negative mutant TCRalpha, TCRbeta, TCRgamma, TCRdelta, CD3gamma, CD3delta, CD3 epsilon, or CD3zeta. In some embodiments, the dominant negative mutant TCR-CD3 complex component is a dominant negative mutant CD3epsilon.

[0117] In some embodiments, the second molecule of the universal allogeneic expression cassette comprises a mutated RFX5 polypeptide. In some embodiments, the mutated RFX5 polypeptide comprises a truncated RFX5 molecule. In some embodiments, the RFX5 polypeptide comprises a sequence selected from the sequences listed in Table 5.

[0118] In some embodiments, the third molecule of the universal allogeneic expression cassette comprises an anti-CD58 PEBL comprising an scFv capable of binding CD58 (anti-Attorney Docket No.: 063384-525001WOCD58 scFv). In some embodiments, the anti-CD58 scFv comprises a sequence selected from the sequences listed in Table 7, Table 8, Table 9, or Table 10. In some embodiments, the protein localization sequence or tag of the PEBL comprises an ER localization tag. In some embodiments, the ER localization tag is selected from the group consisting of KKAHKSKTH (SEQ ID NO: 1), KKKKRD (SEQ ID NO: 2), PKNRYKKH (SEQ ID NO: 3), KKYL (SEQ ID NO: 4), LLEALTLASARGPLRKRSVPMAKAKPKFSISPDSLS (SEQ ID NO: 5), LLEALTLASARGPLRKRSVPMAKAKPKFSISPKKYL (SEQ ID NO: 6), CFRKLAKTGKKKKRD (SEQ ID NO: 7), KHILFRRRRRGFRQ (SEQ ID NO: 8), LYKYKSRRSFIDEKKMP (SEQ ID NO: 9) KKMP (SEQ ID NO: 10), and AEKDEL (SEQ ID NO: 11).

[0119] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette further comprises a fourth molecule capable of blocking the CD8-MHC class I i nteraction. In some embodiments, the fourth molecule capable of blocki ng the CD8-MHC class I interaction comprises an MHC class I binder. In some embodiments, the MHC class I binder comprises a CD8alpha extracellular domain with a cysteine to serine (C to S) mutation at amino acid position 54 and a serine to asparagine ( S to N) mutation at amino acid position 74 in SEQ ID NO: 407. In some embodiments, the MHC class I binder comprises SEQ ID NO: 411.

[0120] In some embodiments, the MHC class I binder additionally comprises a B2M polypeptide or a fragment thereof.

[0121] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expressi on cassette further encodes one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CUT A, CD3epsilon, TRAC, RFX5, and / or CD58. In some embodiments, the one or more shRNAs are located in an intron of a promoter. In some embodiments, the promoter is an EF-1 alpha, a MND, MNDU3, an SFFV promoter, a CAG promoter, a CBA promoter, a Gamma Retro 5’ LTR promoter, or a hUbC promoter. In some embodiments, the one or more shRNAs further comprises a mirE or mirl55 scaffold.

[0122] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is tricistronic and encodes, from 5’ end to 3’ end, a mutated RFX5, a 2A ribosome skipping sequence, a 54mer MHC class I binder fused to B2M, a 2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, a CD3z shRNA located in an EF-lalpha promoter in a mirE scaffold, and an RFX5 shRNA located in an EFlalpha promoter in a mirl55 scaffold. In some embodiments, the recombinant polynucleotideAttorney Docket No.: 063384-525001WOencoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 440.

[0123] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is bicistronic and encodes, 5’ end to 3’ end, a mutated RFX5, a T2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, and a CD3z shRNA located in an EF-1 alpha promoter in a mirE scaffold. In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 441.BRIEF DESCRIPTION OF THE DRAWINGS

[0124] FIG. 1 shows process performance of total viable cell (“TVC”) enrichment on the Alerion™ and Prodigy® cell isolation systems within the Allo-process.

[0125] FIG. 2 shows frequency distributions of CD4+ / CD8+ T cells and impurities following the Alerion™ and Prodigy® cell isolation systems within the ALLo-process.

[0126] FIG. 3 shows TVC counts post-isolation and 24-hours post-culture.

[0127] FIG. 4 shows calculated cell recovery using TVC counts post-isolation and 24-hours post-culture Total Nucleated Cell Count (TNC). CD3e+ cell recovery leveraged flow cytometry data to estimate CD4+ / CD8+ frequencies within TVC counts.

[0128] FIG. 5 shows TVC counts using NC-200 also measured cell viability post-isolation and 24-hours post-culture. This indirectly measures cell damage due to Isolation unit op- & activation unit op-related stress on cells.

[0129] FIG. 6 shows Allo CAR T productivity at a range of seeding densities in viable cells per square centimeter for MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP).

[0130] FIG. 7 shows Allo CAR T productivity at a range of activation reagent concentrations for MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP).

[0131] FIG. 8 shows Allo CAR T productivity at a range of activation volumes normalized to G-Rex® culture surface area for MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP).

[0132] FIG. 9 shows a summary of CRG-023 vector (pSync3811, CAR+), ALLO (pSync5126, TCR-), and CAR+ / TCR- (cells comprising both pSync3811 and pSync5126, post depletion) transduction efficiencies of T Cells.Attorney Docket No.: 063384-525001WO

[0133] FIG. 10 shows a summary of CRG-023 vector (pSync3811, CAR+), ALLO (pSync5126, TCR-), and CAR+ / TCR- (cells comprising both pSync3811 and pSync5126, post-depletion) transduction efficiencies of T Cells.

[0134] FIG. 11 shows a summary of CRG-023 vector (pSync3811, CAR+), ALLO (pSync5126, TCR-), and CAR+ / TCR- (cells comprising both pSync3811 and pSync5126, post depletion) transduction efficiencies of T Cells following co-transduction.

[0135] FIG. 12 shows a summary of CRG-023 vector (pSync3811, CAR+), ALLO (pSync5126, TCR-), and CAR+ / TCR- (cells comprising both pSync3811 and pSync5126, post depletion) transduction efficiencies of T Cells following serial transduction.

[0136] FIG. 13 shows a summary of CRG-023 vector (pSync3811, CAR+), ALLO (pSync5126, TCR-), and CAR+ / TCR- (cells comprising both pSync3811 and pSync5126, post depletion) transduction efficiencies of T Cells following co-transduction.

[0137] FIG. 14 shows a summary of TVC counts during the expansion phase with various cell seeding densities post-dual transduction. Vessels were seeded with 5 * 106, 10* 106, 15* 106, or 30* 106cells per 6M G-Rex vessel and allowed to culture until the Day 8 harvest unit operation (6-day culture).

[0138] FIG. 15 shows a summary of the fold expansion that was determined from cell counts during the expansion phase with various cell seeding densities post-dual transduction. Vessels were seeded with 5 * 106, 10*106, 15*106, or 30><106cells per 6M G-Rex vessel and allowed to culture until the Day 8 harvest unit operation (6-day culture).

[0139] FIG. 16 shows a summary of cell viability using NC-200-based TVC counts during the expansion phase with various cell seeding densities post-dual transduction. Vessels were seeded with 5*106, 10xl06, 15xl06, or 30xl06cells per 6M G-Rex vessel and allowed to culture until the Day 8 harvest unit operation (6-day culture).

[0140] FIG. 17 shows that Allo CAR T cells growth and production was achieved at a normalized expansion seeding density range of 0.50xl06cells / cm2to 3.0xl06cells / cm2

[0141] FIG. 18 shows a summation of all depletion unit operati ons performed with either the CliniMACS® Plus or the Alerion™. The Allo CAR T cells were measured for TCRaP expression frequency via flow cytometry before and after the depletion unit operation.

[0142] FIG. 19 shows a summation of all depletion unit operations performed with either the CliniMACS® Plus or the Alerion™. The Allo CAR T cells were measured for TCRaP expression frequency via flow cytometry before and after the depletion unit operation. TVC counts were also measured before and after the depletion unit operation. The TCR P- TVCAttorney Docket No.: 063384-525001WOYield was calculated by dividing the TCRaP- TVCs in the unit operation’s output from the input of TCRaP- TVCs for each run.DETAILED DESCRIPTION OF THE DISCLOSURE

[0143] The present disclosure generally relates to, inter alia, improved methods of making and / or manufacturing a population of allogeneic immune cells expressing one or more chimeric antigen receptors (CARs). Also provided are populations of allogeneic CAR-expressing immune cells made and / or manufactured by the improved methods, as well as pharmaceutical compositions comprising a population of allogeneic CAR-expressing immune cells of the disclosure. The disclosure also provid es methods for treating a health condition in a subject in need thereof.

[0144] As discussed in greater detail below, the present disclosure provides methods that allow efficient manufacturing processes for rapid clinical-scale production of allogeneic CAR-T cells that enable durable, specific reduction of TCR-CD3 expression, MHC class I and MHC class II expression, and expressi on of related stimulatory and / or co-stimulatory signaling pathways associated with T cell activation and expansion without (1) relying on high risk and clinically unproven gene editing technologies or (2) altering the expression or functional activity of the CAR(s) co-expressed with such constructs and compositions, thereby solving the long-felt art-recognized need for methods of manufacturing allogeneic CAR T cells.

[0145] In one aspect, some embodiments of the disclosure relate to a method of making a population of allogeneic CAR-expressing immune cells, the method including the steps of obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject; processing the initial population of cells comprising immune cells; on day 0, enriching the population of cells comprising immune cells for CD4+ and CD8+ T cells to generate an enriched population of cells comprising immune cells; culturing the enriched population of cells in a volume of a medium comprising an activation agent to generate an enriched and activated population of cells comprising immune cells; transducing the enriched and activated population of cells comprising immune cells with one recombinant polynucleotide encoding three CARs and one recombinant polynucleotide encoding a universal allogeneic expressi on cassette comprising (i) a first molecul e capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surfaceAttorney Docket No.: 063384-525001WOof an immune cell and, optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58, thereby generating an enriched, activated, and transduced population of cells comprising allogeneic CAR-expressing immune cells; expanding the enriched, activated, and transduced population of cells comprising allogeneic CAR-expressing immune cells in medium to yield an expanded population of enriched, activated, and transduced cells comprising CAR-expressing allogeneic immune cells; harvesting the expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells on or after Day 6 after the culturing; depleting CD3 / TCR+ immune cells from the harvested population of cells; and formulating the harvested populati on of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells for cryopreservation and administration to patients.DEFINITIONS

[0146] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the embodiments provided may be practiced without these details. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.

[0147] Certain ranges are presented herein with numerical values being preceded by the term “about” which, as used herein, has its ordinary meaning of approximate.

[0148] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the disclosure are speci fically embraced by the present di sclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub¬Attorney Docket No.: 063384-525001WOcombinations of the various embodiments and elements thereof are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub- combination was individually and explicitly disclosed herein.METHODS OF MANUFACTURING A POPULATION OF CAR-EXPRESSING ALLOGENEIC IMMUNE CELLS

[0149] In one aspect, provided herein are methods of making a population of allogeneic chimeric antigen receptor- (CAR-) expressing immune cells. In certain embodiments, the methods described herein may include one or more of the following steps: cell collection, cell processing (e.g., diluting, washing and / or concentration), cell cryopreservation, cell thawing, cell seeding, cell co-transduction, cell expansion, cell harvesting, CD3 / TCR+ immune cell depletion, cell packaging, and cell storing. For purposes of the methods described herein, Day 0 is the day on which a processed, cryopreserved leukapheresis or apheresis product is thawed, and the method is initiated.

[0150] In one aspect, described herein is a method of making a population of chimeric antigen receptor CAR-expressing immune cells, the method including the steps of: (a) obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject; (b) processing the initial population of cells comprising immune cells; (c) on day 0, enriching the population of cells comprising immune cells for CD4+ and CD8+ T cells to generate an enriched population of cells comprising immune cells; (d) culturing the enriched population of cells in a volume of a medium comprising an activation agent to generate an enriched and activated population of cells comprising immune cells; (e) cotransducing the enriched and activated population of cells comprising immune cells with one recombinant polynucleotide encoding three CARs and one recombinant polynucleotide encoding a universal allogeneic expression cassette comprising (i) a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surface of an immune cell and, optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58, thereby generating an enriched, activated, and transduced population of cells comprising allogeneic CAR- expressing immune cells; (f) expanding the enriched, activated, and transduced population of comprising allogeneic cells CAR-expressing immune cells in medium to yield an expandedAttorney Docket No.: 063384-525001WOpopulation of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells; (g) harvesting the expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells on or after Day 6 after the culturing in step (c); (h) depleting CD3 / TCR+ immune cells from the harvested population of cells; and (i) formulating the harvested population of enriched, activated, and transduced cells comprising CAR-expressing allogeneic immune cells for cryopreservation and administration to patients.Cell Collection

[0151] The first step in the method described herein involves obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject.

[0152] In some embodiments, obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject includes receiving a liquid sample of cells (e.g., apheresis). In some embodiments, obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject includes collecting a liquid sample of cells (e.g., apheresis).

[0153] In some embodiments, a human subject can be a healthy volunteer.

[0154] As described above, the liquid sample comprises an initial population of cells (not patient-derived) comprising immune cells. In some embodiments, the liquid sample including an initial population of cells comprising immune cells comprises a leukapheresis product or an apheresis product. As used herein, the terms “leukapheresis” and “apheresis” are used interchangeably to refer to a process involving the removal of certain blood components e.g., stem cells, platelets, white blood cells, red blood cells) from subject’s bloodstream.

[0155] The term “immune cells” used in reference to the cells present in the liquid sample refers to cells that are involved in an adaptive immune response, e.g., in the promotion of an immune effector response. Exemplary immune cell types include T cells. In some instances, the T cells are CD8-positive T cells, CD4-positive T cells, regulatory T cells, cytotoxic T cells, or tumor infiltrating lymphocytes. The immune cells can also be precursor cells, e.g., cells that are capable of differentiating into immune cells.

[0156] The initial population of cells described herein are allogeneic (e.g., obtained from a healthy donor and administered to multiple subjects, e.g., patients). In some embodiments, the cells are T cells obtained from a mammal. In some embodiments, the T cells obtained from a mammal are CD8-positive T cells, CD4-positive T cells, regulatory T cells (Tregs),Attorney Docket No.: 063384-525001WOcytotoxic T cells (TCTLS), helper T cells (TH) or tumor infiltrating lymphocytes (TILs). In some instances, the mammal is a primate. In some instances, the primate is a human.

[0157] T cells can also be obtained from a number of sources including, but not limited to, peripheral blood, peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In some instances, T cells are obtained from a unit of blood collected from an individual using any number of known techniques such as sedimentation, e.g, FICOLL™ separation or apheresis. In some embodiments, the T cells are from a blood sample. In some embodiments, the T cells are obtained by apheresis.

[0158] In some instances, an isolated or purified population of T cells is used. In some instances, TCTL and TH lymphocytes are purified from PBMCs. In some embodiments, the T cells are obtained directly from the subject by leukapheresis and / or apheresis. In some instances, the TCTL and TH lymphocytes are sorted into naive (TN), memory (TMEM), stem cell memory (TSCM), central memory (TCM), effector memory (TEM), and effector (TEFF) T cell subpopulations either before or after activation, expansion, and / or genetic modification. In some embodiments, the T cell subsets may be CD45RA+, CCR7+, CD45RO+, or a combination thereof. In some embodiments, the T cell subsets may be CD45RA-, CCR7-, CD45RO-, or a combination thereof. Suitable approaches for such sorting are known and include, e.g., magnetic-activated cell sorting (MACS), where TN are CD45RO-CD45RA+ CD62L+ CD95-; TSCM are CD45RO-CD45RA+CCR7+; TC are CD45RO+CD45RA-CCR7+; TMEM are CD45RO+, (TEFF) are CD45RO+CD45RA-CCR7-, and TEM are CD45RO+CCR7-CD45RA-. An exemplary approach for such sorting is described in Wang etal., (2016) Blood 127(24):2980- 90.

[0159] In some instances, the initial population of cells is a heterogeneous mixture of cells of different cell types. In some instances, the initial population of cells comprises a heterogenous mixture of different cell types comprising at least about 1x104cells, about 1 x IO5cells, about 1 x 106cells, about 1 x 107cells, about 1 x 108cells, or about 1 x 109cells. In some instances, the initial population of cells comprises at least about IxlO9cells. In some instances, the population of cells comprises at least about 2x109cells. In some instances, the population of cells comprises at least about 3xl09cells. In some instances, the population of cells comprises at least about 4xl09cells. In some instances, the population of cells comprises at least about 5xl09cells. In some instances, the population of cells comprises at least about 6x 109cells. In some instances, the population of cells comprises at least about 7xl09cells.Attorney Docket No.: 063384-525001WOCell Processing

[0160] Following obtention of the initial population of cells, the initial population of cells is processed. In instances where the liquid sample containing the initial population of cells is a cryopreserved sample, the cryopreserved sample is thawed prior to processing.

[0161] In some embodiments, the processing of the initial population of cells comprises diluting the liquid sample comprising the initial population of cells with media.

[0162] The volume of dilution media added to the cell population can be at least about 5 mL, at least about 10 mL, at least about 15 mL, at least about 20 mL, at least about 25 mL, at least about 30 mL, at least about 40 mL, at least about 50 mL, at least about 75 mL, at least about100 mL, at least about 150 mL, at least about 200 mL, at least about 250 mL, at least about300 mL, at least about 400 mL, at least about 500 mL, at least about 600 mL, at least about700 mL, at least about 800 mL, at least about 900 mL, at least about 1 L, at least about 1.5 L, at least about 2 L, at least about 2.5 L, at least about 3 L, at least about 3.5 L, at least about 4 L, at least about 4.5 L, or at least about 5 L. In some embodiments, volume of dilution media added to the cell population is 100 mL. In some embodiments, the volume of dilution media added to the cell population is more than the volume of the cell population. In some embodiments, the volume of dilution media added to the cell population is less than the volume of the cell population. In some embodiments, the volume of the dilution media added to the cell population is the same as the volume of the cell population (i.e., a 1:1 dilution).

[0163] In some embodiments, the initial population of cells is diluted in Prime XV CDM Medium supplemented with a 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0164] In some embodiments, the processing of the initial population of cells further comprises the step of washing the cells to generate a washed population of cells comprising immune cells.

[0165] In some embodiments, the initial population of cells is processed by washing the cells in a buffer comprising HSA.

[0166] In some embodiments, the concentration of HSA in the buffer may be between about 0.25-2% (w / v), about 1-4% (w / v), about 2-6% (w / v), about 4-8% (w / v), about 5-10% (w / v), or about 0.25% (w / v), about 0.5% (w / v), about 0.75% (w / v), about 1% (w / v), about 1.25% (w / v), about 1.5% (w / v), about 1.75% (w / v), about 2% (w / v), about 2.25% (w / v), about 2.5% (w / v), about 2.75% (w / v), about 3% (w / v), about 3.25% (w / v), about 3.5% (w / v), aboutAttorney Docket No.: 063384-525001WO3.75% (w / v), about 4% (w / v), about 4.25% (w / v), about 4.5% (w / v), about 4.75% (w / v), about 5% (w / v), about 5.25% (w / v), about 5.5% (w / v), about 5.75% (w / v), about 6% (w / v), about 6.25% (w / v), about 6.5% (w / v), about 6.75% (w / v), about 7% (w / v), about 7.25% (w / v), about 7.5% (w / v), about 7.75% (w / v), about 8% (w / v), about 8.25% (w / v), about 8.5% (w / v), about 8.75% (w / v), about 9% (w / v), about 9.25% (w / v), about 9.5% (w / v), about 9.75% (w / v), or about 10% (w / v). In some embodiments, the concentration of HSA in the buffer is 0.5% (w / v).

[0167] In some embodiments, the wash buffer may include HSA, Plasma-Lyte A®, phosphate buffered saline (PBS), ethylenediamine tetraacetic acid (EDTA), sodium chloride, sodium bicarbonate buffer, glutathione, biotin, vitamin B 12, inositol, choline, L-glutamine, sodium pyruvate, glucose, or a combination thereof.

[0168] In some embodiments, the initial population of cells is processed by washing the cells in buffer comprising PBS / EDTA + 0.5% HSA.

[0169] Depending upon the method used for the later enrichment step, the initial population of cells can be washed and concentrated using a variety of techniques. In some embodiments, the initial population of cells is washed and concentrated on a closed system. In some embodiments, the closed system is a CliniMACS® Prodigy® system. In some embodiments, the closed system is a Rotea™ Counterflow Centrifugation System.

[0170] In some embodiments, the method then proceeds to the enrichment and activation step (c) as further described in the next section.

[0171] In some embodiments, the diluted, washed and concentrated population of cells is eluted or resuspended in a buffer comprising human serum albumin (HSA), Plasma-Lyte A, phosphate buffered saline (PBS), sodium chloride, ethylenediamine tetraacetic acid (EDTA), sodium bicarbonate buffer, glutathione, biotin, vitamin B 12, inositol, choline, L-glutamine, sodium pyruvate, glucose, or any combination thereof. In some embodiments, the buffer comprises human serum albumin (HSA). In some embodiments, the buffer comprises Plasma-Lyte A®. In some embodiments, the buffer comprises equal volumes of Plasma-Lyte A® and 4% (w / v) human serum albumin.

[0172] In some embodiments, the diluted, washed and concentrated cell population is transferred to a sterile container after elution / resuspension. In some embodiments, the transfer is performed manually. In some embodiments, the transfer is automated. The sterile container can include a bag, a bottle, a tube, a glass jar, or a plastic container. In some embodiments, before transfer to a sterile container, the cell population can be diluted after elution / resuspension into a dilution buffer. The dilution buffer may include dimethylAttorney Docket No.: 063384-525001WOsulfoxide (DMSO), sucrose, sodium hydroxide, potassium hydroxide, fructose, HSA, Plasma-Lyte A®, phosphate buffered saline (PBS), sodium chloride, sodium bicarbonate buffer, glutathione, biotin, vitamin B 12, inositol, choline, L-glutamine, sodium pyruvate, glucose, or a combination thereof. In some embodiments, the cell population may be cryopreserved after transfer to a sterile container. In some embodiments, the cell population can be cryopreserved after dilution and transfer to a sterile container. In some embodiments, the sterile packaged cell population is cryopreserved using a controlled rate freezer. In some embodiments, the sterile packaged cell population is cryopreserved by immersion in liquid nitrogen.

[0173] In some embodiments, the diluted, washed and concentrated population of cells is resuspended in a buffer comprising equal volumes of Plasma-Lyte A® and 4% (w / v) HSA and further diluted 1:1 with a cryoprotectant to generate a cryopreserved population of cells. In some embodiments, the cryoprotectant is CryoStor®.T Cell Enrichment and Activation

[0174] As described above, following the processing of the initial population of cells to generate the diluted, washed and concentrated, or cryopreserved population of cells, the method described herein next involves the step of, on day 0, enriching the diluted, washed and concentrated, or cryopreserved population of cells comprising immune cells for CD4+ and CD8+ T cells to generate an enriched population of cells comprising immune cells. The enriched population of cells is then cultured in a volume of a medium comprising an activation agent to generate an enriched and activated population of cells comprising immune cells.

[0175] In embodiments where a cryopreserved population of cells has been generated following cell processing, the cryopreserved population of cells is thawed before it is enriched and activated in step (c) to generate a thawed population of cells. For purposes of the methods described herein, Day 0 is the day on which a freshly processed population of cells is enriched and activated or a processed and cryopreserved leukapheresis or apheresis product is thawed, enriched, and activated.

[0176] In some embodiments, the enriching for CD4+ and CD8+ T cells further comprises a step of measuring the total viable cells and determining the percentage (%) of cells that are CD3+ (%CD3+), CD4+CD8- (%CD4+CD8-), CD8+CD4- (%CD8+CD4-), and CD4+CD8+ (%CD4+CD8+) in the population of cells.

[0177] A variety of techniques can be used for enrichment of CD4+ and CD8+ T cells. For example, targeted separation (for positive or negative selection) can be achieved through theAttorney Docket No.: 063384-525001WOuse of a targeting moiety conjugated to a separable particle (e.g., a nanomagnetic particle, a conventional magnetic particle, a buoyant particle (e.g., a microbubble)). The targeting moiety is typically a high affinity binding reagent that can be conjugated to the separable particle by a suitable chemistry (preferably one involving covalent bonding that does not disrupt binding between the high affinity binding reagent and a targeted biomolecule (e.g., CD4 and CD8 on T cells). Examples of such high affinity binding reagents include members of high affinity binding pairs. Such members include antibodies (particularly monoclonal antibodies), antigen-binding antibody fragments (e.g., Fab fragments), or another member of a high affinity bending pair (one of which is conjugated to the separable particle and the other of which is the “target” present on the biomolecule). In some embodiments, the high affinity binding reagent and / or separable particle to which it is conjugated is labeled with a detectable agent suitable for cell separation (e.g., FACS), such as a fluorescent dye.

[0178] In some embodiments, the step of enriching for CD4+ and CD8+ T cells comprises positive selection of CD4+ and CD8+ cells.

[0179] In some embodiments, the enriching for CD4+ and CD8+ T cells comprises a step of mixing the diluted, washed and concentrated population of cells with magnetic beads derivatized with CD4-specific binding agents and CD8-specific binding agents, followed by washing and eluting to generate the enriched population of cells. In some embodiments, this enrichment step takes place within a CliniMACS Prodigy® system.

[0180] In some embodiments, the step of enriching for CD4+ and CD8+ T cells comprises negative selection of CD4+ and CD8+ cells.

[0181] In some embodiments, the enriching for CD4+ and CD8+ T cells comprises a step of mixing the diluted, washed and concentrated population of cells with anti-CD14, anti-CD16, anti-CD19, anti-CD20, anti-CD36, anti-CD56, anti-CD123, and anti-CD235ab (anti-glycophorin A / glycophorin B ) antibodies to generate the enriched population of cells. In some embodiments, this enrichment step is performed on an Akadeum Alerion™. In some embodiments, the enrichment step is performed on a CliniMACS.

[0182] In some embodiments, the enrichment step yields about 3xl09, 3.1x109, 3.2xl09, 3.3xl09, 3.4xl09, 3.5xl09, 3.6xl09, 3.7x109, 3.8x109, 3.9xl09, 4xl09, 4.1xl09, 4.2xl09, 4.3xl09, 4.4xl09, or 4.5xl09CD4+ and CD8+ enriched cells.

[0183] In some embodiments, the enrichment step yields a CD4+ and CD8+ enriched population of cells that is about 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% CD3+ T cells.

[0184] Following generation of the enriched population of cells comprising CD4+ and CD8+ T cells, the enriched population of cells is cultured in a volume of a medium comprising anAttorney Docket No.: 063384-525001WOactivation agent to generate an enriched and activated population of cells comprising CD4+ and CD8+ immune cells.

[0185] In some embodiments, the enriched population of cells is cultured by seeding between at least 3xl06cells / cm2and at least 30* IO6cells / cm2from the enriched population of cells in a vessel. In some embodiments, the enriched population of cells is cultured by seeding at least about 2.5 xlO6, 3xl06, 3.5xl06, 4xl06, 4.5xl06, 5xl06, 5.5x106, 6xl06, 6.5x106, 7x106, 7.5xl06, 8xl06, 8.5xl06, 9x106, 9.5xl06, IxlO7, 1.5xl07, 2xl07, 2.5x107, 3x107, 3.5x107, 4xl07, 4.5xl07, 5xl07, 5.5x107, 6xl07, 6.5xl07, 7x107, 7.5xl07, 8xl07, 8.5xl07, 9xl07, 9.5xl07, IxlO8, 1.5xl08, 2xl08, 2.5xl08, 3xl08, 3.5x108, 4xl08, 4.5x108, or 5x108cells / cm2from the enriched population in a vessel. In some embodiments, the vessel is a G-REX® vessel.

[0186] In some embodiments the enriched population of cells is seeded in modified T Cell Culture Medium. In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL- 15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0187] In some embodiments, the modified T Cell Culture medium further comprises an effective amount of a reagent comprising agonists of CD3 and CD28. In some embodiments, the reagent comprising CD3 and CD28 agonists comprises the T cell TransAct™ reagent. In some embodiments, the reagent comprising CD3 and CD28 agonists comprises CTS™ Detachable Dynabeads™ CD3 / CD28.Co- Transduction

[0188] As described for the methods herein, the enriched and activated population of cells is then transduced with one recombinant polynucleotide encoding three CARs and one recombinant polynucleotide encoding a universal allogeneic expression cassette comprising (i) a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surface of an immune cell and optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / orAttorney Docket No.: 063384-525001WOCD58, thereby generating an enriched, activated, and transduced population of cells comprising CAR-expressing immune cells.

[0189] Transduction can refer to a process by which exogenous nucleic acid is transferred or introduced into the host cell. For example, a “transduced” cell is one which has been transduced with exogenous nucleic acid, e.g., a lentiviral expression vector encoding one or more CARs. The term “transduced” can include the primary subject cell and its progeny.

[0190] In some embodiments, the one recombinant polynucleotide encoding three CARs comprises a first lentiviral expression vector and the one recombinant polynucleotide encoding a universal allogeneic expression cassette comprises a second lentiviral expression vector. In some embodiments, the first lentiviral expression vector comprises one recombinant polynucleotide encoding three separate and distinct CARs.

[0191] A lentiviral vector as used herein can refer to a vector derived from at least a portion of a lentivirus genome, including especially a self-inactivating lentiviral vector as provided in Milone etal., Mol. Ther. 17(8): 1453-1464 (2009). Nonclinical types of lentiviral vectors are also available and would be known to one skilled in the art. As used herein, the term “lentivirus” refers to members of a genus in the Retroviridae family. Lentiviruses are unique among the retroviruses in being able to infect non-dividing cells. In addition, they can deliver a considerable amount of genetic information into the DNA of the host cell, so they are one of the most efficient methods of a gene delivery vector used in immune cell engineering. HIV, SIV, and FIV are all examples of lentiviruses.

[0192] A “lentiviral expression vector” can refer to a lentiviral vector including a recombinant polynucleotide to be expressed and various expression control sequences operatively linked to the recombinant nucleotide sequence. A lentiviral expression vector includes sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Lentiviral vectors and various lentiviral components useful for the production of a lentiviral vector are known in the art. For example, an expression cassette encoding a CAR construct may be incorporated into a lentiviral vector backbone, which may then be packaged using a packaging system known in the art. Vector backbones suitable for use include the pCCL-c-MNDU3-X expression vector (Logan et al., “Factors influencing the titer and infectivity of lentiviral vectors,” Hum Gene Ther. 15(10):976-88 (2004)) for use in mammalian cells. In some embodiments, nucleic acid inserts encoding the subject CARs can be operably linked to a promoter, which is selected based on, for example, the cell type in which expression is sought. In some embodiments, theAttorney Docket No.: 063384-525001WOpCCL-c-MNDU3-X expression vector further comprises the MNDU3 promoter. In some embodiments, the MNDU3 promoter is replaced with the EFla promoter.

[0193] A number of techniques suitable for lentiviral manufacturing are also generally known in the art and described in the technical and scientific literature. In some embodiments, the lentiviral expression vector comprising an expression cassette encoding a CAR construct and the lentiviral expression vector encoding a universal allogeneic cassette are manufactured using an adherent cell-based process. In some embodiments, the lentiviral expression vector comprising an expression cassette encoding a CAR construct and the lentiviral expression vector encoding a universal allogeneic cassette are manufactured using a suspension cell-based process, which may help ease lentiviral manufacturing at scale with the use of stirred tank bioreactors and, in some instances, provides significantly better transduction efficiency of the lentivirus construct into T cells. In some embodiments of the disclosure, immune cells are transduced with a first lentiviral expression vector comprising one recombinant polynucleotide encoding three separate and distinct CARs and a second lentiviral expression vector encoding a universal allogeneic expression cassette, and the first and second lentiviral expression vectors are produced using an adherent cell-based lentiviral vector manufacturing platform. In some other embodiments of the disclosure, immune cells are transduced with a first lentiviral expression vector comprising one recombinant polynucleotide encoding three separate and distinct CARs and a second lentiviral expression vector encoding a universal allogeneic expression cassette, and the first and second lentiviral expression vectors are produced using a suspension cell culture-based LV manufacturing platform.

[0194] In some embodiments, the three CAR constructs comprise a CD19-specific CAR, a CD20-specific CAR, and a CD22-specific CAR. Such CAR constructs are described in more detail in sections herein below.

[0195] In some embodiments, the transduction in step (e) is performed on Day 1. In some embodiments, the transduction in step (e) is performed 22-26 hours after culturing of the enriched and activated population of cells comprising immune cells on Day 0.

[0196] In some embodiments, the amount of vector used to transduce the enriched population of cells comprising immune cells in step (e) is determined based on the infectious titer of the first and second lentiviral vectors and the number of cells used to culture the enriched population of cells comprising immune cells such that the transduction is performed with a multiplicity of infection (MOI) of 1.7 for the first lentiviral expression vector comprising oneAttorney Docket No.: 063384-525001WOrecombinant polynucleotide encoding three CARs and an MOI of 2.5 for the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette. In some embodiments, the transduction is performed with a MOI of at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2.0, at least 2.1, at least 2.2, at least 2.3, at least 2.4, at least 2.5, at least 2.6, at least 2.7, at least 2.8, at least 2.9, at least 3.0, at least 3.5, at least 4.0, at least 4.5, or at least 5.0 for each vector.

[0197] In some embodiments, the first lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs and the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette are thawed, diluted into modified T Cell Culture Medium, and added to the enriched population of cells comprising immune cells. In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0198] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 2.5 mL. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 5 mL. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 7 mL. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 10 mL.

[0199] In some embodiments, the final volume in which the transduction in step (e) is performed comprises 0.25 mL / cm2. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 0.5 mL / cm2. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 0.75 mL / cm2. In some embodiments, the final volume in which the transduction in step (e) is performed comprises 1 mL / cm2.

[0200] In some embodiments, the transduction is performed as a co-transduction.

[0201] In some embodiments, the transduction is performed as a serial transduction. In some embodiments, the cells are first transduced with the lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs. After 22 to 26 hours, the cells are then transduced with the lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette for an additional 22 to 26 hours.Attorney Docket No.: 063384-525001WOExpansion and Harvest

[0202] As described herein, following the transduction step (e), the enriched, activated, and transduced population of cells comprising CAR-expressing immune cells is expanded in growth medium to yield an expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells.

[0203] In some embodiments, cells are expanded in growth medium comprising modified T Cell Culture Medium. In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0204] In some embodiments, the expansion step (e) comprises seeding the enriched, activated, and transduced population of cells at density range of 0.50* 106cells / cm2to 3.0 * 106cell s / cm2in a vessel.

[0205] The cells are expanded for a period of at least 6 days. In some embodiments, the cells are expanded and harvested on Day 6. In some embodiments, the cells are expanded and harvested on Day 7. In some embodiments, the cells are expanded and harvested on Day 8. In some embodiments, the cells are expanded and harvested on Day 9. In some embodiments, the cells are expanded and harvested on Day 10. In some embodiments, the cells are expanded and harvested on Day 11. In some embodiments, the cells are expanded and harvested on Day 12. In some embodiments, the cells are expanded and harvested on Day 13. In some embodiments, the cells are expanded and harvested on Day 14.

[0206] In some embodiments, the expanded population of cells is analyzed for TCRa0 expression prior to harvesting. In some embodiments, this analysis is performed via flow cytometry.

[0207] In some embodiments, the harvesting step further includes removing at least at least about 80%, 85%, or 90% of the supernatant from the culture vessel.

[0208] In some the harvesting step further includes filtering the harvested population of cells to reduce and remove cellular aggregates.

[0209] In some embodiments, the harvested population of cells including viable CAR- expressing immune cells comprises allogeneic CAR-expressing immune cells that are CD3 / TCR negative.

[0210] In some embodiments, the harvested population of cells including CAR-expressing immune cells comprises allogeneic T cells expressing a CD19-specific CAR, a CD20-specificAttorney Docket No.: 063384-525001WOCAR, a CD22-specific CAR, a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and a third molecule capable of reducing CD58 expression on the surface of an immune cell.

[0211] In some embodiments, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, or 97% of the cells in the harvested population of cells are viable.Depletion

[0212] Following the harvesting step, the harvested cell population is then prepared for CD3+ depletion.

[0213] The harvested cell popul ation can be washed and concentrated prior to the depleting step (h). In some embodiments, the washing and concentrating of the harvested cells is performed on a CTS™ Rotea™ Counterflow Centrifugation System.

[0214] In some embodiments, the harvested cells are concentrated into modified T Cell Culture Medium. In some embodiments, the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15). In some embodiments, the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

[0215] In some embodiments, the harvested cells are concentrated into Phosphate Buffered Saline (PBS) + 1 mM Ethylenediaminetetraacetic acid (EDTA) + 0.5% Human Serum Albumin (HSA).

[0216] A variety of techniques can be used for depletion of CD3 / TCR+ T cells. Similar to the enrichment process described above, targeted separation of CD3 / TCR+ T cells can be achieved through the use of a targeting moiety conjugated to a separable particle (e.g., a nanomagnetic particle, a conventional magnetic particle, a buoyant particle (e.g.,a microbubble)). The targeting moiety is typically a high affinity binding reagent that can be conjugated to the separable particle by a suitable chemistry (preferably one involving covalent bonding that does not di srupt binding between the high affinity binding reagent and a targeted biomolecule (e.g., CD3 on T cells). Examples of such high affinity binding reagents include members of high affinity binding pairs. Such members include antibodies (particularly monoclonal antibodies), antigen-binding antibody fragments (e.g., Fab fragments), or another member of a high affinity bending pair (one of which is conjugated to the separable particle and the other of which is the “target” present on the biomolecule). InAttorney Docket No.: 063384-525001WOsome embodiments, the high affinity binding reagent and / or separable particle to which it is conjugated is labeled with a detectable agent suitable for cell separation (e.g, FACS), such as a fluorescent dye.

[0217] In some embodiments, depleting CD3 / TCR+ immune cells comprises mixing the harvested population of cells with magnetic beads derivatized with CD3-specific binding agents. In some embodiments, this step is performed on a CliniMACS® Plus.

[0218] In some embodiments, depleting CD3 / TCR+ immune cells comprises bubble assisted cell separation. In some embodiments, this step is performed on the Alerion™ Microbubble Cell Separation System.

[0219] The depletion step must result in a highly pure, TCRaP- cell population such that the final drug product does not cause GvHD upon administration. In some embodiments, the harvested and depleted cell population comprises about 98%, 98.5%, 99%, 99.1%, 99.2% 99.3%, 99.4%, 99.5%, 99.6% 99.7%, 99.8%, or 99.9% TCRap- cells.Formulation

[0220] Upon completion of cell harvesting, the harvested population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells is formulated for cryopreservation and administration to patients.

[0221] In some embodiments, the formulation step is automated. In some embodiments, the automated formulation step is performed using a Cue ScaleReady Cell Processing System.

[0222] In some embodiments, the harvested population of enriched, activated, and transduced cells comprising CAR-expressing immune cells is resuspended to the desired concentration in Final Formulation Medium comprising a 1:1 mixture of Plasma-Lyte A®+4% HSA (w / v) that is subsequently diluted 1:1 with Cryostor® CS10 and cryopreserved. In some embodiments, the desired concentration comprises 2.5><106CAR+ cells / mL. In some embodiments, the desired concentration comprises 1.0* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 1.5 *106CAR+ cells / mL. In some embodiments, the desired concentration comprises 2.0* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 2.5* IO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 3.0><106CAR+ cells / mL. In some embodiments, the desired concentration comprises 3.5* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 4.0* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 4.5 xlO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 5.0xl06CAR+ cells / mL. In someAttorney Docket No.: 063384-525001WOembodiments, the desired concentration comprises 5.5 xlO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 6.0* IO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 6.5* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 7.0* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 7.5 *106CAR+ cells / mL. In some embodiments, the desired concentration comprises 8.0* IO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 8.5* IO6CAR+ cells / mL. In some embodiments, the desired concentration comprises 9.0* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 9.5* 106CAR+ cells / mL. In some embodiments, the desired concentration comprises 10.0* 106CAR+ cells / mL.RECOMBINANT POLYNUCLEOTIDES ENCODING CARS

[0223] As described above, the methods described herein involve transducing a population of cells with one or more recombinant polynucleotides encoding three chimeric antigen receptors or alternatively “CARs”. As used herein, the term “CAR” refers to a class of synthetic receptors encoded by one or more polypeptides including at least the following functional domains: an extracellular antigen-binding domain, a transmembrane domain or a hinge and transmembrane domain, and an intracellular or cytoplasmic signaling domain. When expressed in an immune cell, the CAR can provide the cell with the ability to specifically bind a target cell expressing a particular antigen, for example a cancer cell, and the ability to generate an activation signal in a non-MHC-restricted fashion (z'.e., without engaging the T cell receptor) via the intracellular signaling domain following engagement of the antigen-binding domain by its cognate antigen.

[0224] In some embodiments, a CAR includes at least an extracellular antigen binding domain, a transmembrane domain or a hinge and transmembrane domain and an intracellular or cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) including a functional signaling domain derived from one or more primary T cell activation molecules and / or one or more costimulatory molecules.

[0225] In some embodiments, the one or more recombinant polynucleotides encode an autologous CD19-specific CAR, CD20-specific CAR, and CD22-specific CAR.

[0226] In another aspect, the present disclosure describes a recombinant polynucleotide comprising a sequence encoding a polypeptide of an anti-CD19 chimeric antigen receptor (CAR), a recombinant polynucleic acid molecule comprising a sequence encoding a polypeptide of an anti-CD20 chimeric antigen receptor (CAR), and a recombinantAttorney Docket No.: 063384-525001WOpolynucleic acid molecule comprising a sequence encoding a polypeptide of an anti-CD22 chimeric antigen receptor (CAR).

[0227] In some embodiments, the recombinant polynucleotide comprises a sequence encoding a polypeptide of an anti -CD 19 CAR, an anti-CD20 C AR, and an anti-CD22 C AR.

[0228] In some embodiments, the recombinant polynucleotide comprises a sequence from 5’ to 3’ encoding an anti-CD22 CAR, an anti-CD19 CAR and an anti-CD20 CAR.

[0229] In some embodiments, the three CARs are separated by a self-cleavage site. In some embodiments, the self-cleavage site is a P2A or T2A self-cleaving peptide (also referred to as “viral ribosome skipping peptide”). These viral peptide sequences cause the ribosome to skip ahead along an mRNA transcript such that it does not make a peptide bond at the skipped position, thereby terminating translation of the upstream polypeptide. As used herein, the terms “self-cleaving peptide” and “viral ribosome skipping peptide” refer to the same virus-derived peptides and the terms are used interchangeably herein. In some embodiments, the recombinant polynucleotide comprises a polynucleotide sequence encoding the CD19- specific CAR, a polynucleotide sequence encoding the CD20-specific CAR, and a polynucleotide sequence encoding the CD22-specific CAR, wherein each CAR-encoding polynucleotide sequence is separated from the other CAR-encoding polynucleotide sequences by a sequence encoding a viral ribosome skipping peptide selected from the group consisting of a P2A peptide, a T2A peptide, an E2A peptide, and an F2A peptide.

[0230] In some embodiments, the sequence encoding an anti-CD19 CAR, the sequence encoding an anti-CD20 CAR, and the sequence encoding an anti-CD22 CAR are separated by a sequence encoding a P2A site, a T2A self-cleaving peptide, an E2A self-cleaving peptide or an F2A self-cleaving peptide.

[0231] In some embodiments, the recombinant polynucleotide comprises from 5’ to 3’, a sequence encoding the CD22-specific CAR; a sequence encoding a viral P2A ribosome skipping peptide; a sequence encoding the CD19-specific CAR; a sequence encoding a viral T2A ribosome skipping peptide; and a sequence encoding the CD20-specific CAR.

[0232] In some embodiments, the recombinant polynucleic acid molecule is a viral expression vector. In some embodiments, the viral expression vector is a lentiviral expression vector.Chimeric Antigen Receptors

[0233] As described above, each CAR contains at least an extracellular antigen binding domain, a transmembrane domain and an intracellular or cytoplasmic signaling domain (alsoAttorney Docket No.: 063384-525001WOreferred to herein as “an intracellular signaling domain”) including a functional signaling domain derived from one or more primary T cell activation molecules and / or one or more costimulatory molecules. In some embodiments, the one or more recombinant polynucleotides encode an autologous CD19-specific CAR, CD20-specific CAR, and CD22-specific CAR.CD22-specific CARs

[0234] In some embodiments, the CD22-specific CAR comprises a CD22-specific binding domain, a transmembrane domain, and an intracellular domain. In some embodiments, the CD22-specific CAR comprises a CD22-specific binding domain, a spacer, a hinge domain, a transmembrane domain, a peptide linker, and an intracellular domain.

[0235] The CD22-specific binding domain can be any molecule that binds to CD22 with sufficient affinity and specificity, and is often an antibody or an antibody derivative, such as an scFv, single domain antibody (sdAb), Fab' fragment, (Fab')2 fragment, nanobody, diabody, or the like. As used herein, “sufficient affinity and specificity” can refer to the property that, under designated conditions, binding domain binds preferentially to its particular target protein ( / .<., CD22) and does not bind in a significant amount to other proteins in a sample or subject. In certain embodiments, the anti-CD22 binding domain will have a sufficiently high binding affinity for CD22, for example, the antibody may bind CD22 with a Kd value of between IxlO'7M to 10xl0'10M. Antibody affinities may be determined, e.g., by a surface plasmon resonance based assay (such as the BIAcore® assay as described in PCT Application Publication No. W02005 / 012359); enzyme-linked immunoabsorbent assay (ELISA); and competition assays (e.g., radioimmunoassays (RIAs)). Alternatively, the anti-CD22 binding domain can be a receptor or a receptor fragment that binds specifically to CD22. The anti-CD22 binding domain can be attached to the rest of the receptor directly (covalently) or indirectly (for example, through the noncovalent binding of two or more binding partners). Antibody derivatives are molecules that resemble antibodies in their mechanism of ligand binding, and include, for example, nanobodies, duobodies, diabodies, triabodies, minibodies, F(ab')2 fragments, Fab fragments, single chain variable fragments (scFv), single domain antibodies (sdAb), and functional fragments thereof. See for example, D. L. Porter et al., N Engl J Med ( 2011) 365(8): 725-33 (scFv); E. L. Smith et al, Mol Ther (2018)26(6): 1447-56 (scFv); S. R. Banihashemi et al., Iran J Basic Med Sci (2018) 21(5):455-64 (CD19 nanobody); F. Rahbarizadeh et al Adv Drug Deliv Rev (2019) 141:41-46 (sdAb); S. M. Kipriyanov et al., Int J Cancer (1998) 77(5):763-72 (diabody); F. Le Gall etAttorney Docket No.: 063384-525001WOal., FEBS Lett (1999) 453(1-2): 164-68 (triabody); M. A. Ghetie et al., Blood (1994) 83(5): 1329-36 (F(ab')2); and M. A. Ghetie et al., Clin Cancer Res (1999) 5(12):3920-27 (F(ab')2 and Fab'). Antibody derivatives can also be prepared from therapeutic antibodies, for example without limitation, by preparing a nanobody, duobody, diabody, triabody, minibody, F(ab')2 fragment, Fab fragment, single chain variable fragment (scFv), or single domain antibody (sdAb) based on a therapeutic antibody. Antibody derivatives can also be designed using phage display techniques (see, e.g., E. Romao et al., Curr Pharm Des (2016) 22(43):6500-18).

[0236] In some embodiments, the CD22-specific binding domain is a single chain variable fragment (scFv). In some embodiments, the anti-CD22 scFv comprises an antibody heavy chain variable domain polypeptide (VH) covalently linked to an antibody light chain variable domain polypeptide (VL). In some embodiments, the anti-CD22 scFv further comprises a peptide linker disposed between the VFI and VL polypeptides. In some embodiments, the anti-CD22 scFv comprises, from N-terminus to C -terminus, a VH polypeptide, a polypeptide linker, and a VL polypeptide. In some embodiments, the anti-CD22 scFv comprises, from N-terminus to C -terminus, a VL polypeptide, a polypeptide linker, and a VH polypeptide. In some embodiments, the polypeptide linker comprises a polypeptide having the sequence GGGGS (SEQ ID NO: 22).

[0237] In some embodiments, the CD22-specific binding domain includes a VH comprising a heavy chain CDR1 (HCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR1 sequence in Table 1. In some embodiments, the CD22-specific binding domain comprises a VH that comprises an FICDRl sequence in Table 1. In some embodiments, the CD22-specific binding domain includes a VH that includes a heavy chain CDR2 (HCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR2 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes a VH that includes an HCDR2 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes a heavy chain variable region (VH) comprising a heavy chain CDR3 (HCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR3 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes a VH that includes an HCDR3 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, HCDR3) sequences as set forth in SEQ ID NOs: 4, 5, and 6, respectively. In some embodiments, the CD22-specific binding domain includes the heavy chain HCDR1, HCDR2, HCDR3 sequences as set forth in SEQ ID NOs:Attorney Docket No.: 063384-525001WO10, 11, and 12, respectively. In some embodiments, the CD22-specific binding domain includes the heavy chain HCDR1, HCDR2, HCDR3 sequences as set forth in SEQ ID NOs: 16, 17, and 18, respectively.

[0238] In some embodiments, the CD22-specific binding domain includes a VL comprising a light chain CDR1 (LCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR1 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes a VL comprising an LCDR1 sequence in Table 1. In some embodiments, the CD22-specific binding domain comprises a VL that comprises a light chain CDR2 (LCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR2 sequence in Table 1. In some embodiments, the CD22-specific binding domain comprises a VL that comprises an LCDR2 sequence in Table 1. In some embodiments the CD22-specific binding domain comprises a VL that comprises a light chain CDR3 (LCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR3 sequence in Table 1. In some embodiments, the anti-CD22 binding domain comprises a VL that comprises an LCDR3 sequence in Table 1. In some embodiments, the CD22-specific binding domain includes the light chain CDRs 1, 2, and 3 (LCDR1, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 7, 8, and 9, respectively. In some embodiments, the CD22-specific binding domain includes the light chain LCDR1, LCDR2, LCDR3 sequences as set forth in SEQ ID NOs: 13, 14, and 15, respectively. In some embodiments, the anti-CD22 binding domain includes the light chain LCDR1, LCDR2, LCDR3 sequences as set forth in SEQ ID NOs: 19, 20, and 21, respectively.

[0239] In some embodiments, the CD22-specific binding domain comprises a VII with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSS (SEQ ID NO: 2). In some embodiments, the CD22-specific binding domain comprises a VII with the sequence QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSS (SEQ ID NO: 2).

[0240] In some embodiments, the CD22-specific binding domain comprises a VL with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,Attorney Docket No.: 063384-525001WO90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequenceDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGV PSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIK (SEQ ID NO: 3). In some embodiments, the CD22-specific binding domain comprises a VL with the sequenceDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGV PSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIK (SEQ ID NO: 3).

[0241] In some embodiments, the CD22-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (FICDR1, HCDR2, HCDR3) sequences and the light chain CDRs 1, 2, and 3 (LCDR1, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 4, 5, 6, 7, 8, and 9, respectively. In some embodiments, the CD22-specific binding domain includes the heavy chain HCDR1, HCDR2, HCDR3 sequences and the light chain LCDR1, LCDR2, LCDR3 sequences as set forth in SEQ ID NOs: 10, 11, 12, 13, 14, and 15, respectively. In some embodiments, the CD22-specific binding domain includes the heavy chain HCDR1, HCDR2, HCDR3 sequences and the light chain LCDR1, LCDR2, LCDR3 sequences as set forth in SEQ ID NOs: 16, 17, 18, 19, 20, and 21, respectively.

[0242] In some embodiments, the CD22-specific binding domain is an scFv. In some embodiments, the anti-CD22 scFv comprises a peptide linker between the VFI and the VL domains. In some embodiments, the peptide linker comprises the sequence GGGGS (SEQ ID NO: 22). In some embodiments, the CD22-specific binding domain comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPG KAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIK (SEQ ID NO: 1). In some embodiments, the CD22-specific binding domain comprises the sequenceQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGAttorney Docket No.: 063384-525001WOKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIK (SEQ ID NO: 1).

[0243] In some embodiments, the antigen binding domain is a mouse anti-human CD22 binding domain. In some embodiments, the antigen binding domain is a chimeric mouse antihuman CD22 binding domain. In some embodiments, the antigen binding domain is a humanized anti-human CD22 binding domain. In some embodiments, the antigen binding domain is a fully human anti-human CD22 binding domain.TABLE 1: Exemplary anti-CD22 scFv ConstructsAttorney Docket No.: 063384-525001WO

[0244] In some embodiments, the CD22-specific binding domain is a humanized binding domain. For example, a humanized anti-CD22 binding domain may include heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and / or VL sequence has been altered to be more “human-like”, i.e., more similar to the corresponding human sequences. One type of humanized anti-CD22 binding domain is a CDR-grafted binding domain in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding non-human CDR sequences. Another type of humanized antibody is a framework region (FWR)-grafted antibody in which human FWR sequences are introduced into non-human VH and VL sequences to replace corresponding non-human FWR sequences. In some embodiments, the anti-CD22 binding domain of the CD22 CARs disclosed herein is or comprises a scFv derived from a fully human anti-CD22 antibody.

[0245] In some embodiments, the recombinant polynucleotide encodes a CD22-specific CAR comprising: (i) an extracellular domain comprising an anti-CD22 binding domain, (ii) a transmembrane domain, and (iii) a cytoplasmic domain comprising an intracellular signaling domain. In some embodiments, the polypeptide is a CD22-specific CAR comprising: (i) an extracellular domain comprising an anti-CD22 binding domain and a hinge domain from CD8a or CD28, (ii) a transmembrane domain from CD8a or CD28, and (iii) a cytoplasmic domain comprising an intracellular co-stimulatory signaling domain from 4- IBB and an intracellular signaling domain from CD3ζ. In some embodiments, the polypeptide is an anti-CD22 CAR comprising: (i) an extracellular domain comprising an anti-CD22 binding domain and a hinge domain from CD8a, (ii) a transmembrane domain from CD8a, and (iii) a cytoplasmic domain comprising an intracellular co-stimulatory signaling domain from 4-1BB and an intracellular signaling domain from CD3ζ.

[0246] In some embodiments, the linker between the anti-CD22 binding domain and the hinge domain from CD8a or CD28 comprises the sequence AAA.

[0247] In some embodiments, the hinge domain of the CD22-specific CAR is derived from CD8a. In some embodiments, the CD8a hinge domain of the CD22-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to theAttorney Docket No.: 063384-525001WOsequence TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 23). In some embodiments, the CD8a hinge domain of the CD22-specific CAR comprises the sequenceTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 23).

[0248] In some embodiments, the transmembrane domain of the CD22-specific CAR is from CD8a. In some embodiments, the CD8a tran smembrane domain of the CD22-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 24). In some embodiments, the transmembrane domain of the anti-CD22 CAR comprises the sequence IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 24).

[0249] In some embodiments, the CD22-specific CAR comprises a portion of a CD8a cytoplasmic domain. In some embodiments, the portion of a CD8a cytoplasmic domain of the anti-CD22 CAR comprises the sequence LYC.

[0250] In some embodiments, the intracellular co-stimulatory domain of the CD22-specific CAR is derived from 4-1BB. In some embodiments, the 4-1BB co-stimulatory signaling domain of the CD22-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 25). In some embodiments, the 4- IBB co-stimulatory signaling domain of the CD22-specific CAR comprises the sequence KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 25).

[0251] In some embodiments, the CD22-specific CAR comprises an intracellular signaling domain comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) or ITAM-containing signaling domain. In some embodiments, the intracellular signaling domain can be an ITAM-containing domain. In some embodiments, the ITAM-containing domain is derived from CD3ζ. In some embodiments, the intracellular signaling domain of the CD22-specific CAR is derived from CD3ζ. In some embodiments, the CD3ζ intracellular signaling domain of the CD22-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequenceRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26). In some embodiments, the CD3q intracellular signaling domain of the CD22-specific CAR comprises the sequenceAttorney Docket No.: 063384-525001WORVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26).

[0252] In some embodiments, the CD22-specific CAR comprises a signal peptide sequence derived from CD8a or GMCSFRa. In some embodiments, the signal peptide sequence is derived from GMCSFRa and comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27).

[0253] In some embodiments, the signal peptide sequence is derived from GMCSFRa and comprises the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27).

[0254] In some embodiments, the signal peptide sequence is derived from CD8a and comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28).

[0255] In some embodiments, the signal peptide sequence is derived from CD8a and comprises the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28).

[0256] In some embodiments, the CD22-specific CAR comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPG KAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG GCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR (SEQ ID NO: 29).

[0257] In some embodiments, the CD22-specific CAR comprises the sequence QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRS KWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIW GQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPG KAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQ GTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRAttorney Docket No.: 063384-525001WOKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR (SEQ ID NO: 29).

[0258] In some embodiments, the CD22-specific CAR comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVT ITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQ AEDFATYYCQQSYSIPQTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFM RPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 30).

[0259] In some embodiments, the CD22-specific CAR comprises the sequenceMLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVT ITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQ AEDFATYYCQQSYSIPQTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFM RPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 30).

[0260] In some embodiments, the CD22-specific CAR comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequenceMALPVTALLLPLALLLHAARPEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMS WVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKIEVMYPPPYL DNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVKR KKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSH RPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEAttorney Docket No.: 063384-525001WOGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 31).

[0261] In some embodiments, the CD22-specific CAR comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MLLLVTSLLLCELPHPAFLLIPEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMS WVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAED TALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIVMTQSP DSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVP DRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKIEVMYPPPYL DNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVKR KKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSH RPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNR VKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 32).CD19-specific CAR

[0262] In some embodiments, the CD19-specific CAR comprises a CD19-specific binding domain, a transmembrane domain, and an intracellular domain. In some embodiments, the CD19-specific CAR comprises a CD19-specific binding domain, a spacer, a hinge domain, a transmembrane domain, and an intracellular domain.

[0263] The CD19-specific binding domain can be any molecule that binds to CD 19 with sufficient affinity and specificity, and is often an antibody or an antibody derivative, such as an scFv, single domain antibody (sdAb), Fab' fragment, (Fab')2 fragment, nanobody, diabody, or the like. As used herein, “sufficient affinity and specificity” can refer to the property that, under designated conditions, binding domain binds preferentially to its particular target protein (z.e., CD19) and does not bind in a significant amount to other proteins in a sample or subject. In certain embodiments, the CD19-specific binding domain will have a sufficiently high binding affinity for CD 19, for example, the antibody may bind CD 19 with a Kd value of between IxlO'7to 10x1 O'10M. Antibody affinities may be determined, e.g., by a surface plasmon resonance based assay (such as the BIAcore® assay as described in PCT Application Publication No. W02005 / 012359); enzyme-linked immunoabsorbent assay (ELISA); and competition assays (e.g., radioimmunoassays (RIAs)).Attorney Docket No.: 063384-525001WOAlternatively, the anti-CD19 binding domain can be a receptor or a receptor fragment that binds specifically to CD 19. The CD19-specific binding domain can be attached to the rest of the receptor directly (covalently) or indirectly (for example, through the noncovalent binding of two or more binding partners). Antibody derivatives are molecules that resemble antibodies in their mechanism of ligand binding, and include, for example, nanobodies, duobodies, diabodies, triabodies, minibodies, F(ab')2 fragments, Fab fragments, single chain variable fragments (scFv), single domain antibodies (sdAb), and functional fragments thereof. See, for example, D. L. Porter et al., N Engl J Med ( 2011) 365(8):725-33 (scFv);E. L. Smith et al, Mol Ther (2018)26(6): 1447-56 (scFv); S. R. Banihashemi et al., Iran J Basic Med Sci (2018) 21(5):455-64 (CD19 nanobody); F. Rahbarizadeh et al Adv Drug Deliv Rev (2019) 141:41-46 (sdAb); S. M. Kipriyanov et al., Int J Cancer (1998) 77(5):763-72 (diabody);F. Le Gall et al., FEBS Lett (1999) 453(1-2): 164-68 (triabody); M. A. Ghetie et al., Blood (1994) 83(5): 1329-36 (F(ab')2); and M. A. Ghetie et al., Clin Cancer Res (1999) 5(12):3920-27 (F(ab')2 and Fab'). Antibody derivatives can also be prepared from therapeutic antibodies, for example without limitation, by preparing a nanobody, duobody, diabody, triabody, minibody, F(ab')2 fragment, Fab fragment, single chain variable fragment (scFv), or single domain antibody (sdAb) based on a therapeutic antibody. Antibody derivatives can also be designed using phage display techniques (see, e.g., E. Romao et al., Curr Pharm Des (2016) 22(43):6500-18).

[0264] In some embodiments, the CD19-specific binding domain is a single chain variable fragment (scFv). In some embodiments, the anti-CD19 scFv comprises an antibody heavy chain variable domain polypeptide (VH) covalently linked to an antibody light chain variable domain polypeptide (VL). In some embodiments, the anti-CD19 scFv further comprises a peptide linker disposed between the VH and VL polypeptides. In some embodiments, the anti-CD19 scFv comprises, from N-terminus to C-terminus, a VH polypeptide, a polypeptide linker, and a VL polypeptide. In some embodiments, the anti-CD19 scFv comprises, from N-terminus to C-terminus, a VL polypeptide, a polypeptide linker, and a VH polypeptide. In some embodiments, the polypeptide linker comprises a polypeptide having the sequence AAASGGGGSGGGGSGGGGSAL (SEQ ID NO: 33).

[0265] In some embodiments, the CD19-specific binding domain includes a VH comprising a heavy chain CDR1 (HCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR1 sequence in Table 2. In some embodiments, the CD19-specific binding domain comprises a VH that comprises an HCDR1 sequence in Table 2. In some embodiments, the CD19-specific binding domain includes a VH that includes aAttorney Docket No.: 063384-525001WOheavy chain CDR2 (HCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR2 sequence in Table 2. In some embodiments, the CD19-specific binding domain includes a VH that includes an HCDR2 sequence in Table 2.In some embodiments, the CD19-specific binding domain includes a heavy chain variable region (VH) comprising a heavy chain CDR3 (HCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR3 sequence in Table 2. In some embodiments, the CD19-specific binding domain includes a VH that includes an HCDR3 sequence in Table 2. In some embodiments, the CD19-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, HCDR3) sequences as set forth in SEQ ID NOs: 37-39, 66-68, or 72-74, respectively.

[0266] In some embodiments, the CD19-specific binding domain includes a VL comprising a light chain CDR1 (LCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR1 sequence in Table 2. In some embodiments, the CD 19-specific binding domain includes a VL comprising an LCDR1 sequence in Table 2. In some embodiments, the CD19-specific binding domain comprises a VL that comprises a light chain CDR2 (LCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR2 sequence in Table 2. In some embodiments, the CD19-specific binding domain comprises a VL that comprises an LCDR2 sequence in Table 2. In some embodiments, the CD19-specific binding domain comprises a VL that comprises a light chain CDR3 (LCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR3 sequence in Table 2. In some embodiments, the CD19-specific binding domain comprises a VL that comprises an LCDR3 sequence in Table 2. In some embodiments, the CD19-specific binding domain includes the light chain CDRs 1, 2, and 3 (LCDR1, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 40-42, 69-71, or 75-77, respectively.

[0267] In some embodiments, the CD19-specific binding domain comprises a VH with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence EVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDS YTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSS (SEQ ID NO: 35). In some embodiments, the CD19-specific binding domain comprises a VH with the sequenceEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDSAttorney Docket No.: 063384-525001WOYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSS (SEQ ID NO: 35).

[0268] In some embodiments, the CD19-specific binding domain comprises a VL with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequenceQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 36). In some embodiments, the CD19-specific binding domain comprises a VL with the sequenceQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSG IPDRFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 36).

[0269] In some embodiments, the CD19-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, HCDR3) sequences and the light chain CDRs 1, 2, and 3 (LCDR1, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 37-42, 66-71, or 72-77, respectively.

[0270] In some embodiments, the CD19-specific binding domain is an scFv. In some embodiments, the anti-CD19 scFv comprises a peptide linker between the VH and the VL domains. In some embodiments, the peptide linker comprises the sequence AAASGGGGSGGGGSGGGGSAL (SEQ ID NO: 33). In some embodiments, the CD19-specific binding domain comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequenceEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDS YTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSS SNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDE ADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 34). In some embodiments, the CD19-specific binding domain comprises the sequenceEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDS YTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSSAttorney Docket No.: 063384-525001WOSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDE ADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 34).

[0271] In some embodiments, the antigen binding domain is a mouse anti-human CD19 binding domain. In some embodiments, the antigen binding domain is a chimeric mouse antihuman CD 19 binding domain. In some embodiments, the antigen binding domain is a humanized anti-human CD 19 binding domain. In some embodiments, the antigen binding domain is a fully human anti -human CD 19 binding domain.TABLE 2: Exemplary anti-CD19 scFv ConstructsAttorney Docket No.: 063384-525001WO

[0272] In some embodiments, the recombinant polynucleic acid comprises a sequence encoding a polypeptide encoding a CD19-specific CAR comprising: (i) an extracellular domain comprising an anti-CD19 binding domain, (ii) a transmembrane domain, and (iii) a cytoplasmic domain comprising an intracellular signaling domain. In some embodiments, the polypeptide is an anti-CD19 CAR comprising: (i) an extracellular domain comprising an anti-CD19 binding domain and a hinge domain from CD8a or CD28, (ii) a transmembrane domain from CD8a or CD28, and (iii) a cytoplasmic domain comprising an intracellular costimulatory signaling domain from CD28 and an intracellular signaling domain from CD3ζ. In some embodiments, the polypeptide is a CD19-specific CAR comprising: (i) an extracellular domain comprising an anti-CD19 binding domain and a hinge domain from CD28, (ii) a transmembrane domain from CD28, and (iii) a cytoplasmic domain comprising an intracellular co-stimulatory signaling domain from CD28 and an intracellular signaling domain from CD3ζ. The anti-CD19 binding domain can be any of the anti-CD19 binding domains provided herein.

[0273] In some embodiments, the hinge domain sequence of the C D19-specific CAR comprises a hinge domain derived from CD28. In some embodiments, the CD28 hinge domain of the anti-CD19 CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43). In some embodiments, the CD28 hinge domain of the CD19-specific CAR comprises the sequence IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43).

[0274] In some embodiments, the transmembrane domain sequence of the CD19-specific CAR comprises a transmembrane domain derived from CD28. In some embodiments, the CD28 transmembrane domain of the CD19-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44). In some embodiments, the CD28 transmembrane domain of the CD19-specific CAR comprises the sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).Attorney Docket No.: 063384-525001WO

[0275] In some embodiments, the intracellular co-stimulatory signaling domain of the CD 19-specific CAR is a CD28 intracellular co-stimulatory signaling domain. In some embodiments, the CD28 intracellular co-stimulatory signaling domain of the CD19-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 45). In some embodiments, the CD28 intracellular co-stimulatory signaling domain of the CD19-specific CAR comprises the sequence RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 45).

[0276] In some embodiments, the CD19-specific CAR comprises an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) or ITAM-containing signaling domain. In some embodiments, the ITAM-containing signaling domain is a CD3ζ intracellular signaling domain. In some embodiments, the CD3ζ intracellular signaling domain of the CD19-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26). In some embodiments, the CD3ζ intracellular signaling domain of the CD19-specific CAR comprises the sequenceRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26).

[0277] In some embodiments, the CD19-specific CAR comprises a signal peptide sequence derived from CD8a or granulocyte-macrophage colony-stimulating factor receptor (GMCSFRa). In some embodiments, the CD19-specific CAR comprises a signal peptide sequence derived from CD8a. In some embodiments, the CD8a signal peptide sequence comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28). In some embodiments, the CD8a signal peptide sequence comprises the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28).

[0278] In some embodiments, the CD19-specific CAR comprises a signal peptide sequence derived from GMCSFRa. In some embodiments, the GMCSFRa signal peptide sequence comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27). In someAttorney Docket No.: 063384-525001WOembodiments, the GMCSFRa signal peptide sequence comprises the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27).

[0279] In some embodiments, the CD19-specific CAR comprises a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular costimulatory signaling domain and a CD3ζ intracellular signaling domain comprising a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequenceIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSA DAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 46). In some embodiments, the CD19-specific CAR comprises a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular costimulatory signaling domain and a CD3ζ intracellular signaling domain comprising the sequenceIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSA DAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 46).

[0280] In some embodiments, the CD19-specific CAR comprises an scFv derived from a human CD19 antibody designated 19c493, a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain together having the sequenceEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDS YTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVW GQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSS SNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDE ADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMYPPPYLDNEKSNGTIIHVKGKHLCPS PLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPG PTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLD KRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLY QGLSTATKDTYDALHMQALPPR (SEQ ID NO: 47)

[0281] In some embodiments, the CD19-specific CAR comprises a signal sequence derived from CD8a, an scFv derived from a human CD 19 antibody designated 19c493, a CD28 hingeAttorney Docket No.: 063384-525001WOdomain, a CD28 transmembrane domain, a CD28 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain together having the sequenceMALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIA WVRQRPGKGLEWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDT AMYYCARPGDILTGWAMDVWGQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSV LTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPD RFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMYPPP YLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWV RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQ GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 48).CD20-specific CAR

[0282] In some embodiments, the CD20-specific CAR comprises a CD20-specific binding domain, a transmembrane domain, and an intracellular domain.

[0283] The CD20-specific binding domain can be any molecule that binds to CD20 with sufficient affinity and specificity, and is often an antibody or an antibody derivative, such as an scFv, single domain antibody (sdAb), Fab' fragment, (Fab')2 fragment, nanobody, diabody, or the like. As used herein, the phrase “sufficient affinity and specificity” refers to the property that, under designated conditions, binding domain binds preferentially to its particular target protein (i.e., CD20) and does not bind in a significant amount to other proteins in a sample or subject. In certain embodiments, the CD20-specific binding domain will have a sufficiently high binding affinity for CD20, for example, the antibody may bind CD20 with a Kd value of between lx IO"7to 6x1 O'10M. Antibody affinities may be determined, e.g., by a surface plasmon resonance based assay (such as the BIAcore® assay described in PCT Application Publication No. W02005 / 012359); enzyme-linked immunoabsorbent assay (ELISA); and competition assays (e.g, radioimmunoassays (RIAs)). Alternatively, the CD20-specific binding domain can be a receptor or a receptor fragment that binds specifically to CD20. The CD20-specific binding domain can be attached to the rest of the receptor directly (covalently) or indirectly (for example, through the noncovalent binding of two or more binding partners). Antibody deri vatives are molecules that resemble antibodies in their mechanism of ligand binding, and include, for example, nanobodies, duobodies, diabodies, triabodies, minibodies, F(ab')2 fragments, Fab fragments, single chain variable fragments (scFv), single domain antibodies (sdAb), and functional fragmentsAttorney Docket No.: 063384-525001WOthereof. See for example, D. L. Porter et al., N Engl J Med ( 2011) 365(8):725-33 (scFv); E. L. Smith et al, Mol Ther (2018)26(6): 1447-56 (scFv); S. R. Banihashemi et al., Iran J Basic Med Sci (2018) 21(5):455-64 (CD19 nanobody); F. Rahbarizadeh et al Adv Drug Deliv Rev (2019) 141:41-46 (sdAb); S. M. Kipriyanov et al., Int J Cancer (1998) 77(5):763-72 (diabody); F. Le Gall et al., FEBS Lett (1999) 453(1-2): 164-68 (triabody); M. A. Ghetie et al., Blood (1994) 83(5): 1329-36 (F(ab')2); and M. A. Ghetie et al., Clin Cancer Res (1999) 5(12):3920-27 (F(ab')2 and Fab'). Antibody derivatives can also be prepared from therapeutic antibodies, for example without limitation, by preparing a nanobody, duobody, diabody, triabody, minibody, F(ab')2 fragment, Fab fragment, single chain variable fragment (scFv), or single domain antibody (sdAb) based on a therapeutic antibody. Antibody derivatives can also be designed using phage display techniques (see, e.g., E. Romao et al., Curr Pharm Des (2016) 22(43):6500-18).

[0284] In some embodiments, the CD20-specific binding domain is a single chain variable fragment (scFv). In some embodiments, the anti-CD20 scFv comprises an antibody heavy chain variable domain polypeptide (VH) covalently linked to an antibody light chain variable domain polypeptide (VL). In some embodiments, the anti-CD20 scFv further comprises a peptide linker disposed between the VH and VL polypeptides. In some embodiments, the anti-CD20 scFv comprises, from N-terminus to C -terminus, a VH polypeptide, a polypeptide linker, and a VL polypeptide. In some embodiments, the anti-CD20 scFv comprises, from N-terminus to C -terminus, a VL polypeptide, a polypeptide linker, and a VH polypeptide. In some embodiments, the polypeptide linker comprises a polypeptide having the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 49).

[0285] In some embodiments, the CD20-specific binding domain includes a VH comprising a heavy chain CDR1 (HCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDRl sequence in Table 3. In some embodiments, the CD20-specific binding domain comprises a VH that comprises an HCDRl sequence in Table 3. In some embodiments, the CD20-specific binding domain includes a VH that includes a heavy chain CDR2 (HCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR2 sequence in Table 3. In some embodiments, the CD20-specific binding domain includes a VH that includes an HCDR2 sequence in Table 3. In some embodiments, the CD20-specific binding domain includes a heavy chain variable region (VH) comprising a heavy chain CDR3 (HCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an HCDR3 sequence in Table 3. In some embodiments, the CD20-specific binding domain includes a VH that includes an HCDR3Attorney Docket No.: 063384-525001WOsequence in Table 3. In some embodiments, the CD20-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, HCDR3) sequences as set forth in SEQ ID NOs: 53-55, 78-80, or 84-86, respectively.

[0286] In some embodiments, the CD20-specific binding domain includes a VL comprising a light chain CDR1 (LCDR1) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR1 sequence in Table 3. In some embodiments, the CD20-specific binding domain includes a VL comprising an LCDR1 sequence in Table 3. In some embodiments, the CD20-specific binding domain comprises a VL that comprises a light chain CDR2 (LCDR2) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR2 sequence in Table 3. In some embodiments, the CD20-specific binding domain comprises a VL that comprises an LCDR2 sequence in Table 3. In some embodiments, the CD20-specific binding domain comprises a VL that comprises a light chain CDR3 (LCDR3) sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to an LCDR3 sequence in Table 3. In some embodiments, the CD20-specific binding domain comprises a VL that comprises an LCDR3 sequence in Table 3. In some embodiments, the CD20-specific binding domain includes the light chain CDRs 1, 2, and 3 (LCDR1, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 56-58, 81-83, or 87-89, respectively.

[0287] In some embodiments, the CD20-specific binding domain comprises a VH with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence EVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNG GSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDI WGQGTMVTVSS (SEQ ID NO: 51). In some embodiments, the CD20-specific binding domain comprises a VH with the sequence EVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNG GSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDI WGQGTMVTVSS (SEQ ID NO: 51).

[0288] In some embodiments, the CD20-specific binding domain comprises a VL with a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequenceDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWAAttorney Docket No.: 063384-525001WOSTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIK(SEQ ID NO: 52). In some embodiments, the CD20-specific binding domain comprises a VL with the sequenceDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIK(SEQ ID NO: 52).

[0289] In some embodiments, the CD20-specific binding domain includes the heavy chain CDRs 1, 2, and 3 (HCDR1, HCDR2, HCDR3) sequences and the light chain CDRs 1, 2, and 3 (LCDRl, LCDR2, LCDR3) sequences as set forth in SEQ ID NOs: 53-58, 78-83, or 84-89, respectively.

[0290] In some embodiments, the CD20-specific binding domain is an scFv. In some embodiments, the anti-CD20 scFv comprises a peptide linker between the VH and the VL domains. In some embodiments, the peptide linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 49). In some embodiments, the CD20-specific binding domain comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPG KGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA RKSYYGSGSPDVFDIWGQGTMVTVSS (SEQ ID NO: 50). In some embodiments, the CD20-specific binding domain comprises the sequenceDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPG KGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA RKSYYGSGSPDVFDIWGQGTMVTVSS (SEQ ID NO: 50).

[0291] In some embodiments, the antigen binding domain is a mouse anti-human CD20 binding domain. In some embodiments, the antigen binding domain is a chimeric mouse anti¬ human CD20 binding domain. In some embodiments, the antigen binding domain is a humanized anti-human CD20 binding domain. In some embodiments, the antigen binding domain is a fully human anti-human CD20 binding domain.TABLE 3: Exemplary anti-CD20 scFv ConstructsAttorney Docket No.: 063384-525001WO

[0292] In some embodiments, the recombinant polynucleic acid comprises a sequence encoding a polypeptide encoding a CD20-specific CAR comprising: (i) an extracellular domain comprising an anti-CD20 binding domain, (ii) a transmembrane domain, and (iii) aAttorney Docket No.: 063384-525001WOcytoplasmic domain comprising an intracellular signaling domain. In some embodiments, the polypeptide is a CD20-specific CAR comprising: (i) an extracellular domain comprising an anti-CD20 binding domain and a hinge domain from CD28, (ii) a transmembrane domain from CD28, and (iii) a cytoplasmic domain comprising an intracellular co-stimulatory signaling domain from CD2 and an intracellular signaling domain from CD3ζ. The anti-CD20 binding domain can be any of the anti-CD20 binding domains provided herein.

[0293] In some embodiments, the hinge domain sequence of the CD20-specific CAR comprises a hinge domain derived from CD28. In some embodiments, the CD28 hinge domain of the CD20-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43). In some embodiments, the CD28 hinge domain of the CD20-specific CAR comprises the sequence IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43).

[0294] In some embodiments, the transmembrane domain sequence of the CD20-specific CAR comprises a transmembrane domain derived from CD28. In some embodiments, the CD28 transmembrane domain of the CD20-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44). In some embodiments, the transmembrane domain of the CD20-specific CAR comprises the sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).

[0295] In some embodiments, the intracellular co-stimulatory signaling domain of the CD20-specific CAR is derived from CD2. In some embodiments, the CD2 intracellular co-stimulatory signaling domain of the CD20-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence KRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAP SHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN(SEQ ID NO: 59). In some embodiments, the CD2 intracellular co-stimulatory signaling domain of the CD20-specific CAR comprises the sequenceKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN(SEQ ID NO: 59).

[0296] In some embodiments, the CD20-specific CAR comprises an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) or ITAM-containing signaling domain. In some embodiments, the intracellular signaling domain canAttorney Docket No.: 063384-525001WObe derived from an ITAM-containing domain. In some embodiments, the ITAM-containing domain is derived from CD3ζ. In some embodiments, the intracellular signaling domain of the CD20-specific CAR is derived from CD3ζ. In some embodiments, the CD3ζ intracellular signaling domain of the CD20-specific CAR comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequenceRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 26). In some embodiments, the CD3ζ intracellular signaling domain of the CD20-specific CAR comprises the sequenceRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR (SEQ ID NO: 26).

[0297] In some embodiments, the CD20-specific CAR comprises a signal peptide sequence derived from CD8a or granulocyte-macrophage colony-stimulating factor receptor (GMCSFRa). In some embodiments, the CD20-specific CAR comprises a signal peptide sequence derived from CD8a. In some embodiments, the signal peptide sequence derived from CD8a comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28). In some embodiments, the signal peptide sequence derived from CD8a comprises the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 28).

[0298] In some embodiments, the CD20-specific CAR comprises a signal peptide sequence derived from granulocyte-macrophage colony-stimulating factor receptor (GMCSFRa). In some embodiments, the CD20-specific CAR comprises a signal peptide sequence derived from GMCSFRa. In some embodiments, the signal peptide sequence derived from GMCSFRa comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27). In some embodiments, the signal peptide sequence derived from GMSCFR a comprises the sequence MLLLVTSLLLCELPHPAFLLIP (SEQ ID NO: 27).

[0299] In some embodiments, the CD20-specific CAR comprises a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain comprising a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPAttorney Docket No.: 063384-525001WOPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAA ENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR (SEQ ID NO: 60).

[0300] In some embodiments, the CD20-specific CAR comprises a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain comprising the sequenceIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPP PGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR (SEQ ID NO: 60).

[0301] In some embodiments, the CD20-specific CAR comprises a Flag tag, an scFv derived from a human CD20 antibody designated 20c27, a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain together having the sequenceDYKDDDDKDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQ PPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQ GTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGM SWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAE DTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLWVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEEL ETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQ PQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAY KQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR (SEQ ID NO: 61).

[0302] In some embodiments, the CD20-specific CAR comprises an scFv derived from a human CD20 antibody designated 20c27, a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain together having the sequenceDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA STRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFGQGTKVEIKGGAttorney Docket No.: 063384-525001WOGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPL FPGPSKPFWVLWVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEELETRAFI VAT EERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLY NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 62).

[0303] In some embodiments, the CD20-specific CAR comprises a signal sequence derived from GMCSFRa, a FLAG tag, an scFv derived from a human CD20 antibody designated 20c27, a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3ζ intracellular signaling domain together having the sequenceMLLLVTSLLLCELPHPAFLLIPDYKDDDDKDIVMTQSPDSLAVSLGERATINCKSSQS VLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQ AEDVAVYYCQQYYSFYQTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVV RPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGR FTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSI EVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVKRKKQRSRRNDEELETRAFIRVATEERGRKPFIQIPASTPQNPATSQHPPPP PGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR (SEQ ID NO: 63).

[0304] In some embodiments, the CD20-specific CAR comprises a signal sequence derived from GMCSFRa, an scFv derived from a human CD20 antibody designated 20c27, a CD28 hinge domain, a CD28 transmembrane domain, a CD2 intracellular costimulatory signaling domain, and a CD3(^ intracellular signaling domain together having the sequenceMLLLVTSLLLCELPFIPAFLLIPDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKN YLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYC QQYYSFYQTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSC TASGFTFGDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKN SLYLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVKRAttorney Docket No.: 063384-525001WOKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSH RPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNR VKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 64).Exemplary Recombinant Polynucleotides Encoding CARs

[0305] In some embodiments, the recombinant polynucleotide described herein comprises a single polynucleic acid comprising a sequence encoding a CD22 CAR, a P2A ribosome skipping peptide, a CD 19 CAR, a T2A ribosome skipping peptide, and a CD20 CAR together having the sequence:MLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAW NWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPED TAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVT ITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQ AEDFATYYCQQSYSIPQTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFM RPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPRATNFSLLKQAGDVEENPGPMALPVTALLL PLALLLHAARPEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGL EWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDI LTGWAMDVWGQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVSAAPG QKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATL GITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMYPPPYLDNEKSNGTIIH VKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDY MNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPREGRGSLLTCGDVEENPGPMLLLVTS LLLCELPHPAFLLIPDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQ QKPGQPPKLLIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFY QTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTF GDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQM NSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPPPYLDNEKSNAttorney Docket No.: 063384-525001WOGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ IDNO: 90).

[0306] In some embodiments, the recombinant polynucleotide described herein comprises a single polynucleic acid comprising the sequence atgcttctgctcgtgacaagcctgctgctgtgcgagctgccccaccctgcctttctgctgatccctCAAGTCCAGCTGCAGCAATCTGGCCCTGGCCTGGTGAAGCCTAGCCAGACCCTGAGCCTGACATGTGCCATCAGCGGAGATTCTGTTAGCAGCAACAGCGCGGCCTGGAACTGGATCAGACAGAGCCCTAGCAGAGGACTGGAGTGGCTGGGCCGGACCTACTACAGAAGCAAGTGGTACAACGACTACGCCGTGTCCGTGAAAAGCAGAATCACCATCAACCCCGACACCAGCAAGAACCAGTTCTCCCTGCAACTGAATAGCGTCACACCCGAGGATACAGCCGTGTACTACTGCGCCAGAGAGGTTACAGGCGACCTGGAAGATGCCTTTGACATCTGGGGCCAGGGCACGATGGTGACCGTCAGTAGCGGCGGCGGAGGAAGCGACATCCAGATGACCCAATCTCCTAGCAGCCTGTCTGCCTCTGTGGGCGACAGAGTGACCATCACCTGCCGCGCCTCTCAAACAATCTGGTCCTACCTGAACTGGTATCAGCAAAGACCTGGCAAAGCCCCAAACCTGCTGATCTACGCCGCCAGCTCCCTGCAAAGCGGAGTGCCCAGCAGATTCAGCGGCCGGGGCAGCGGCACTGATTTTACCCTGACTATTTCTTCCCTGCAAGCCGAGGACTTCGCCACATACTACTGTCAGCAGAGCTACAGCATCCCTCAGACCTTCGGCCAGGGCACCAAGCTGGAAATCAAGGCGGCCGCCACAACCACCCCTGCTCCCCGCCCACCTACCCCTGCTCCTACAATCGCCTCGCAACCTCTGAGCCTGAGACCTGAGGCCTGTAGACCCGCCGCTGGCGGCGCCGTGCACACCAGAGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCACTGGCCGGCACATGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTATTGCAAGAGAGGCAGAAAGAAACTGCTGTACATCTTCAAGCAGCCTTTCATGCGGCCCGTGCAGACCACCCAGGAGGAAGATGGTTGCTCATGCCGGTTCCCCGAGGAAGAGGAAGGCGGATGTGAACTGAGAGTGAAGTTCAGCCGCTCCGCTGACGCACCCGCCTATAAACAGGGGCAGAATCAACTTTATAACGAACTGAACCTTGGAAGAAGGGAGGAATATGACGTGCTTGATAAGAGAAGAGGCAGAGATCCTGAAATGGGAGGGAAACCTCGGAGAAAAAATCCACAAGAGGGGCTCTACAATGAACTCCAGAAAGACAAGATGGCTGAAGCTTACTCTGAGATTGGAATGAAAGGGGAGCGGCGCCGGGGCAAAGGGCACGACGGATTGTACCAAGGACTCAGTACAGCTACTAAAGACACATATGACGCCCTGCATATGCAGAttorney Docket No.: 063384-525001WOGCACTGCCCCCACGGGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAAGAGAACCCCGGCCCTATGGCCTTGCCCGTGACTGCTCTGCTCCTGCCCCTCGCACTGCTGCTGCACGCCGCGAGGCCCGAAGTGCAGCTGGTCCAATCTGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATCAGCTGTAAAGCCAGCGGATATAGATTCACCAACTACTGGATCGCCTGGGTGCGGCAGCGGCCTGGCAAGGGCCTGGAATGGATGGGCAGAATCGACCCATCTGATAGCTACACCCACTACAGCCCTAGCTTCCAAGGCCACGTGACCATGAGCACAGATAAGAGCATCAGCACCGCCTACCTGCAGTGGTCCTCCCTGAAAGCTAGCGACACCGCTATGTACTACTGCGCCAGACCTGGCGACATCCTGACCGGCTGGGCTATGGATGTGTGGGGCCAGGGAACACTGGTGACAGTGTCCAGCGCTGCAGCAAGTGGAGGCGGAGGAAGTGGAGGCGGTGGTTCAGGAGGAGGAGGATCTGCTCTGCAATCTGTGCTCACACAGCCCCCCAGCGTGTCTGCCGCTCCTGGACAGAAAGTGACCATCAGCTGCAGCGGATCTAGCTCCAACATCGGCAACAACTACGTGTCCTGGTATCAGCAGCTGCCTGGCACCGCCCCTAAGCTGCTGATCTACGACAACAACAAGCGGCCATCTGGCATCCCTGATCGCTTCAGCGGCAGCAAGTCCGGCACCAGCGCCACCCTGGGAATCACCGGCCTGCAGGCCGAGGACGAAGCCGACTACTACTGTCAGAGCTACGATAGCAGCCTGAGCGGCAATTACGTGTTCGGCACAGGCACAAAGGTCACCGTGCTGATCGAGGTGATGTACCCTCCTCCTTACCTGGATAATGAGAAGTCCAACGGAACAATCATCCACGTGAAGGGCAAGCACCTGTGCCCCTCTCCTCTGTTTCCGGGCCCTTCTAAGCCCTTCTGGGTGCTGGTCGTGGTGGGCGGAGTGCTCGCTTGTTACTCTCTGCTTGTGACCGTGGCCTTCATTATCTTCTGGGTCCGCAGCAAGCGGTCCAGACTGCTGCACAGCGACTACATGAACATGACCCCTCGGAGACCTGGACCCACCAGAAAGCACTACCAGCCTTACGCCCCTCCACGCGACTTCGCCGCTTATCGCAGCCGCGTTAAATTTTCACGCAGCGCGGACGCCCCTGCGTACAAGCAGGGACAGAACCAGCTGTACAACGAGCTCAACCTGGGCCGCCGGGAGGAGTACGACGTGCTGGACAAGCGCCGGGGGCGTGATCCAGAGATGGGCGGCAAACCCCGCCGCAAGAATCCTCAGGAGGGCTTATACAACGAGCTGCAGAAGGACAAAATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGAGAGCGCCGGCGTGGAAAGGGCCATGACGGCCTCTATCAGGGTCTGTCCACCGCCACCAAGGACACCTACGACGCTCTACACATGCAGGCCTTGCCTCCGCGCGAGGGCAGAGGCAGCCTGCTGACCTGCGGCGATGTGGAGGAGAACCCCGGACCTATGCTGTTGCTTGTTACAAGCCTCCTCCTGTGCGAATTGCCTCACCCCGCATTTCTCCTGATACCCGACATCGTGATGACCCAGTCCCCAGACAGCCTGGCTGTGTCCCTGGGCGAACGGGCCACCATCAACTGCAAGAGCAGCCAGAGCGTGCTGTACAGCAGCAACAACAAGAATTACCTGGCCTGGTACCAGCAGAAACCTGGCCAGCCTCCCAAGCTGCTGATCTACTGGGCCAGCAttorney Docket No.: 063384-525001WOACCAGAGAGAGCGGAGTGCCTGATAGATTCAGCGGCAGCGGATCTGGCTCTGAT TTTACCCTGACAATCAGCAGCCTCCAGGCCGAGGACGTCGCCGTGTACTATTGTC AGCAATACTACTCCTTCTACCAAACATTCGGCCAGGGCACCAAAGTTGAAATCA AGGGAGGAGGAGGGTCTGGAGGTGGAGGAAGTGGCGGAGGGGGAAGTGAGGTG CAGCTGGTCGAGAGCGGCGGAGGCGTGGTGCGGCCTGGAGGATCTCTCAGACTG AGCTGTACCGCCAGCGGATTTACCTTCGGCGACTACGGCATGAGCTGGGTGCGCC AGGCCCCTGGCAAAGGCCTGGAATGGGTTTCCGGCATCAACTGGAACGGCGGCT CTACAGGCTACGCCGACAGCGTGAAGGGCAGATTCACCATCAGCCGGGACAACG CCAAGAATAGCCTGTACCTGCAAATGAACAGCCTGAGAGCTGAAGATACAGCTC TGTATTACTGCGCCAGAAAGTCCTACTACGGCTCTGGCAGCCCCGATGTGTTCGA CATCTGGGGCCAGGGCACAATGGTGACCGTGTCCAGCATAGAAGTAATGTACCC TCCGCCTTATCTCGATAATGAAAAAAGCAACGGGACAATTATTCATGTGAAGGG CAAGCATCTTTGTCCCTCACCGCTTTTCCCTGGACCATCAAAACCATTTTGGGTGC TCGTCGTCGTGGGAGGGGTCCTCGCCTGCTATTCTCTGTTGGTGACTGTAGCCTTT ATCATTTTTTGGGTTAAACGGAAGAAGCAGAGATCTAGACGGAACGACGAGGAA CTGGAAACCCGCGCtCACAGGGTGGCCACCGAGGAAAGAGGCAGAAAGCCACAC CAGATCCCCGCCTCAACACCTCAGAATCCCGCCACAAGCCAGCACCCCCCACCTC CTCCTGGCCATCGCAGCCAGGCCCCTAGCCACCGGCCTCCACCTCCCGGTCACAG AGTGCAGCACCAACCTCAAAAACGGCCCCCCGCTCCAAGCGGCACCCAAGTTCA CCAGCAGAAGGGCCCTCCTCTGCCTAGACCTAGAGTCCAGCCTAAGCCTCCTCAC GGCGCTGCTGAGAACAGCCTGAGCCCTTCTTCgAATCGGGTCAAATTCAGTCGCT CTGCCGATGCTCCAGCCTACAAACAAGGCCAAAACCAATTATACAATGAACTTA ATCTCGGGCGCAGGGAAGAGTACGATGTTCTCGATAAAAGGCGGGGACGCGACC CCGAAATGGGTGGAAAGCCAAGAAGGAAGAACCCGCAGGAAGGACTGTATAAT GAGTTACAAAAGGATAAGATGGCAGAGGCATATTCAGAAATCGGGATGAAGGG CGAAAGAAGAAGAGGCAAGGGACACGATGGGCTTTATCAAGGCTTAAGCACTGC AACAAAGGATACTTATGATGCACTCCATATGCAAGCTCTCCCACCTAGA (SEQ ID NO: 65).RECOMBINANT POLYNUCLEOTIDES ENCODING UNIVERSAL ALLOGENEIC CASSETTE

[0307] As described above, the methods described herein involve transducing a population of cells with one recombinant polynucleotide encoding a universal allogeneic expression cassette.Attorney Docket No.: 063384-525001WO

[0308] In some embodiments, the universal allogeneic expression cassette comprises (i) a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surface of an immune cell and optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58.

[0309] In some embodiments, the recombinant polynucleotide further includes, but is not limited to, at least one or more of an exogenous promoter, a post-transcriptional response element (PRE), and a polyadenylation signal sequence.

[0310] In some embodiments, the recombinant polynucleotide further includes, but is not limited to, a ribosome skipping sequence disposed between each cistron.

[0311] In some embodiments, the recombinant polynucleotide is tricistronic. In some embodiments, the recombinant polynucleotide is bicistronic.Reduction of TCR-CD3 Complex Expression on the cell surface

[0312] As described above, the recombinant polynucleotide encodes molecules capable of reducing TCR-CD3 complex expression on the cell surface. Selective deletion of the endogenous TCR-CD3 can be performed using any of several genome editing tools including, for example, Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR / Cas9 and related reagents, ARCUS, or base editing. Other non-limiting exemplary molecules capable of reducing TCR-CD3 complex expression on the cell surface include PEBLs, shRNAs, dominant negative mutant proteins or protein subunits targeting surface expression of TCR-CD3 complex components, and combinations thereof. In some embodiments, the TCR-CD3 complex component that has reduced expression on the surface of an engineered immune cell compared to a non-engineered immune cell comprises one or more of a TCRa / TCRalpha / TCRa, TCRp / TCRbeta / TCRb, TCRy / TCRgamma / TCRg, TCR5 / TCRdelta / TCRd, CD3y / CD3gamma / CD3g, CD35 / CD3delta / CD3d, CD3s / CD3epsilon / CD3e, or CD3ζ / CD3zeta / CD3z protein subunit.

[0313] In some embodiments, the first molecule of the universal allogeneic expression cassette comprises a dominant negative mutant TCR-CD3 complex component capable of binding an unmutated or wild-type TCR-CD3 complex component.Attorney Docket No.: 063384-525001WO

[0314] In some embodiments, the recombinant nucleic acids can include a nucleotide sequence encoding a dominant negative mutant protein subunit of the TCR-CD3 complex that reduces TCR-CD3 complex expression on the surface of an immune cell.

[0315] Dominant negative (DN) mutant proteins or polypeptides are mutant proteins or polypeptides that interfere with the normal function of the corresponding wild-type protein or wild-type protein complex. A DN mutant protein can interfere, for example, by competing with the wild-type protein for binding to other cellular components. In some embodiments, the DN mutant protein includes a mutant protein that acts as a “sink” for the wild-type protein, competes with its wild-type counterpart protein for its wild-type binding partners, and / or renders complexes including the wild-type counterpart protein inactive.

[0316] In some embodiments, the nucleotide sequence encodes two or more DN mutant proteins are operably linked together. In some embodiments, the two or more DN mutant proteins are operably linked together in tandem. In some embodiments, the two or more DN mutant proteins can be the same DN mutant protein. In some embodiments, the two or more DN mutant proteins can be different. In some embodiments, the two or more DN mutant proteins can target the same protein or protein complex. In some embodiments, the two or more DN mutant protein can target different proteins or protein complexes.

[0317] In some embodiments, the nucleotide sequence encodes a DN mutant protein that includes an additional protein localization sequence or tag. In some embodiments, the additional protein localization sequence or tag includes an endoplasmic reticulum (ER) localization tag, a Golgi apparatus (Golgi) localization sequence, a lysosome localization sequence, a plasma membrane localization sequence, a mitochondria localization sequence, a peroxisome localization sequence, a cytosolic localization sequence, and a nuclear localization sequence. In some embodiments, the protein localization sequence or tag is operably linked to the N-terminus of the DN mutant protein. In some embodiments, the protein localization sequence or tag is operably linked to the C-terminus of the DN protein.

[0318] In some embodiments, the nucleotide sequence encodes one or more PEBLs and one or more DN mutant proteins that are operably linked together. In some embodiments, the one or more PEBL and the one or more DN mutant proteins target the same protein. In some embodiments, the one or more PEBL and the one or more DN mutant proteins target different proteins.

[0319] In some embodiments, the nucleotide sequence encodes a dominant negative mutant protein subunit of the TCR-CD3 complex that associates with a TCR complex component. The TCR component of the TCR-CD3 complex comprises either a TCRa / p dimer or a TCRAttorney Docket No.: 063384-525001WO6 / y dimer. The CD3 component of the TCR-CD3 complex comprises one CD36 / s heterodimer, one CD3y / s heterodimer and one CD3 / homodimer. Exemplary DN mutant protein subunits of the TCR-CD3 complex comprise, for example, a dominant negative TCRalpha, TCRbeta, TCRgamma, TCRdelta, CD3gamma, CD3delta, CD3epsilon, or CD3zeta subunit. In some embodiments, the dominant negative mutant protein subunit of the TCR-CD3 complex includes a dominant negative mutant TCR-CD3 complex component. In some embodiments, the recombinant nucleic acid molecules comprise a nucleotide sequence encoding a dominant negative mutant TCR-CD3 complex component that binds a wild-type TCR-CD3 complex component. In some embodiments, the dominant negative mutant TCR-CD3 complex component includes a dominant negative mutant TCRalpha, TCRbeta, TCRgamma, TCRdelta, CD3gamma, CD3delta, CD3 epsilon, or CD3zeta. In some embodiments, the dominant negative mutant TCR-CD3 complex component includes a dominant negative mutant CD3 epsilon subunit. In some embodiments, the dominant negative mutant CD3epsilon subunit comprises one or more point mutations in its transmembrane domain, wherein such point mutations reduce or eliminate the ability of the dominant negative mutant CD3epsilon subunit to bind and / or interact with the TCRalpha, TCRbeta, TCRdelta, and / or TCRgamma protein subunits. In some embodiments, the dominant negative mutant TCR-CD3 complex component includes a dominant negative mutant CD3zeta subunit. In some embodiments, the dominant negative mutant CD3zeta subunit comprises one or more point mutations in its transmembrane domain, wherein such point mutations reduce or eliminate the ability of the dominant negative mutant CD3zeta subunit to bind and / or interact with the TCRalpha, TCRbeta, TCRdelta, and / or TCRgamma protein subunits.

[0320] In some embodiments, the dominant negative mutant protein subunit of the TCR-CD3 complex component further includes a ubiquitin ligase domain. Exemplary ubiquitin ligase domains are described above.

[0321] In some embodiments, the dominant negative mutant protein subunit includes a dominant negative TCRalpha subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative TCRbeta subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative TCRgamma subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative TCRdelta subunit.Attorney Docket No.: 063384-525001WO

[0322] In some embodiments, the dominant negative mutant protein subunit includes a dominant negative CD3gamma subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative CD3 delta subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative CD3 epsilon subunit. In some embodiments, the dominant negative mutant protein subunit includes a dominant negative CD3zeta subunit.

[0323] In some embodiments, the transmembrane domain of a dominant negative CD3zeta subunit includes one or more mutations relative to that of the endogenous or wild-type CD3zeta. The wild-type CD3zeta transmembrane domain comprises the sequence of LCYLLDGILFIYGVILTALFL (SEQ ID NO: 96). In some embodiments, the mutation disrupts the ionic interaction between the transmembrane domain of the dominant negative CD3zeta subunit and other endogenous or wild-type TCR-CD3 complex subunits (e.g., TCRalpha, TCRbeta, TCRdelta, or TCRgamma,). In some embodiments, the mutation in the dominant negative CD3zeta subunit is at the position designated “X” in the amino acid sequence set forth in LCYLLXGILFIYGVILTALFL (SEQ ID NO: 91). In some embodiments, the endogenous CD3zeta transmembrane domain has the sequence of SEQ ID NO: 96. In some embodiments, the dominant negative CD3zeta subunit transmembrane domain has a non-conservative mutation at the position designated “X” in SEQ ID NO: 91. In some embodiments, the endogenous CD3zeta transmembrane domain has a non-conservative mutation comprising an aspartic acid (D) at the position designated “X” in SEQ ID NO: 91. In some embodiments, the endogenous CD3zeta transmembrane domain has a non-conservative mutation comprising an arginine (R) at the position designated “X” in SEQ ID NO: 91. In some embodiments, the dominant negative CD3zeta subunit transmembrane domain has a non-conservative mutation at the position designated “K” in SEQ ID NO: 91. In some embodiments, the dominant negative CD3zeta subunit transmembrane domain has a lysine (K), alanine (A), serine (S), or arginine (R) at the position designated “X” in SEQ ID NO: 91.

[0324] In some embodiments, the transmembrane domain of a dominant negativeCD3 epsilon subunit includes one or more mutations relative to that of the endogenous CD3epsilon. In some embodiments, the mutation disrupts the ionic interaction between the transmembrane domain of the dominant negative CD3 epsilon subunit and other endogenous TCR-CD3 complex subunits (e.g., TCRalpha, TCRbeta, TCRdelta, or TCRgamma, CD3zeta, CD3gamma, or CD3delta). In some embodiments, the mutation in the dominant negative CD3epsilon subunit is at the position designated “X” in the amino acid sequence set forth inAttorney Docket No.: 063384-525001WOMSVATIVIVXICITGGLLLLVYYWS (SEQ ID NO: 92). In some embodiments, the endogenous wild-type CD3 epsilon transmembrane domain includes the sequence of SEQ ID NO: 99. In some embodiments, the endogenous wild-type CD3epsilon transmembrane domain includes an aspartic acid (D) residue at the amino acid designated X in (SEQ ID NO: 92). In some embodiments, the mutant CD3 epsilon transmembrane domain includes a nonconservative mutation at the amino acid position designated X in (SEQ ID NO: 92). In some embodiments, the dominant negative CD3 epsilon subunit transmembrane domain has a lysine (K) or alanine (A) at the position designated “X” in SEQ ID NO: 92. In some embodiments, the non-conservative dominant negative CD3 epsilon subunit transmembrane domain has a lysine (K) at the position designated “X” in SEQ ID NO: 92. In some embodiments, the nonconservative dominant negative CD3 epsilon subunit transmembrane domain has an alanine (A) at the position designated “X” in SEQ ID NO: 92.

[0325] Amino acid and nucleic acid sequences encoding certain exemplary dominant negative mutant protein subunits of the TCR-CD3 complex for use in the recombinant nucleic acids described herein are set forth in Table 4 below:Table 4: Exemplary dominant negative mutant protein subunits of the TCR-CD3 complexAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOReduction of MHC class I and MHC class II Expression on the cell surface

[0326] The recombinant polynucleotide encoding the universal allogeneic cassette also comprises molecules capable of reducing MHC class I and MHC class II expression on the surface of an immune cell.

[0327] The major histocompatibility complex (MHC) consists of a linked set of genetic loci encoding proteins involved in antigen presentation to T cells, including the MHC class I and class II glycoproteins that present antigenic peptides to the TCR-CD3 complex. MHC molecules are sometimes referred to interchangeably as human leucocyte antigen (HLA) molecules.

[0328] MHC class I molecules consist of two polypeptides, the a polypeptide and P2 microglobulin (B2M) polypeptide. The a polypeptide is polymorphic and includes a transmembrane glycoprotein encoded by the HLA class I molecules including an HLA-A, HLA-B, or HLA-C gene product. Class I MHC molecules bind and present antigenic peptides to T cells. The antigenic peptides are generated mainly from the degradation of cytosolic proteins by the proteasome. MHC class I molecules also serve as an inhibitory ligand for natural killer cells (NKs). MHC class II molecules consist of two polypeptide chains, an a and P chain. The a chain and P chain are polymorphic and both include a transmembrane glycoprotein encoded by HLA-DP, HLA-DM, HLA-DO, HLA-DQ, or HLA-DR. Class II MHC molecules bind and present peptides generated mainly from extracellular pathogens and viruses to T cells.

[0329] In a patient with an allogeneic graft, graft cells are vulnerable to elimination by the host immune system. NK and T cells of the host immune system can recognize the graft cells by their non-matching MHC class I or MHC class II molecules and mount a cytotoxic immune response. This host immune response can reduce the lifespan of an allogeneic graft in the patient.

[0330] To reduce the occurrence of host vs graft elimination in patients with allogeneic T cell grafts, the donor T cells can be engineered to reduce MHC class I and MHC class II expression on the cell surface.

[0331] In some embodiments, the recombinant nucleic acids provided herein encode a molecule capable of reducing MHC class I and MHC class II expression on the surface of anAttorney Docket No.: 063384-525001WOimmune cell. Exemplary molecules capable of reducing MHC class I and MHC class II expression on the surface of an immune cell include, without limitation, a protein expression blocker (PEBL), a dominant negative mutant protein, and an shRNA.

[0332] In some embodiments, the molecule that reduces MHC class I and MHC class II expression on the surface of an immune cell comprises a dominant negative (DN) mutant protein that regulates transcription of certain components of the MHC class I and MHC class II protein complexes. In some embodiments, such DN mutant protein reduces cell surface expression of MHC class I and MHC class II. In some embodiments, the DN mutant protein includes a B2M dominant negative protein. In some embodiments, the DN mutant protein includes an MHC class I alpha chain dominant negative protein. In some embodiments, the DN mutant protein includes an MHC class II alpha chain dominant negative protein. In some embodiments, the DN mutant protein includes an MHC class II beta chain dominant negative protein. In some embodiments, such DN mutant protein includes a DN mutant transcription factor. In some embodiments, the DN mutant transcription factor comprises a truncated version of a wild-type transcription factor that retains the ability to bind its cognate promoter but lacks the ability to drive transcription from that promoter. In some embodiments, the recombinant nucleic acids provided herein comprise a nucleotide sequence encoding a mutated Regulatory factor X5 (RFX5) (NCBINM_001025603.2, NP_001020774.1) polypeptide. In some embodiments, the mutated RFX5 polypeptide includes a truncated RFX5 polypeptide (i.e., an RFX5 DN).

[0333] The full-length amino acid sequence of RFX5 is set forth in SEQ ID NO: 247 as follows:MAEDEPDAKSPKTGGRAPPGGAEAGEPTTLLQRLRGTISKAVQNKVEGILQDVQKFS DNDKLYLYLQLPSGPTTGDKSSEPSTLSNEEYMYAYRWIRNHLEEHTDTCLPKQSVY DAYRKYCESLACCRPLSTANFGKIIREIFPDIKARRLGGRGQSKYCYSGIRRKTLVSM PPLPGLDLKGSESPEMGPEVTPAPRDELVEAACALTCDWAERILKRSFSSIVEVARFL LQQHLISARSAHAHVLKAMGLAEEDEHAPRERSSKPKNGLENPEGGAHKKPERLAQ PPKDLEARTGAGPLARGERKKSVVESSAPGANNLQVNALVARLPLLLPRAPRSLIPPI P VSPPIL APRLS SGALKVATLPLS SRAGAPPAAVPIINMILPTVPALPGPGPGPGRAPPG GLTQPRGTENREVGIGGDQGPHDKGVKRTAEVPVSEASGQAPPAKAAKQDIEDTAS DAKRKRGRPRKKSGGSGERNSTPLKSAAAMESAQSSRLPWETWGSGGEGNSAGGA ERPGPMGEAEKGAVLAQGQGDGTVSKGGRGPGSQHTKEAEDKIPLVPSKVSVIKGS RSQKEAFPLAKGEVDTAPQGNKDLKEHVLQSSLSQEHKDPKATPP.Attorney Docket No.: 063384-525001WO

[0334] Amino acid sequences of exemplary truncated RFX5 polypeptides ( / .<., RFX5 DN) for use in the recombinant nucleic acids provided herein are set forth in Table 5 below:Attorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOReduction of CD58 Expression on the Cell Surface

[0335] The recombinant polynucleotide encoding the universal allogeneic cassette also comprises a third nucleotide sequence encoding molecules capable of reducing CD58 expression on the surface of an immune cell. Non-limiting exemplary molecules capable of reducing CD58 expression on the surface of an immune cell include anti-CD58 PEBLs, dominant negative mutant proteins, or shRNAs targeting CD58 expression. PEBLs, dominant negative mutant proteins or protein subunits, or shRNAs are described above.

[0336] CD58, or lymphocyte function-associated antigen 3 (LFA-3) (NCBINP_001138294.1, NM_001144822.2), is a cell adhesion molecule expressed on T cells and antigen presenting cells (APCs), particularly macrophages. CD58 binds to CD2 (LFA-2) on T cells. This co-stimulatory interaction strengthens the adhesion and recognition between the T cells and APCs, facilitating the signal transduction necessary to trigger a robust immune response.Attorney Docket No.: 063384-525001WO

[0337] In a patient with an allogeneic graft, graft cells expressing CD58 are vulnerable to elimination by the host immune system. T cells of the host immune system can recognize CD58 on graft cells and are activated through their CD2 axis to mount a cytotoxic immune response and kill the graft cells. This host immune response reduces the lifespan and efficacy of allogeneic graft cells in a patient.

[0338] SEQ ID NO: 265 comprises the full-length amino acid sequence of human CD58: MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLW KKQKDK VAELENSEFRAF S SFKNRVYLDT VSGSLTIYNLTS SDEDEYEMESPNITDTM KFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSlYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYM NGILKCDRKPDRTK (SEQ ID NO: 265).

[0339] SEQ ID NO: 266 comprises a full-length cDNA encoding human CD58: gaacttaggg ctgcttgtgg ctgggcactc gcgcagaggc cggcccgacg agccatggtt gctgggagcg acgcggggcg ggccctgggg gtcctcagcg tggtctgcct gctgcactgc tttggtttca tcagctgttt ttcccaacaa atatatggtg ttgtgtatgg gaatgtaact ttccatgtac caagcaatgt gcctttaaaa gaggtcctat ggaaaaaaca aaaggataaa gttgcagaac tggaaaattc tgaattcaga gctttctcat cttttaaaaa tagggtttat ttagacactg tgtcaggtag cctcactatc tacaacttaa catcatcaga tgaagatgag tatgaaatgg aatcgccaaa tattactgat accatgaagt tctttcttta tgtgcttgag tctcttccat ctcccacact aacttgtgca ttgactaatg gaagcattga agtccaatgc atgataccag agcattacaa cagccatcga ggacttataa tgtactcatg ggattgtcct atggagcaat gtaaacgtaa ctcaaccagt atatatttta agatggaaaa tgatcttcca caaaaaatac agtgtactct tagcaatcca ttatttaata caacatcatc aatcattttg acaacctgta tcccaagcag cggtcattca agacacagat atgcacttat acccatacca ttagcagtaa ttacaacatg tattgtgctg tatatgaatg gtattctgaa atgtgacaga aaaccagaca gaaccaagta agtacactgc aggctgtgca ctctgtgcca gaacaacagc agccctgctg tagatgccca ttacttggga agccagattg tactcatctg ttggttgcct tgtacagtaa taagaagtaa catcagcaga tatactaacc atagtgtatt aagtaccaac tgtgtgccat gcactgcact agccactctc tgcatatcgt ttcctggaac cctctcaatg agccttgcag gaggagtatc ataccccttg cttagagaca gcgcatatga gattcataga agtcaagtga gatatcaaag tcacgttgct agtaagtgat gggctgggat ttaaatctag gtctttggac tccaagagtt atactgttaa ccactacaat acactccctc cacctcccat cccagaaaaa gttggatcag ggatagggtt cacttcagga gccagggtca gagctgggcc tgtagtcaca tataaaagat aggacacaaa cacaattagc agcagtgttg gtttaataaa ccgccgta (SEQ ID NO: 266).

[0340] In some embodiments, the recombinant polynucleotide further includes a nucleotide sequence encoding a protein expression blocker (PEBL) that reduces CD58 expression on the surface of an immune cell. The PEBL includes an scFv capable of binding CD58 (termed an “anti-CD58 scFv”). The PEBL includes an scFv capable of binding CD58 (termed an “anti-CD58 scFv”) and a protein localization sequence. In some embodiments, the anti-CD58 scFvAttorney Docket No.: 063384-525001WOcomprises a murine scFv or a humanized scFv. In some embodiments, the anti-CD58 scFv comprises an scFv derived from a human antibody. In some embodiments the anti-CD58 scFv is a humanized anti-CD58 scFv.

[0341] In some embodiments, the protein localization sequence or tag includes an endoplasmic reticulum (ER) localization sequence or tag. In some embodiments, the ER localization sequence includes the amino acid sequence LYKYKSRRSFIDEKKMP (SEQ ID NO: 275). In some embodiments, the ER localization tag consists of the amino acid sequence of SEQ ID NO: 275. In some embodiments, the ER localization sequence includes an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to SEQ ID NO: 275. In some embodiments, the ER localization tag consists of an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to SEQ ID NO: 275. In some embodiments, the ER localization sequence includes the amino acid sequence KKMP (SEQ ID NO: 276). In some embodiments, the ER localization tag consists of the amino acid sequence of SEQ ID NO: 276. In some embodiments, the ER localization sequence includes an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to SEQ ID NO: 276. In some embodiments, the ER localization tag consists of an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to SEQ ID NO: 276.

[0342] In some embodiments, the protein localization sequence or tag includes a Golgi retention sequence or tag. In some embodiments, the Golgi retention sequence includes the amino acid sequence YQRL (SEQ ID NO: 278). In some embodiments, the Golgi retention tag consists of the amino acid sequence YQRL (SEQ ID NO: 278). In some embodiments, Golgi retention sequence includes an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to SEQ ID NO: 278. In some embodiments, the protein localization sequence or tag includes a lysosome retention sequence. In some embodiments, the lysosome retention sequence includes the amino acid sequence KFERQ (SEQ ID NO: 279). In some embodiments, the lysosome retention tag consists of the amino acid sequence KFERQ (SEQ ID NO: 279). In some embodiments, theAttorney Docket No.: 063384-525001WOlysosome retention tag includes an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to SEQ ID NO: 279. In some embodiments, the protein localization sequence or tag includes an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity to a SEQ ID NO: listed in Table 6.Table 6: Exemplary Protein Localization Sequences or Tags

[0343] Amino acid sequences and / or nucleic acid sequences encoding exemplary anti-CD58 scFv and PEBL sequences for use in the recombinant nucleic acids provided herein as set forth in Tables 7, 8, 9, and 10 below:Table 7.Attorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WO

[0344] In some embodiments, the anti-CD58 scFv includes a nucleic acid sequence ofATGGATATCCTGCTGACACAGAGCCCTGCTATCCTGAGCGTGTCTCCAGGCGAGCGGGTGTCCTTCAGCTGTAGAGCCAGCCAGAGCATTGGCACCAGCATCCACTGGTAttorney Docket No.: 063384-525001WOATCAGCAGCGGACAATCGGCAGCCCCAGACTGCTGATTAAGTACGCCTCTGAGA GCATCAGCGGCATCCCTAGCAGATTCAGCGGATCTGGCTCTGGCACAGACTTCAC CCTGACCATCAACTCCGTGGAAAGCGAGGACATCGCCGACTACTACTGCCAGCA AAGCAACAGCTGGCCTTTTACCTTCGGCTCCGGAACCAAGCTGGAAATCAAGGG CAGCACATCTGGATCTGGCAAGCCCGGCAGCGGAGAAGGCTCCACCAAGGGACA AGTGCAGCTGCAGCAGAGCGGACCTGAGCTGGTGCGGCCCGGCGAGAGCGTGAA GATCAGCTGCAAGGGCAGCGGCTACACCTTCACCGACTACGCCATCCACTGGGT CAAGCAGTCTCACGCCAAGAGCCTGGAATGGATCGGCGTGATCTCTGTGCACTA CGACAAAACCAACTACAACCAGAAATTCAAGGGCAAGGCCAGCATGACCGTGG ACAAGTCCAGCTCTACAGCCTACATGGAACTGGCTAGACTGACAAGCGAGGACA GCGCTATCTACTATTGTGCCCGGAGCTTCTACTACGGCAGAGATTTTGATAATTG GGGACAGGGCACAACCCTGACCGTGTCCTCTATCTACATCTGGGCCCCACTGGCC GGCACATGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTATTGCgcggccgcatc gacaGGTTCCAGCGGCGGTGGAGGAGGATCAGGAGGATTGTACAAGTACAAAAGC AGACGCTCTTTTATAGATGAGAAGAAGATGCCG, (SEQ ID NO: 312) or a nucleic acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to SEQ ID NO: 312.

[0345] In some embodiments, the anti-CD58 scFv includes an amino acid sequence of MDILLTQSPAILSVSPGERVSFSCRASQSIGTSIHWYQQRTIGSPRLLIKYASESISGIPS RFSGSGSGTDFTLTINSVESEDIADYYCQQSNSWPFTFGSGTKLEIKGSTSGSGKPGSG EGSTKGQVQLQQSGPELVRPGESVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVI SVHYDKTNYNQKFKGKASMTVDKSSSTAYMELARLTSEDSAIYYCARSFYYGRDFD NWGQGTTLTVSSIYIWAPLAGTCGVLLLSLVITLYCAAASTGSSGGGGGSGGLYKYK SRRSFIDEKKMP (SEQ ID NO: 313) or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to SEQ ID NO: 313.

[0346] In some embodiments, the anti-CD58 scFv includes a nucleic acid sequence of ATGGATATCCTGCTGACACAGAGCCCTGCTATCCTGAGCGTGTCTCCAGGCGAGC GGGTGTCCTTCAGCTGTAGAGCCAGCCAGAGCATTGGCACCAGCATCCACTGGT ATCAGCAGCGGACAATCGGCAGCCCCAGACTGCTGATTAAGTACGCCTCTGAGA GCATCAGCGGCATCCCTAGCAGATTCAGCGGATCTGGCTCTGGCACAGACTTCAC CCTGACCATCAACTCCGTGGAAAGCGAGGACATCGCCGACTACTACTGCCAGCA AAGCAACAGCTGGCCTTTTACCTTCGGCTCCGGAACCAAGCTGGAAATCAAGGGAttorney Docket No.: 063384-525001WOCAGCACATCTGGATCTGGCAAGCCCGGCAGCGGAGAAGGCTCCACCAAGGGACA AGTGCAGCTGCAGCAGAGCGGACCTGAGCTGGTGCGGCCCGGCGAGAGCGTGAA GATCAGCTGCAAGGGCAGCGGCTACACCTTCACCGACTACGCCATCCACTGGGT CAAGCAGTCTCACGCCAAGAGCCTGGAATGGATCGGCGTGATCTCTGTGCACTA CGACAAAACCAACTACAACCAGAAATTCAAGGGCAAGGCCAGCATGACCGTGG ACAAGTCCAGCTCTACAGCCTACATGGAACTGGCTAGACTGACAAGCGAGGACA GCGCTATCTACTATTGTGCCCGGAGCTTCTACTACGGCAGAGATTTTGATAATTG GGGACAGGGCACAACCCTGACCGTGTCCTCTGGCGGCGGCAGCGGCGGCGGATC TGCCGAAAAGGACGAGCTGATCTACATCTGGGCCCCACTGGCCGGCACATGCGG CGTGCTGCTGCTGTCCCTGGTGATCACCCTGTATTGCgcggccgcatcgacaGGTTCCAGC GGCGGTGGAGGAGGATCAGGAGGATTGTACAAGTACAAAAGCAGACGCTCTTTT ATAGATGAGAAGAAGATGCCG, (SEQ ID NO:314) or a nucleic acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to SEQ ID NO: 314.

[0347] In some embodiments, the anti-CD58 scFv includes an amino acid sequence of MDILLTQSPAILSVSPGERVSFSCRASQSIGTSIHWYQQRTIGSPRLLIKYASESISGIPS RFSGSGSGTDFTLTINSVESEDIADYYCQQSNSWPFTFGSGTKLEIKGSTSGSGKPGSG EGSTKGQVQLQQSGPELVRPGESVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVI SVHYDKTNYNQKFKGKASMTVDKSSSTAYMELARLTSEDSAIYYCARSFYYGRDFD NWGQGTTLTVSSGGGSGGGSAEKDELIYIWAPLAGTCGVLLLSLVITLYCAAASTGS SGGGGGSGGLYKYKSRRSFIDEKKMP, (SEQ ID NO: 315) or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to SEQ ID NO: 315.

[0348] Amino acid sequences for certain exemplary Variable Heavy (VH) and Variable Light (VL) chains of anti-CD58 scFvs for use in the recombinant nucleic acids provided herein are set forth in Table 8 below:Attorney Docket No.: 063384-525001WOTable 8: Exemplary Variable Heavy (VH) and Variable Light (VL) Chain Sequences for Anti-CD58 Polypeptides with CDRs UnderlinedTable 9: Exemplary humanized anti-CD58 scFv sequencesAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOTable 11: Exemplary Tandem PEBL sequencesAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WO

[0349] In some embodiments, the scFv further includes a protein localization sequence or tag. Exemplary protein localization sequences or tags are described supra.

[0350] In some embodiments, the PEBL is a tandem PEBL comprising an anti-TCRalpha scFv and an anti-CD58 scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-TCRbeta scFv and an anti-CD58 scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-TCRgamma scFv and an anti- CD58 scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-TCRdelta scFv and an anti- CD58 scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-CD58 scFv and an anti-TCR scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-CD58 scFv and an anti-TCRalpha scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-CD58 scFv and an anti-TCRbeta scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-CD58 scFv and an anti-TCRgamma scFv, and the DN mutant protein is a CD3epsilon DN mutant protein. In some embodiments, the PEBL is a tandem PEBL comprising an anti-CD58 scFv and an anti-TCRdelta scFv, and the DN mutant protein is a CD3epsilon DN mutant protein.

[0351] In some embodiments, the two or more scFvs are operably connected with a linker. Exemplary linker sequences are listed in Table 16.

[0352] In some embodiments, the tandem PEBL further comprises a protein localization sequence. In some embodiments, the protein localization sequence is selected from Table 6.

[0353] In some embodiments, the DN mutant protein is selected from the DN mutant protein in Table 5. In some embodiments, the TCRalpha / beta scFv is selected from Table 3. In someAttorney Docket No.: 063384-525001WOembodiments, the CD58 scFv is selected from Table 7, 8 or 9. Exemplary sequences of tandem PEBLs are listed in Table 10, Table 11, and Table 16.

[0354] Non-limiting examples of protein localization sequences or tags include but are not limited to an endoplasmic reticulum (ER) localization tag, a Golgi apparatus (Golgi) localization tag, a lysosome localization tag, a plasma membrane localization tag, a mitochondria localization tag, a peroxisome localization tag, a cytosolic localization tag, and a nuclear localization tag. The protein localization sequence or tag can be operably linked to the N-terminus of a protein-binding domain. The protein localization sequence or tag can be operably linked to the C-terminus of a protein-binding domain. The protein localization sequence or tag can be selected from the sequences in Table 6.Reduction ofMHC class I - CD8 Interaction

[0355] The recombinant polynucleotide encoding the universal allogeneic cassette can also optionally comprise a fourth nucleotide sequence encoding a fourth molecule capable of reducing the MHC class I --- CD8alpha interaction between graft cells and CD8 positive host T cells.

[0356] In some embodiments, the recombinant nucleic acids provided herein include a fourth nucleotide sequence encoding a CD8alpha blocker or CD8alpha inhibitor. In some embodiments, the CD8alpha blocker or CD8alpha inhibitor comprises an MHC class I binder ( / .<., a protein domain capable of binding MHC class I, or a synthetic MHC class I binder).

[0357] In some embodiments, the CD8alpha inhibitor comprises from N to C terminus an MHC class I binder, a linker, and a B2M or fragment thereof. In some embodiments, the CD8alpha inhibitor comprises a CD8alpha extracellular domain or a fragment thereof. In some embodiments, the CD8alpha inhibitor comprises from N to C terminus a CD8alpha extracellular domain and a B2M or fragment thereof. In some embodiments, the CD8alpha inhibitor additionally comprises a linker. In some embodiments, the CD8alpha inhibitor comprises from N to C terminus a CD8alpha extracellular domain or a fragment thereof, a linker, and a B2M or fragment thereof. Exemplary linkers are listed in Table 16.

[0358] In some embodiments, the MHC class I binder comprises a sequence set forth in SEQ ID NOs: 371or 372. In some embodiments, the MHC class I binder comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NOs: 371 or 372.Attorney Docket No.: 063384-525001WO

[0359] Exemplary amino acid and nucleic acid sequences for CD8 blockers are shown inTable 12A-12B.Table 12A. Amino Acid Sequences for exemplary constructs for universal vectors withCD8 BlockersTable 12B. Nucleic Acid Sequences for exemplary constructs for universal vectors withCD8 BlockersAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WO

[0360] In some embodiments, the CD8alpha inhibitor comprises a sequence set forth in SEQ ID NOs: 366, 367, 370-372. In some embodiments, the CD8alpha inhibitor comprises a sequence set forth in SEQ ID NOs: 366, 367, 370-372 and a B2M. In some embodiments, the CD8alpha inhibitor comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NOs: 366, 367, 370-372.

[0361] In some embodiments, the CD8alpha inhibitor comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequenceSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGASWLFQPRGAAASPTFLLYLNQNKP KAAEGLDTQRF SGKRLGDTF VLTLSDFRRENEGYYFC S ALSNSIMYF SHF VPVFLP A SEQ ID NO: 373. In some embodiments, the CD8alpha inhibitor comprises the sequence of SEQ ID NO: 373.

[0362] In some embodiments, the CD8alpha inhibitor is encoded by a nucleic acid sequence comprising the sequence of TCTCAATTTCGAGTGTCCCCTCTGGACAGAACCTGGAACCTGGGCGAGACAGTGG AACTGAAATGCCAGGTGCTGCTGTCTAATCCTACCAGCGGCGCTAGCTGGCTGTT CCAGCCTAGAGGCGCCGCTGCTTCTCCAACCTTCCTGCTGTATCTGAACCAGAAC AAGCCCAAGGCCGCCGAGGGACTGGACACCCAGCGGTTCAGCGGCAAGCGGCTG GGAGATACCTTCGTGCTCACCCTGAGCGACTTCAGACGCGAAAACGAGGGCTAC TACTTCTGCAGCGCCCTGTCCAACAGCATCATGTACTTTAGCCACTTCGTCCCCGT GTTCCTGCCTGCC (SEQ ID NO: 374).Attorney Docket No.: 063384-525001WOEmbedded shRNA

[0363] In another aspect, the recombinant polynucleotides can include a promoter having an intron, wherein the intron comprises one or more embedded shRNAs. In some embodiments, the shRNA is a single shRNA. In some embodiments, the shRNA is a multiplexed shRNA comprising two, three, four, five, or more shRNAs. Exemplary multiplexed shRNAs are described below.

[0364] In some embodiments, the promoter having an intron comprises an EF-1 alpha, an hUbC, or an MNDU3 promoter. In some embodiments, a nucleotide sequence encoding one or more shRNAs to reduce one, two, or three of TCR-CD3 complex expression, MHC class I and MHC class II expression and / or CD58 expression on the surface of an immune cell comprises one or more shRNA coding sequences embedded in an intron of the promoter. In some embodiments, the promoter can be an EF-1 alpha promoter. In some embodiments, the promoter can be a hUbC promoter. In some embodiments, the promoter can be an MNDU3 promoter. In some embodiments, the promoter and the intron sequence are from the same promoter. In some embodiments, the promoter and the intron sequence are from different promoters. In some embodiments, the promoter is an MNDU3 promoter and the intron sequence is from an EF-1 alpha promoter.

[0365] In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a CD3zeta-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a FasR-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a B2M-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a CIITA-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a CD3 epsilon-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a Trac-specific shRNA. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a CD58-specific shRNA. In some embodiments the shRNA coding sequence embedded in an intron of a promoter sequence comprises one or more shRNAs selected from the shRNAs listed in Table 13A-13B.Table 13A: Exemplary shRNAs targeting the TCR-CD3 complexAttorney Docket No.: 063384-525001WOTable 13B: Exemplary shRNA constructs targeting the TCR-CD3 complex

[0366] In some embodiments the shRNA coding sequence embedded in an intron of a promoter sequence comprises a shRNA selected from the shRNAs listed in Table 14.

[0367] In some embodiments the shRNA coding sequence embedded in an intron of a promoter sequence comprises a shRNA selected from the shRNAs listed in Table 15.Attorney Docket No.: 063384-525001WO

[0368] In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence listed in Table 13, Table 14, or Table 15.

[0369] The shRNA coding sequence embedded in an intron of a promoter sequence can be flanked by additional sequences that can enhance shRNA processing in the cell. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence can include a mirE microRNA scaffold sequence. In some embodiments, the shRNA coding sequence embedded in an intron of a promoter sequence can include a mirl55 microRNA scaffold sequence. Exemplary shRNA coding sequences embedded in mirE and mirl55 scaffold sequences are listed in Tables 14 and 15.

[0370] The embedded shRNA can be flanked by an intronic region from a promoter. In some embodiments, the embedded shRNA comprises an intronic sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence listed in Table 14, or Table 15

[0371] Exemplary promoter sequences, microRNA scaffold regions, shRNA coding sequences embedded in an intron of a promoter sequence and related sequences that are useful in the recombinant nucleic acids disclosed herein include those in Table 14 and Table 15 below.Table 14: Exemplary Sequences for embedded shRNAAttorney Docket No.: 063384-525001WOMultiplexed shRNA

[0372] In another aspect, the recombinant nucleic acids provided herein can further include multiplexed shRNAs. Multiplexed shRNAs can comprise 2, 3, 4, 5 or more shRNAs that are expressed from the same promoter.

[0373] In some embodiments, the multiplexed shRNAs comprise 2, 3, 4, 5 or more shRNAs targeting one or more genes. In some embodiments, the recombinant nucleic acids provided herein further comprise multiplexed shRNAs embedded in an intron of a promoter sequence.

[0374] In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a CD3zeta-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a FasR-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a B2M-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a CIITA-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a CD3epsilon-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a TRAC-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA embedded in an intron of a promoter sequence comprises a CD58-specific shRNA coding sequence. In some embodiments, the multiplexed shRNA comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence listed in Table 13, Table 14, or Table 15. In some embodiments, the multiplexed shRNA comprises a sequence listed in Table 13, Table 14, or Table 15. In some embodiments, the multiplexed shRNA comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,Attorney Docket No.: 063384-525001WO94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence according to SEQ ID NOs: 391-401.Table 15: Exemplary sequences for multiplexed shRNAAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOLinkers

[0375] In another aspect, provided herein are linkers useful in the recombinant polynucleotide encoding the universal allogeneic cassette.

[0376] In some embodiments, the linker includes a sequence with at least 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a linker sequence in Table 16. In some embodiments, the linker comprises a linker with a sequence set forth in Table 16.Table 16: Exemplary linker sequencesAttorney Docket No.: 063384-525001WOPromoters

[0377] In another aspect, provided herein are certain expression control sequences useful for expressing the recombinant polynucleotides encoding the universal allogeneic cassette. Nonlimiting exemplary embodiments of the recombinant polynucleotides of the disclosure can include one or more of the following features.

[0378] In some embodiments, any of the recombinant polynucleotides can be operably linked, e.g., placed under the control of, other structural elements (e.g., promoter sequences) required for expression of such recombinant nucleic acids in host cells, in subjects, or in ex-vivo cell-free expression systems.

[0379] As used herein, the terms “promoter” and “promoter sequence” are used interchangeably to refer to a DNA sequence that promotes the expression of a protein coding open reading frame or a nucleotide sequence encoding a functional RNA (e.g., an shRNA). Those skilled in the art understand that different promoters direct gene expression in different tissues or cell types, at different stages of development, or in response to different environmental or physiological conditions.

[0380] In some embodiments, the nucleotide sequences encoding nucleic acids or proteins to reduce one, two, three, or more of TCR-CD3 complex expression, MHC class I and MHC class II expression, and / or CD58 expression on the surface of an immune cell can be operably linked to a single promoter sequence. In some embodiments, each of the nucleotide sequences encoding nucleic acids or proteins to reduce one or more of TCR-CD3 complex expression, MHC class I and MHC class II expression, and / or CD58 expression on the surface of an immune cell can be operably linked a promoter sequence.

[0381] In some embodiments, the recombinant nucleic acids provided here, comprising one, two, three, or more nucleotide sequences encoding nucleic acids or proteins to reduce one, two, three, or more of TCR-CD3 complex expression, MHC class I and MHC class II expression and / or CD58 expression on the surface of an immune cell can be operably linkedAttorney Docket No.: 063384-525001WOto two different promoter sequences. In some embodiments, the first and second nucleic acid nucleotide sequences can be operably linked to a first promoter sequence and the third nucleotide sequence is operably linked to a second promoter sequence. In some embodiments, the second and third nucleotide sequences can be operably linked to a first promoter sequence and the first nucleotide sequence is operably linked to a second promoter sequence. In some embodiments, the first, second, and third nucleotide sequences can be operably linked to the same promoter sequence. In some embodiments, the first and third nucleotide sequences can be operably linked to a first promoter sequence and the second nucleotide sequence is operably linked to a second promoter sequence. In some embodiments, the nucleotide sequences encoding nucleic acids or proteins to reduce one, two, three, or more of TCR-CD3 complex expression, MHC class I and MHC class II expression and / or CD58 expression on the surface of an immune cell can be each operably linked to a different promoter sequence. In some embodiments, two or more promoter sequences each can be operably linked to a nucleotide sequence in the same direction. In some embodiments two or more promoter sequences each can be operably linked to a nucleotide sequence in opposite directions. In some embodiments, a first promoter can be operably linked to a nucleotide sequence encoding an shRNA and a second promoter can be operably linked to nucleotide sequences encoding the polypeptides. In some embodiments, the first promoter sequence can be operably linked to a nucleotide sequence encoding a polypeptide and the second promoter sequence can be operably linked to a nucleotide sequence encoding an shRNA.

[0382] In some embodiments, the single promoter sequence is selected from the group consisting of a MND promoter, an MNDU3 promoter, an EF-lalpha promoter, a core EFlalpha promoter, an hUbC promoter, a PGK promoter, a U6 promoter, a SFFV promoter, and an NFkB-responsive promoter. In some embodiments, the single promoter sequence is selected from the group consisting of a MND promoter, an MNDU3 promoter, an EF-lalpha promoter, a core EF-lalpha promoter, an hUbC promoter, a PGK promoter, a U6 promoter, a SFFV promoter, and an NFkB-responsive promoter and the first, second, and third nucleic acid sequence are under the control of the single promoter. In some embodiments, the single promoter sequence is an MNDU3 promoter. In some embodiments, the single promoter sequence is an EF-lalpha promoter. In some embodiments, the single promoter sequence is a core EF-lalpha promoter. In some embodiments, the single promoter sequence is an hUbC promoter. In some embodiments, the single promoter sequence is a PGK promoter. In some embodiments, the single promoter is a U6 promoter. In some embodiments, the singleAttorney Docket No.: 063384-525001WOpromoter sequence is a SFFV promoter. In some embodiments, the single promoter sequence is an NFkB -responsive promoter.

[0383] In some embodiments, the first promoter sequence is selected from the group consisting of a MND promoter, an MNDU3 promoter, an EF-lalpha promoter, a core EFlalpha promoter, an hUbC promoter, a PGK promoter, a U6 promoter, a SFFV promoter, and an NFkB-responsive promoter. In some embodiments, the second promoter is selected from the group consisting of a MND promoter, an MNDU3 promoter, an EF-lalpha promoter, a core EF-lalpha promoter, an hUbC promoter, a PGK promoter, a U6 promoter, a SFFV promoter, a CAG promoter, a CBA promoter, a Gamma Retro 5’ LTR promoter, and an NFkB-responsive promoter. In some embodiments, the third promoter is selected from the group consisting of a MND promoter, an MNDU3 promoter, an EF-lalpha promoter, a core EF-lalpha promoter, an hUbC promoter, a PGK promoter, a U6 promoter, a SFFV promoter, a CAG promoter, a CBA promoter, a Gamma Retro 5’ LTR promoter, and an NFkB-responsive promoter. In some embodiments, the first, second, or third promoter can be an MND promoter. In some embodiments, the first, second, or third promoter can be an MNDU3 promoter. In some embodiments, the first, second, or third promoter can be an hUbC promoter. In some embodiments, the first, second, or third promoter can be an EF-lalpha promoter. In some embodiments, the first, second, or third promoter can be a core EF-lalpha promoter. In some embodiments, the first, second, or third promoter can be an SFFV promoter. In some embodiments, the first, second, or third promoter can be an NFkB-responsive promoter. In some embodiments, the first, second, or third promoter can be U6 promoter. In some embodiments, the first, second, or third promoter can be CAG promoter. In some embodiments, the first, second, or third promoter can be CBA promoter. In some embodiments, the first, second, or third promoter can be Gamma Retro 5’ LTR promoter.

[0384] Table 17 provides certain exemplary promoter sequences for use in the recombinant nucleic acids described herein:Table 17: Exemplary Promoter SequencesAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAttorney Docket No.: 063384-525001WOAdditional Elements

[0385] In another aspect, the recombinant nucleic acids provided herein further comprise additional regulatory elements. In some embodiments, the additional regulatory element can be a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) sequence, an insulator sequence, a polyA sequence, and / or an LTR sequence. In some embodiments, the recombinant nucleic acids provided herein further comprise a polyadenylation (PolyA) signal. In some embodiments, the polyadenylation signal includes a simian virus 40 (SV40),Attorney Docket No.: 063384-525001WOa-globin, P-globin, a human growth hormone (hGH), a bovine growth hormone (BGH), a herpes simplex virus type 1, a thymidine kinase (HSV TK), or a synthetic polyadenylation (Synt poly A) polyadenylation signal.

[0386] In some embodiments, the WPRE is a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence a nucleic acid sequence comprising SEQ ID NO: 430.AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATG TTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATT GCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTT TATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTG CTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGG GACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTC GGGGAAGCTGACGTCCTTTCCGGGGCTGCTCGCCTGTGTTGCCACCTGGATTCTG CGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTC CCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAAA CGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC (SEQ ID NO: 430).

[0387] In some embodiments, the insulator is a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence a nucleic acid sequence comprising SEQ ID NO: 431.Gagctcacggggacagccccctcccaaagcccccagggatgtaattacgtccctcccccgctagggggcagcagcgagccgccc ggggctccgctccggtccggcgctccccccgcatccccgagccggcagcgtgcggggacagcccgggcacggggaaggtggca cgggatcgctttcctctgaacgcttctcgctgctctttgagcctgcagacacctggggggatacggggaaaaagctt (SEQ ID NO: 431).

[0388] In some embodiments, the recombinant nucleic acids can include one or more coding sequences for ribosome skipping sequences or autoproteolytic peptide sequences.

[0389] In some embodiments, the recombinant nucleic acid can additionally include one or more ribosome skipping sequences located between the first, second, and / or third nucleotide sequence. Exemplary ribosome skipping sequences are described supra.

[0390] In some embodiments, the coding sequence for a polypeptide construct in the recombinant nucleic acids described herein can include one or more molecular alterations. Exemplary types of molecular alterations in the coding sequences described herein can beAttorney Docket No.: 063384-525001WOone or more of deletions, substitutions, insertion, duplications, mutations, frameshift variants, splice variants, and combinations of any thereof.

[0391] A coding sequence for a polypeptide construct can be a construct of genetic material that includes coding sequences and enough regulatory information to direct proper transcription and / or translation of the coding sequences in a cell, in vivo and / or ex vivo. The coding sequence for a polypeptide construct can be inserted into a vector for targeting to a desired host cell and / or into a subject. Accordingly, in some embodiments, the term “coding sequence for a polypeptide construct” can be used interchangeably with the term “expression construct.” In some embodiments, a coding sequence for a polypeptide construct can be a nucleic acid construct that includes a gene encoding a protein or functional RNA operably linked to regulatory elements such as, for example, a promoter and / or a termination signal, and optionally, any or a combination of other nucleic acid sequences that affect the transcription or translation of the gene.Exemplary Recombinant Polynucleotides Encoding Universal Allogeneic Cassettes

[0392] In some embodiments, the recombinant nucleic acids can include two or more nucleotide sequences arranged in a bi-cistronic, tri-cistronic, or multi-cistronic configuration expressed via one or more promoter sequences. In some embodiments, the individual nucleotide sequences in the bi-cistronic, tri-cistronic, or multi-cistronic configuration are separated by one or more ribosome skipping sequences disposed between each individual nucleotide sequence.

[0393] The term “ribosome skipping sequence” as used herein refers to certain virus-derived peptide sequences that induce ribosomal skipping during translation resulting an apparent cleavage of a polypeptide sequence. Consequently, ribosome skipping sequences are sometimes interchangeably referred to as “self-cleaving” peptides. Exemplary ribosome skipping sequences include, but are not limited to, the F2A peptide derived from foot-and-mouth disease virus, the E2A peptide derived from equine rhinitis A virus, the P2A peptide derived from porcine teschovirus-1, the T2A peptide derived from thosea asigna virus, and the Furin cleavable P2A sequence. In some embodiments, the F2A peptide sequence includes the amino acid sequence VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 432), the E2A sequence includes the amino acid sequence QCTNYALLKLAGDVESNPGP (SEQ ID NO: 433), the T2A sequence includes the amino acid sequence EGRGSLLTCGDVEENPGP (SEQ ID NO: 434), the P2A sequence includes the amino acid sequence ATNFSLLKQAGDVEENPGP (SEQ ID NO: 435), and the Furin cleavable P2A sequenceAttorney Docket No.: 063384-525001WOincludes the amino acid sequence RAKRGSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 436).

[0394] In some embodiments, the T2A sequence is encoded by the nucleic acid sequence GAGGGCAGAGGCTCCCTTCTCACGTGCGGAGATGTCGAGGAAAATCCAGGACCC(SEQ ID NO: 437) or GAGGGCAGAGGCAGCCTGCTGACCTGCGGCGATGTGGAGGAGAACCCCGGACCT(SEQ ID NO: 438).

[0395] In some embodiments, the P2A sequence is encoded by the nucleic acid sequence GCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAAGAGAACCCCGGC OCT (SEQ ID NO: 439).

[0396] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is tricistronic and encodes, from 5’ end to 3’ end, a mutated RFX5, a 2A ribosome skipping sequence, a 54mer MFIC class I binder fused to B2M, a 2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, a CD3z shRNA, and an RFX5 shRNA.

[0397] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 440 below ATGGCCGAAGATGAGCCCGACGCTAAGAGCCCTAAGACCGGCGGCAGAGCCCCT CCAGGAGGCGCCGAGGCTGGAGAGCCTACAACACTGCTGCAACGGCTGAGAGGC ACAATCAGCAAGGCCGTGCAGAACAAGGTGGAAGGCATCCTGCAAGATGTTCAG AAGTTCAGCGACAACGACAAACTGTACCTGTACCTGCAGCTGCCCTCCGGCCCTA CCACCGGCGATAAGAGCAGCGAGCCTAGCACCCTGTCTAATGAAGAATATATGT ACGCCTACAGATGGATCAGAAACCACCTGGAAGAGCACACCGACACCTGTCTGC CCAAACAGAGCGTCTACGACGCCTATAGAAAGTACTGCGAGAGCCTGGCCTGCT GCAGACCTCTGAGCACCGCTAATTTCGGCAAGATCATCCGGGAAATCTTCCCTGA TATCAAGGCCCGGAGACTGGGAGGCAGAGGCCAGAGCAAGTACTGCTACAGCG GCATCCGGAGAAAAACACTGGTTTCTATGCCTCCTCTGCCTGGACTGGACCTGAA GGGCAGCGAGTCCCCTGAGGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGA CGTGGAAGAGAACCCCGGCCCTATGGCACTGCCAGTCACTGCTCTGCTTCTGCCC CTGGCCCTGCTGCTACACGCCGCTCGTCCCGACGAGGAACGCGCCCTGATTCTGG AGATCCACCAGCTGCAGCTGCAGGCCGCACGCTTGGCCGGCGAGAGGGCCGCCC TGCCTCAGACCCAGGCCCTGCTGGCTCGGATCAGAGCCCGCATCGCCGCTCTGAG AGCCAGACTGCGGGCGCTGGAGGCCGCTGGCGGTGGAGGTTCAGGAAGTACCAGAttorney Docket No.: 063384-525001WOCGGTTCTGGCAAACCCGGGTCCGGAGAGGGGTCAACAAAGGGCGGTGGTGGAGGCTCTATCCAGAGAACACCTAAGATCCAGGTGTACAGCAGACACCCAGCCGAGAACGGCAAGAGTAACTTCCTGAACTGCTACGTTTCCGGCTTCCACCCATCTGATAT CGAGGTGGACCTGCTGAAGAACGGAGAGAGAATCGAGAAGGTGGAACACAGCGATCTGTCCTTCAGCAAGGACTGGAGCTTCTACCTGCTGTACTACACCGAGTTCACCCCTACAGAGAAAGACGAGTACGCCTGTAGAGTGAACCACGTTACCTTGTCCCA ACCTAAAATCGTCAAGTGGGACAGGGACATGGAGGGCAGAGGCTCCCTTCTCACGTGCGGAGATGTCGAGGAAAATCCAGGACCCATGCTGCTGCTCGTGACCAGCCTGCTGTTGTGCGAGCTGCCCCACCCCGCTTTTCTGCTGATTCCCGAGATTGTGCTGACCCAGTCTCCAGACTTCCAGTCCGTCACACCTAAAGAGAAGGTGACCATCACCTGTAGAGCCTCTCAGTCGATTGGCACCAGCATCCACTGGTATCAGCAGAAGCCCGATCAGTCCCCGAAGCTGCTGATTAAGTACGCCAGCGAGAGCATCAGCGGCATCCCCAGCCGCTTCAGCGGCTCCGGGTCTGGTACCGACTTCACCCTGACAATCAACTCCCTGGAGGCCGAGGACGCGGCTACCTACTACTGCCAGCAAAGCAACAGCTGGCCTT TTACCTTCGGCGGCGGAACTAAGCTGGAAATCAAGGGCAGCACATCTGGATCTGGCAAGCCCGGCAGCGGAGAAGGCTCCACCAAGGGACAGGTGCAGCTGGTCCAGTCTGGCGCCGAGGTCAAGAAGCCTGGCGCATCTGTCAAAGTGTCCTGCAAGGCCAGCGGCTACACCTTTACCGACTACGCCATCCACTGGGTGCGGCAGGCTCCCGGACAAGGTCTGGAGTGGATCGGCGTGATCTCCGTGCACTACGATAAGACCAACTACAA C C AG A AGT T C A AGG GC AG AGT G AC CAT G AC C GT GG AC AC C A GT ATTTCCACT GC CTACATGGAACTGAGCAGGCTGAGAAGCGACGATACAGCCGTGTACTACTGTGCGCGCAGCTTCTATTACGGGCGCGACTTCGACAACTGGGGCCAGGGCACCACCGTAACAGTGTCCTCTGGCGGCGGCAGCGGCGGCGGATCTGATAAGAACATCGGCTCTGATGAGGATCACCTGTCTCTGAAGGAGTTCAGCGAGCTGGAGCAGAGCGGTTATTACGTGTGTTACCCTCGGGGCAGCAAGCCTGAGGACGCCAATTTCTACCTGTACCTTAGAGCCAGAGTGTGCGAGAACTGCATGGAAATGGATGTGATGAGCGTGGCC ACCATCGTGATTGTGAAAATCTGCATCACCGGCGGCCTGCTCCTGCTGGTGTACTACTGGTCCAAGAACAGAAAGGCTAAAGCCAAGCCCTTGTACAAGTACAAAAGCA GACGCTCTTTT AT AGATGAGA AG AAGATGCCGtaaggatccgccgccagaacacaggtaagtgccgt gtgtggttcccgcTCGACTTCTTAACCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCGATGGTGTCATTCTCACTGCCTTTAGTGAAGCCACAGATGTAAAGG CAGTGAGAATGACACCAGTGCCTACTGCCTCGGACTTCAAGGGGCTACTTTAGGActggaggcttgctgaaggctgtatgctg AAC AGT ACC ATCTCCCTGAC CgttttggccactgactgacGGTCAttorney Docket No.: 063384-525001WOAGGGATGGTACTGTTcaggacacaaggcctgttactagcactcacatggaacaaatggcccaagtggttcaaagttttttt cttccatttcaggtgtcgtga

[0398] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette is bicistronic and encodes, 5’ end to 3’ end, a mutated RFX5, a T2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, and a CD3z shRNA.

[0399] In some embodiments, the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 441ATCGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTAGTTTT GACTCAACAATATCACCAGCTGAAGCCTATAGAGTACGAGCCATAGATAGAATA AAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTGTAG GTTTGGCAAGCTAGGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCA AACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGTT GGAACAGCAGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCC GGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCCGCCCTCAGCAGTTT CTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGT GCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTCGCGCGCTTCTGC TCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGCGCGATCTAGATCTC GAATCGAATTCctcgagccgccaccATGGCCGAAGATGAGCCCGACGCTAAGAGCCCTA AG AC C GGC GGC A G A GC C C C T C C A GG AG GC GC C G AG GC T GG A G AGC C T AC A AC A CTGCTGCAACGGCTGAGAGGCACAATCAGCAAGGCCGTGCAGAACAAGGTGGA AGGCATCCTGCAAGATGTTCAGAAGTTCAGCGACAACGACAAACTGTACCTGTA CCTGCAGCTGCCCTCCGGCCCTACCACCGGCGATAAGAGCAGCGAGCCTAGCAC CCTGTCTAATGAAGAATATATGTACGCCTACAGATGGATCAGAAACCACCTGGAAGAGCACACCGACACCTGTCTGCCCAAACAGAGCGTCTACGACGCCTATAGAAA GTACTGCGAGAGCCTGGCCTGCTGCAGACCTCTGAGCACCGCTAATTTCGGCAAG ATCATCCGGGAAATCTTCCCTGATATCAAGGCCCGGAGACTGGGAGGCAGAGGC CAGAGCAAGTACTGCTACAGCGGCATCCGGAGAAAAACACTGGTTTCTATGCCT CCTCTGCCTGGACTGGACCTGAAGGGCAGCGAGTCCCCTGAGGAGGGCAGAGGC TCCCTTCTCACGTGCGGAGATGTCGAGGAAAATCCAGGACCCATGCTGCTGCTCG TGACCAGCCTGCTGTTGTGCGAGCTGCCCCACCCCGCTTTTCTGCTGATTCCCGA GATTGTGCTGACCCAGTCTCCAGACTTCCAGTCCGTCACACCTAAAGAGAAGGTG ACCATCACCTGTAGAGCCTCTCAGTCGATTGGCACCAGCATCCACTGGTATCAGC AGAAGCCCGATCAGTCCCCGAAGCTGCTGATTAAGTACGCCAGCGAGAGCATCAAttorney Docket No.: 063384-525001WOGCGGCATCCCCAGCCGCTTCAGCGGCTCCGGGTCTGGTACCGACTTCACCCTGAC AATCAACTCCCTGGAGGCCGAGGACGCGGCTACCTACTACTGCCAGCAAAGCAACAGCTGGCCTTTTACCTTCGGCGGCGGAACTAAGCTGGAAATCAAGGGCAGCAC ATCTGG ATCTGGC A AGCCCGGC AGCGG AG AAGGCTCC ACC A AGGG AC AGGT GCA GCTGGTCCAGTCTGGCGCCGAGGTCAAGAAGCCTGGCGCATCTGTCAAAGTGTC CTGCAAGGCCAGCGGCTACACCTTTACCGACTACGCCATCCACTGGGTGCGGCA GGCTCCCGGACAAGGTCTGGAGTGGATCGGCGTGATCTCCGTGCACTACGATAA GACCAACTACAACCAGAAGTTCAAGGGCAGAGTGACCATGACCGTGGACACCAG TATTTCCACTGCCTACATGGAACTGAGCAGGCTGAGAAGCGACGATACAGCCGT GTACTACTGTGCGCGCAGCTTCTATTACGGGCGCGACTTCGACAACTGGGGCCAGGGCACCACCGTAACAGTGTCCTCTGGCGGCGGCAGCGGCGGCGGATCTGATAAGAACATCGGCTCTGATGAGGATCACCTGTCTCTGAAGGAGTTCAGCGAGCTGGAG CAGAGCGGTTATTACGTGTGTTACCCTCGGGGCAGCAAGCCTGAGGACGCCAATTTCTACCTGTACCTTAGAGCCAGAGTGTGCGAGAACTGCATGGAAATGGATGTG ATGAGCGTGGCCACCATCGTGATTGTGAAAATCTGCATCACCGGCGGCCTGCTCCTGCTGGTGTACTACTGGTCCAAGAACAGAAAGGCTAAAGCCAAGCCCTTGTACA AGTACAAAAGCAGACGCTCTTTTATAGATGAGAAGAAGATGCCGtaaggatccgccgcca gaacacaggtaagtgccgtgtgtggttcccgcTCGACTTCTTAACCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCGATGGTGTCATTCTCACTGCCTTTAGTGAAGCC ACAGATGTAAAGGCAGTGAGAATGACACCAGTGCCTACTGCCTCGGACTTCAAG GGGC T ACTTT AGGAagtggttcaaagtttttttcttccatttcaggtgtcgtgagT C GAC A ATC A ACC T C T GGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGC TTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTG GCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCC ACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCC CCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACA GGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGT CCTTTCCGGGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTC TGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCC TTTGGGCCGCCTCCCCGCPHARMACEUTICAL COMPOSITIONSAttorney Docket No.: 063384-525001WO

[0400] In some embodiments, the allogeneic CAR-expressing immune cells of the disclosure can be formulated as compositions, including pharmaceutical compositions. Such compositions generally include the allogeneic CAR-expressing immune cells as described herein and a pharmaceutically acceptable carrier. Accordingly, one aspect of the present disclosure is related to pharmaceutical compositions comprising a population of allogeneic C AR-expressing immune cells made according to the methods described herein.

[0401] The pharmaceutical compositions generally include a therapeutically effective amount of cells. By “therapeutically effective amount” is meant a number of cells sufficient to produce a desired result, e.g., an amount sufficient to effect beneficial or desired therapeutic (including preventative) results, such as a reduction in a symptom of a disease (e.g., cancer) or disorder associated, e.g., with the target cell or a population thereof (e.g., cancer cells), as compared to a control. An effective amount can be administered in one or more administrations. The amount of allogeneic CAR-expressing immune cells that comprises a “therapeutically effective amount” may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the cells to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the cells are outweighed by the therapeutically beneficial effects. The term “therapeutically effective amount” includes an amount that is effective to “treat” an individual, e.g., a patient. When a therapeutic amount is indicated, the precise amount of the compositions contemplated in particular embodiments to be administered, can be determined by a physician in view of the specification and with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (individual).

[0402] The allogeneic CAR-expressing immune cells of the present disclosure can be incorporated into a variety of formulations for therapeutic administration. More particularly, the allogeneic CAR-expressing immune cells of the present disclosure can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable excipients or diluents.

[0403] Formulations of the cells suitable for administration to a patient (e.g., suitable for human administration) are generally sterile and may further be free of detectable pyrogens or other contaminants contraindicated for administration to a patient according to a selected route of administration.Attorney Docket No.: 063384-525001WO

[0404] The cells may be formulated for parenteral (e.g., intravenous, intra-arterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrathecal, subcutaneous, etc.) administration, or any other suitable route of administration.

[0405] Pharmaceutical compositions that include the cells of the present disclosure may be prepared by mixing the cells having the desired degree of purity with optional physiologically acceptable carriers, excipients, stabilizers, surfactants, buffers and / or tonicity agents.Acceptable carriers, excipients and / or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid, glutathione, cysteine, methionine and citric acid; preservatives (such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, or combinations thereof); amino acids such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof; monosaccharides, disaccharides and other carbohydrates; low molecular weight (less than about 10 residues) polypeptides; proteins, such as gelatin or serum albumin; chelating agents such as EDTA; sugars such as trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-methylglucosamine, galactosamine, and neuraminic acid; and / or non-ionic surfactants such as Tween, Brij Pluronics, Triton-X, or polyethylene glycol (PEG).

[0406] An aqueous formulation of the recombinant polypeptides, proteases, nucleic acids, expression vectors, and / or cells may be prepared in a pH-buffered solution, e.g., at pH ranging from about 7.0 to 8.0, 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively about 5.5. Examples of buffers that are suitable for a pH within this range include phosphate-, histidine-, citrate-, succinate-, acetate-buffers and other organic acid buffers. The buffer concentration can be from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending, e.g., on the buffer and the desired tonicity of the formulation.

[0407] A tonicity agent may be included in the formulation to modulate the tonicity of the formulation. Exemplary tonicity agents include sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars as well as combinations thereof. In some embodiments, the aqueous formulation is isotonic, although hypertonic or hypotonic solutions may be suitable. The term “isotonic” denotes a solution having the same tonicity as some other solution with which it is compared, such as physiological salt solution or serum. Tonicity agents may be used in an amount of about 5 mM to about 350 mM, e.g., in an amount of 100 mM to 350 mM.Attorney Docket No.: 063384-525001WO

[0408] In some embodiments, a surfactant may also be added to the formulation to reduce aggregation and / or minimize the formation of particulates in the formulation and / or reduce adsorption. Example surfactants include polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene- polyoxypropylene copolymer (Poloxamer, Pluronic), and sodium dodecyl sulfate (SDS). Examples of suitable polyoxyethylenesorbitan-fatty acid esters are polysorbate 20, (sold under the trademark Tween 20™) and polysorbate 80 (sold under the trademark Tween 80™). Examples of suitable polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188™. Examples of suitable Polyoxyethylene alkyl ethers are those sold under the trademark Brij™. Exemplary concentrations of surfactant may range from about 0.001% to about 1% w / v.

[0409] In some instances, the pharmaceutical composition includes allogeneic CAR-expressing immune cells of the present disclosure, and one or more of the above-identified agents (e.g., a surfactant, a buffer, a stabilizer, a tonicity agent) and is essentially free of one or more preservatives, such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof. In other embodiments, a preservative is included in the formulation, e.g., at concentrations ranging from about 0.001 to about 2% (w / v). In some embodiments, the pharmaceutical composition comprises the harvested population of cells comprising allogeneic CAR-expressing immune cells resuspended to the desired concentration in Final Formulation Medium comprising Plasma-Lyte A® +4% (w / v) HSA, diluted 1:1 with Cryostor® CS10 and frozen.METHODS OF TREATMENT

[0410] Administration of any one of the therapeutic compositions described herein, e.g., a pharmaceutical composition comprising a therapeutically effective amount of allogenic CAR- expressing immune cells, can be used in the prevention and / or treatment of relevant health conditions, such as proliferative diseases (e.g., cancer). Further disclosed here include methods for preventing and / or treating a disease, disorder, or health condition in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of CAR-expressing immune cells as disclosed herein, wherein the pharmaceutical composition comprising a therapeutically effective amount of allogeneic CAR-expressing immune cells is administered to the subject individually as a single therapy (monotherapy) or as a first therapy in combination with at least one additional therapies (e.g., second therapy).Attorney Docket No.: 063384-525001WO

[0411] As used herein, the terms “treat”, “treatment” and “treating” refer to the administration of a drug or therapeutic resulting in a reduction or amelioration of the progression, severity and / or duration of a disorder (e.g., a neoplastic disorder such as cancer), or the amelioration of one or more symptoms (e.g., one or more discernible symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as an allogeneic CAR-expressing immune cell as provided herein) into a subject in need thereof, e.g., a patient.

[0412] In some embodiments, the health condition is a cancer, e.g, a hematologic cancer. In some embodiments, the administered allogeneic CAR-expressing immune cells or the pharmaceutical composition is administered to or provide anti -tumor immunity to the subject. In some embodiments, the first therapy and the second therapy are administered concomitantly. In some embodiments, the first therapy is administered at the same time as the second therapy. In some embodiments, the first therapy and the second therapy are administered sequentially. In some embodiments, the first therapy is administered before the second therapy. In some embodiments, the first therapy is administered after the second therapy. In some embodiments, the first therapy is administered before and / or after the second therapy. In some embodiments, the first therapy and the second therapy are administered in rotation. In some embodiments, the first therapy and the second therapy are administered together in a single formulation.

[0413] The allogeneic CAR-expressing immune cells and pharmaceutical compositions of the disclosure can be administered alone or in combination with other agents (e.g., an antibody or an antigen binding fragment thereof, or a molecule). In some embodiments, a vaccine, an oncoloytic virus, a checkpoint inhibitor, a T cell agonist antibody, chemotherapy, and / or a bispecific antibody can be combined with the pharmaceutical composition disclosed herein. In some instances, the pharmaceutical composition is administered with other cells (e.g, CAR T cells or other adoptively transferred T cells). Administration “in combination with” one or more additional therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order. In some embodiments, the one or more additional therapeutic agents, chemotherapeutics, anti-cancer agents, or anti-cancer therapies is selected from the group consisting of chemotherapy, radiotherapy, immunotherapy, hormonal therapy, toxin therapy, and surgery. “Chemotherapy” and “anti-cancer agent” are used interchangeably herein. Various classes of anti-cancer agents can be used. Non-limiting examples of anti-cancer agents include: alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, podophyl lotoxin, antibodies (e.g., monoclonal orAttorney Docket No.: 063384-525001WOpolyclonal), checkpoint inhibitors, immunomodulators, cytokines, nanoparticles, radiation therapy, tyrosine kinase inhibitors (for example, imatinib mesylate), hormone treatments, soluble receptors and other antineoplastics.

[0414] In some instances, the disease, disorder, or condition is cancer. The term “cancer” can refer to a disease characterized by the presence of cells possessing several characteristics typical of cancer-causing cells, such as uncontrolled growth / proliferation of cells (e.g., aberrant cells). Cancer cells can but do not always aggregate into a mass, such as a tumor, or can exist alone within a subject. Cancers for treatment with the manufactured drug products of the present disclosure include liquid cancers (e.g., cancer of myeloid cells (e., myeloma) or B cells (e.g, diffuse large B cell lymphoma). Examples of various cancers are described herein and include but are not limited to, lymphoma and leukemia. The term “cancer” encompasses liquid, e.g, diffuse or circulating, tumors. As used herein, the term “cancer” includes premalignant, as well as malignant cancers and tumors.

[0415] In some instances, the cancer is lymphoma or leukemia. In some instances, the disease, disorder, or condition is a hyperproliferative disorder. Hyperproliferative disorders include cancers and hyperplasia characterized by the unregulated overgrowth of cells.Hyperproliferative disorders frequently display loss of genetic regulatory mechanisms and may express native proteins inappropriately (including expression of proteins from other cell types or developmental stages, expression of mutated proteins, and expression of proteins at levels higher or lower than normal).

[0416] B-cell hyperproliferative disorders include B-cell leukemias and lymphomas such as, but not limited to, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell prolymphocytic leukemia, precursor B lymphoblastic leukemia, hairy cell leukemia, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, Burkitt’s lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, Waldenstrom’s macroglobulinemia, and / or other disorders characterized by the overgrowth of B-lineage cells.

[0417] In some embodiments, the B-cell hyperproliferative disorder is a lymphoma. In some embodiments, the lymphoma is selected from a group consisting of diffuse large B cell lymphoma (DLBCL), large B cell lymphoma (LBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Burkitt’s lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T cell lymphoma, and Hodgkin lymphoma. In some embodiments, the lymphoma is large B cell lymphoma. In some embodiments, the B-cell hyperproliferative disorder is a leukemia. In some embodiments, the leukemia is selectedAttorney Docket No.: 063384-525001WOfrom a group consisting of acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia (ALL), B cell acute lymphocytic leukemia (B-ALL), B cell acute lymphoblastic leukemia IB- ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), B cell prolymphocytic leukemia (B-PLL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), hairy cell leukemia (HCL), juvenile myelomonocytic leukemia (JMML), large granular lymphocytic leukemia (LGLL), and T cell prolymphocytic leukemia (T-PLL). In some embodiments, the leukemia is ALL or B-ALL. In some embodiments, the leukemia is pediatric ALL or B-ALL.

[0418] In some embodiments, the cancer is a relapsed cancer. The term “relapse” as used herein refers to reappearance of a disease (e.g., cancer) after an initial period of remi ssion or response to an anti-cancer treatment, e.g., after prior treatment with a therapy, e.g., cancer therapy (e.g., complete response or partial response). The initial period of responsiveness may involve the level of cancer cells falling below a certain threshold, e.g., below 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or below the limit of detection. The reappearance may involve the level of cancer cells rising above a certain threshold, e.g., above 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, e.g., in the context of B-ALL, the reappearance may involve, e.g., a reappearance of blasts in the blood, bone marrow (BM) (>5%), or any extramedullary site, after a complete response. A complete response, in this context, may involve <5% blasts in the bone marrow. In some embodiments, a response (e.g., complete response or partial response) can involve the absence of detectable disease (e.g., MRD, or minimal residual disease). In some embodiments, the initial period of responsiveness lasts at least 1, 2, 3, 4, 5, or 6 days; at least 1, 2, 3, or 4 weeks; at least 1, 2, 3, 4, 6, 8, 10, or 12 months; or at least 1, 2, 3, 4, or 5 years.

[0419] In some embodiments, the cancer is a refractory cancer. “Refractory” as used herein refers to a cancer that does not respond to a treatment. In embodiments, a refractory cancer can be resistant to a treatment before or at the beginning of the treatment. In other embodiments, the refractory cancer can become resistant during a treatment. A refractory cancer is also called a resistant cancer.Administration of pharmaceutical compositions comprising allogeneic CAR-expressing immune cells to a subject

[0420] Methods for administering pharmaceutical compositions comprising allogeneic CAR-expressing immune cells for the treatment of cancer, e.g., hematological cancers, are knownAttorney Docket No.: 063384-525001WOand may be used in connection with the provided methods and compositions. For example, adoptive T cell therapy methods are described in US 2003 / 0170238; US 4690915; S. A.Rosenberg, Nat Rev Clin Oncol (2011) 8( 10): 577-85. See also M. Themeli et al., Nat Biotechnol (2013) 3 l(10):928-33; and T. Tsukahara etal., Biochem Biophys Res Commun (2013) 438(l):84-89.

[0421] In some embodiments, this administering step can be accomplished using any method of delivery known in the art. For example, the allogeneic CAR-expressing immune cells can be infused intravenously directly into the subject’s bloodstream or otherwise administered to the subject.

[0422] The step of administering, which term is used interchangeably with the terms “introducing,” implanting,” and “transplanting,” allogeneic CAR-expressing immune cells into an individual, by a method or route such that a desired effect(s) is / are produced. The allogeneic CAR-expressing immune cells or their differentiated progeny can be administered by any appropriate route for the disease being treated that results in at least a portion of the administered cells or components of the cells remaining viable. The period of viability of the cells after administration to a subject can be as short as a few hours, e.g., twenty-four hours, to a few days, to as long as several years, or even the lifetime of the individual, e.g., long¬ term engraftment.

[0423] When provided therapeutically in some embodiments, allogeneic CAR-expressing immune cells are provided at (or after) the onset of a symptom or indication of a disease or health condition, e.g., upon the onset of disease or health condition.

[0424] For use in the various embodiments, e.g., the pharmaceutical compositions, described herein, a therapeutically effective amount of allogeneic CAR-expressing immune cells, e.g., T cells, as disclosed herein, can be at least 25* 106cells, at least 30* 106cells, at least 35* 106cells at least 40* 106cells, at least 50* 106cells, at least 55* 106cells, at least 60* 106cells, at least 65* 106cells, at least 70* 106cells, at least 75* 106cells, at least 80* 106cells, at least 85* 106cells, at least 90* 106cells, at least 95><106cells, at least 100x106cells, at least 105xl06cells, atleast HOxlO6cells, atleast H5x106cells, atleast 120xl06cells, at least 125xl06cells, atleast 130x]06cells, atleast 135xl06cells, atleast 140xl06cells, at least 145xio6cells, or at least 150xl06cells.

[0425] In some embodiments, the pharmaceutical compositions include a therapeutically effective amount of allogeneic CD22 / CD20 / CD19 CAR T cells as disclosed herein, which can be at least 25xl06cells, at least 30x l06cells, at least 35xl06cells at least 40xl06cells, at least 50xl06cells, at least 55xl06cells, at least 60xl06cells, at least 65xl06cells, at leastAttorney Docket No.: 063384-525001WO70* 106cells, at least 75* 106cells, at least 80* 106cells, at least 85* 106cells, at least 90* 106cells, at least 95 x ] o6cells, at least 100* 106cells, at least 105x]06cells, at least HOxlO6cells, at least 115x l06cells, at least 120xl06cells, at least 125x l06cells, at least 130xl06cells, at least 135xlObcells, at least 140x] 06cells, at least 145xl06cells, or at least 150xl06cells.

[0426] A pharmaceutical composition comprising a therapeutically effective amount of allogeneic CAR-expressing immune cells can be administered by any appropriate route that results in effective treatment in the subject, e.g., administration results in delivery to a desired location in the subject where at least a portion of the composition delivered, e.g., at least IxlO5cells, at least 25xl06cells, at least 30xl06cells, at least 35xl06cells at least 40xl06cells, at least 50x]06cells, at least 55xl06cells, at least 60xl06cells, at least 65x]06cells, at least 70xl06cells, at least 75xl06cells, at least 80xl06cells, at least 85xl06cells, at least 90xl06cells, at least 95x]O6cells, at least lOOxlO6cells, at least 105x] 06cells, at least HOxlO6cells, at least 115xl06cells, at least 120x l06cells, at least 125xl06cells, at least 130x l06cells, at least 135xl06cells, at least 140x l06cells, at least 145xl06cells, or at least 150x 106cells, is delivered to the desired site for a period of time. For the delivery of cells, delivery by injection or intravenous infusion is often considered a standard mode of administration.

[0427] In some embodiments, the allogeneic CAR-expressing immune cells are administered systemically, e.g., via intravenous infusion or injection.

[0428] The efficacy of a treatment including any of the compositions provided herein for the prevention or treatment of a disease or health condition can be determined by a skilled clinician. However, one skilled in the art will appreciate that a prevention or treatment is considered effective if any one or all of the signs or symptoms or markers of disease are improved or ameliorated. Efficacy can also be measured by failure of a subject to worsen as assessed by decreased hospitalization or need for medical interventions e.g., progression of the disease is halted or at least slowed). Methods of measuring these indicators are known to those of skill in the art and / or described herein. Treatment includes any treatment of a disease in a subject or an animal (some non-limiting examples include a human, or a mammal) and includes: (1) inhibiting the disease, e.g., arresting, or slowing the progression of symptoms; or (2) relieving the disease, e.g., causing regression of symptoms, slowing tumor growth or otherwise reducing tumor burden; and (3) preventing or reducing the likelihood of the development of symptoms.Attorney Docket No.: 063384-525001WO

[0429] Measurement of the degree of efficacy is based on parameters selected with regard to the disease being treated and the symptoms experienced. In general, a parameter is selected that is known or accepted as correlating with the degree or severity of the disease, such as a parameter accepted or used in the medical community. For example, in the treatment of a hematological cancer, suitable parameters can include number of months of progression-free survival, overall survival, stage or grade of the disease, the rate of disease progression, and combinations thereof. It will be understood that the effective dose and the degree of efficacy will generally be determined with relation to a single subject and / or a group or population of subjects. Therapeutic methods of the disclosure reduce symptoms and / or disease severity and / or disease biomarkers by at least about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% as compared to a reference subject that has not been administered with the allogeneic CAR-expressing immune cells of the disclosure.

[0430] As discussed above, a therapeutically effective amount of a pharmaceutical composition can be an amount of the pharmaceutical composition that is sufficient to promote a particular beneficial effect when administered to a subject, such as one who has, is suspected of having, or is at risk for a disease or health condition. In some embodiments, an effective amount includes an amount sufficient to prevent or delay the development of a symptom of the disease or health condition, alter the course of a symptom of the disease or health condition (for example but not limited to, slow the progression of a symptom of the disease), or reverse a symptom of the disease or health condition.EXAMPLES

[0431] The practice of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which are known to those skilled in the art. Such techniques are explained fully in the literature cited herein.

[0432] Additional embodiments are disclosed in further detail in the following examples, which are provided by way of illustration and are not in any way intended to limit the scope of this disclosure or the claims.EXAMPLE 1 - THAW AND ENRICHMENT

[0433] Thaw. Cryopreserved leukapheresis was received from the vendor in aliquots of 30 -70 mL and formulated in 5% v / v dimethyl sulfoxide, 2% HSA, and Isolyte-S. The manufacturing process begins by thawing cryopreserved leukapheresis bag(s) in a BarkeyAttorney Docket No.: 063384-525001WOPlasmatherm set to 36-38°C for 4 minutes ± 30 seconds on the Thaw + Motion setting. At 4 minutes, the cryopreserved leukapheresis bag was checked for thaw progression, and additional thawing increments of 30 seconds were applied, as necessary, until a small amount of ice crystals remained in the bag. The thawed leukapheresis was then processed based on the CD4+ and CD8+ T Cell Enrichment methods described below.

[0434] T cell Enrichment via Positive Selection. For CD4+ and CD8+ T Cell Enrichment via positive selection on the Miltenyi Prodigy®, thawed leukapheresis was diluted with 100 mL Complete T Cell Media (Prime-XV T Cell CDM + 12.5ng / mL IL-7 + 12.5ng / mL IL-15). Diluted, thawed leukapheresis was then sampled and counted for enumeration using the NC-200, Viability and Cell Count - Blood Assay, Solution 17, and the Via-2 Cassette. The CliniMACS Prodigy® TS 520 (Cat # 200-073-613), CliniMACS® CD4 Reagent (Cat # 200-070-213), and CliniMACS® CD8 Reagent (Cat # 200-070-215) were used with the Prodigy® T Cell Transduction (TCT) protocol to enrich 500* 106to 4,000* 106total viable cells as a mixture of CD4+ and CD8+ T Cells in Complete T Cell Media. Briefly, CD4+ and CD8+ cells were loaded on the CliniMACS® Prodigy® for co-enrichment of CD4+ and CD8+ cells based on thawed apheresis cell density value at time of thaw. Within the closed CliniMACS® Prodigy® system, following the pre-defined TCT protocol, the cells were washed with CliniMACS® PBSZEDTA buffer + 2% (v / v) or 0.5% (w / v) HSA, co-labeled with CliniMACS® CD4 and CD8 selection reagents (Miltenyi), and co-enriched via an integrated magnetic cell selection column. Upon protocol completion, CD4+ and CD8+ enriched T Cells were sampled and enumerated using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol and the Via-2 Cassette. CD4+ and CD8+ enriched T Cells can also be sampled for CD4+ and CD8+ purity analysis and cellular impurity analysis via the ALL-in-One (Allo) spectral flow cytometry panel (described below), immune cell subset flow cytometry panel, or other cellular protein identification assay.

[0435] All-in-One Spectral Flow Cytometry. Spectral flow cytometry is a powerful analytical tool for detailed immunophenotypic analysis. This technology provides valuable insights into immune responses, product characterization, and development.

[0436] The Allo Spectral Panel, developed using the Cytek Aurora Flow Cytometer, includes high-complex 17-color marker that predominantly focuses on T cells subsets. It covers various aspects, including T cell activation, memory subsets and Allo CAR-T cells. This comprehensive panel allows for in-depth assessment of CAR-T cell therapy, encompassing in vitro product characterization and product attributes from the healthy donor samples.Attorney Docket No.: 063384-525001WO

[0437] This panel is designed to quantify the Allo Construct TCRaP KD, MHC-I / II KD, CD58 KD and CD3 KD. Additionally, it detects memory phenotype and the CD19 CAR, CD20 CAR and CD22 CAR all within the single panel as outlined in the table below.Table 18. Allo Spectral PanelAttorney Docket No.: 063384-525001WO

[0438] To prepare the cells for the spectral flow cytometry, 15 mL Falcon tubes were prepared with 9 mL of room temperature Cell Staining Buffer (CSB). The cells were thawed in a 37°C water bath until a small ice crystal remained.

[0439] The defrosted cell material was then transferred to the 15 ml falcon tube filled with 9 ml of CSB drop by drop. The residual cells were rinsed from the vial and the remaining volume was added to the tube. 200 pL of cell suspension was taken for cell counts on NC-200 using a Via2-cassette using the appropriate cell counting method.

[0440] Next, the cells were spun at 300xg for 3 minutes. The supernatant was discarded, and the cells were resuspended to 5* 106viable cells / ml with room temperature PBS based on the cell counts.

[0441] 100 pL of cells were then transferred into the 96-well U-bottom plate for 0.5* 106cells / well. 100 pL of PBS was added, and the cells were resuspended. The cells were then spun at 300xg for 3 minutes. The supernatant was discarded, and the cells were washed in 200 pL of PBS one more time. The supernatant was discarded.

[0442] 100 pL of Live / dead stain and FC block cocktail was then added, the pellet was resuspended gently, and the plate was incubated in the dark at 4°C for 20 minutes.

[0443] After the 20-minute incubation, 100 pL of CSB was added, mixed gently, and spun down at 300xg for 3 minutes. This step was repeated by resuspending the pellet in 200 pL of CSB.

[0444] The supernatant was discarded, and 100 pL of antibody cocktails was added and incubated in the dark at 4°C for 20 minutes. Next, 100 pL of CSB was added, the cells wereAttorney Docket No.: 063384-525001WOgently resuspended. The cells were then spun at 300*g for 3 minutes. The supernatant was discarded, and the step was repeated twice with 200 pL of CSB.

[0445] Enrichment via Negative Selection. For CD4+ and CD8+ T Cell Enrichment via negative selection on the Akadeum Alerion™, thawed leukapheresis must be washed and concentrated. Thawed leukapheresis was diluted with 100 mL Complete T Cell Media (Prime XV CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15) either manually prior to initiating the wash and concentration step or during the wash and concentration step on the Rotea™ Counterflow Centrifugation System. Prior to initiation of the wash and concentration step, thawed leukapheresis is sampled and counted for enumeration using the NC-200 Viability and Cell Count - Blood Assay described above. An internally developed Rotea™ Protocol was used with the CTS™ Rotea™ Single-Use Kit (Cat #s A49313, A49585) or the CTS™ Rotea™ Full Flow Single-Use Kit (Cat #s A59173, A59172) to dilute thawed leukapheresis in Complete T Cell Media (if not previous diluted), wash with Complete T Cell Media or PBS + 0.5% v / v HSA + 1 mM EDTA, and harvest into a concentration as high as 500* 106viable cells per milliliter. Upon protocol completion, washed and concentrated thawed leukapheresis was sampled for enumeration using the NC-200 Viability and Cell Count -Blood Assay described above. Additionally, a Complete Blood Count (CBC) was performed on the sample with the Sysmex Automated Hematology Analyzer (Model # XN-330) to determine the ratio of red blood cells to white blood cells used in reagent preparation for the Akadeum Alerion™ T Cell Isolation protocol.

[0446] Next, the washed and concentrated leukapheresis was prepared for CD4+ and CD8+ T Cell Enrichment via negative selection with the Akadeum® Human T Cell Leukopak Isolation Kit - GMP Grade (Cat # 13210-221 GMP). In a BioRise™, the washed and concentrated leukapheresis was mixed with the negative selection Human T Cell Leukopak Biotin Antibody Cocktail - GMP (mixture contains CD 14, CD 16, CD 19, CD20, CD36, CD56, CD123, CD235ab). Then the BACS™ Streptavidin Microbubbles - GMP were added to the mixture, and biotinylated antibodies bound to the streptavidin of the BACS™ Microbubbles. Antibody and BACS™ Microbubble-bound cells were then separated from the remaining cells via centrifugation in the Alerion™. The CD4+ and CD8+ negatively selected T Cells were then removed from the BioRise™ and sampled for enumeration using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol (internally developed) and the Via-2 Cassette.

[0447] The CD4+ and CD8+ Enriched T Cells produced from either method described above are suitable for further manufacturing in the allogeneic CAR T cell manufacturing process.Attorney Docket No.: 063384-525001WOTable 19 below and FIG. 1 shows process performance of the Prodigy® and Alerion™-based CD4+ and CD8+ T Cell Enrichment methods.Table 19. CD4+ / CD8+ Cell Enrichment from Full Donor Leukapheresis

[0448] Differences in data with respect to post enrichment total viable cells between Prodigy® and Alerion™ are shown in FIG. 1. The data demonstrate that the Prodigy® and Alerion™ are capable of producing >3.0><109CD4+ and CD8+ enriched cells

[0449] CD4+ and CD8+ cell purity was also examined after enrichment / i solation with both Alerion™ and Prodigy®. The results are shown in Table 20 below as well as FIG. 2. The data demonstrates that both the Alerion™ and Prodigy® achieved high T-cell purity.Table 20. CD4 / CD8+ Cell Purity from Full Donor Leukapheresis

[0450] Next, the percentage of cell loss was measured from day 0 post-isolation / enrichment to day 1 post-isolation / enrichment, also known as contraction, for both Alerion™ and Prodigy® methods. The results are shown in Tables 21-23 below as well as FIGs. 3-5. The results show that isolation / enrichment had a similar impact on cell recovery during isolation (Table 22 and FIG. 4) and Day 0 to Day 1 cell contraction (Table 21 and FIG. 3) for both methods.Attorney Docket No.: 063384-525001WOTable 21. Post-Isolation Cell Contraction (TVC)Table 22 - Post-Isolation Cell Recovery (% Cell Recovery)Table 23. Post-Isolation Cell Viability (%)EXAMPLE 2 - SEEDING AND ACTIVATION

[0451] Seeding. After enrichment of CD4+ and CD8+ T Cells following the methods inExample 1, enriched T cells were seeded into a G-Rex vessel for activation. Enriched T cellsAttorney Docket No.: 063384-525001WOin Complete T Cell Media (Prime XV CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15) were added to the G-Rex vessel (variable sizes) to achieve the desired viable cells per square centimeter of culture surface area. A range of 3.0* 106viable cells / cm2to 30.0* 106viable cells / cm2were shown to be capable of producing Allo CAR T cells. FIG. 6 shows that a range of seeding densities (viable cells per square centimeter) can successfully produce Allo CAR T cells when using both MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP) activation reagents. Allo CAR T Productivity was defined as the total dual transduced cells (TriCAR+ and TCRaP- as measured by flow cytometry, calculated as %Dual Transduced x Total Viable Cells) per square centimeter of culture surface area during the expansion unit operation. Allo CAR T Productivity was measured on Day 8 of the production process.

[0452] Multiple activation reagents were shown to be capable of producing Allo CAR T cells. MACS® GMP T Cell TransAct™ CR / GMP, 4mL from Miltenyi Biotec was shown to be capable of producing Allo CAR T cells in the reagent concentration range of 75* 106cells / mL of TransAct™ to 750* 106cells / mL of TransAct™. Additionally, CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP) from ThermoFisher Scientific were shown to be capable of producing Allo CAR T Cells in the reagent concentration range of 1 bead per 3 cells to 3 beads per 1 cell. Both the MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP) use CD3 / CD28 stimulation of the enriched T cells to enable gene modification and expansion. ImmunoCult™ Human CD3 / CD28 / CD2 T Cell Activator from StemCell™ Technologies can also generate Allo CAR T cells via CD3 / CD28 / CD2 stimulation when following the manufacturer's recommendations. FIG. 7 shows that a range of concentrations in both MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP) can successfully generate Allo CAR T cells.

[0453] Additional Complete T Cell Media was added to the G-Rex vessel to achieve the final activation volume as a function of G-Rex culture surface area. The ranges of final activation volume per surface area of culture vessel were 0.19 mL / cm2to 0.74 mL / cm2. FIG. 8 shows that a range of activation volumes when using both MACS® GMP T Cell TransAct™ CR / GMP and CTS™ Detachable Dynabeads™ CD3 / CD28 (GMP) can successfully generate Allo CAR T cells.

[0454] Finally, the enriched CD4+ and CD8+ cells formulated for activation were placed in an incubator at 37°C ± 2°C, 5.0% CO2 ± 3%, and 100% humidity. Activation was complete after 24 hours ± 2 hours.Attorney Docket No.: 063384-525001WOEXAMPLE 3 - DUAL TRANSDUCTION

[0455] Co-Dual Transduction. Approximately 24-hours post-activated CD4+ and CD8+ T Cells are sampled for enumeration using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol and the Via-2 Cassette.

[0456] The volume of each vector (CRG-023 / 3811; ALLO / 5126) were calculated using postactivated total viable cells counts and target MOI as calculated using Equation 1 below.Equation 1. MOI DeterminationlTU Vector Volume(mT) * Vector Titer 1 — j-1 Multiplicity of Infection (MOD = - - - — —7; - 7 - 7 — 7777 —Total Viable Cells on Day 1 (ceZZs)The volume of transduction media formulation, Complete T Cell Media (Prime XV CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15), was calculated by subtracting the target “Total Culture Volume” from the sum of the “Activation Culture Volume” plus the sum of each “vector volume”. The calculated volume of each vector was added to the culture, and Complete T Cell Media was added to reach the final transduction volume. The 24-hour postactivated CD4+ and CD8+ T Cell Culture in G-Rex vessel(s) was mixed well and transferred to an incubator set to 35-39°C, 5.0% CO2 (2 - 7%), and 100% humidity.

[0457] The transduction efficiency of dual-transduced cells was then measured. Pre-depletion refers to the frequency distributions of cells in the bulk harvest, before depletion of TCRaP+ cells. Post-depletion refers to the frequency distribution of cells that were determined to be TriCAR+ under the parent gate of TCRaP-. Results are shown in Table 24-25 below and FIG. 9Table 24. Transduction Efficiency of Dual-Transduced T Cells (Co-Transduction)Attorney Docket No.: 063384-525001WO

[0458] Serial-Dual Transduction. Approximately 24-hour post-activated CD4+ and CD8+ T Cells are sampled for enumeration using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol (internally developed) and the Via-2 Cassette.Table 25. Transduction Efficiency of Dual-Transduced T Cells (Serial-Transduction)

[0459] The volume of (CRG-023 / CAR+ 3811) vector were calculated using post-activated total viable cells counts and target MOI as shown in Equation 1 above. The volume of transduction media formulation: Complete T Cell Media (Prime XV CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15) is calculated by subtracting the target “Total Culture Volume” from the sum of the “Activation Culture Volume” plus the sum of each “vector volume”. The calculated volume of the CAR vector (3811) was added to the culture, and Complete T Cell Media was added to reach the final transduction volume, minus the volume of the second vector. The 24-hour post-activated CD4+ and CD8+ T Cell Culture in G-Rex vessel(s) was mixed well and transferred to an incubator set to 35-39°C, 5.0% CO2 (2 - 7%), and 100% humidity. The duration of the first transduction incubation process is 22 - 26 hours.

[0460] Approximately 24-hour post-CRG-023 vector addition (TriCAR+ / 3811), transduced T Cells were removed from the incubator and were sampled for enumeration using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol and the Via-2 Cassette. The volume of (ALLO-5126) vector was calculated using post-CAR+ transduced total viable cell counts, and target MOI as shown in Equation 1 above. The calculated volume of the ALLO vector (5126) was added to G-Rex vessel(s), mixed well and transferred to an incubator set to 35-39°C, 5.0% CO2 (2 - 7%), and 100% humidity. The duration of the second incubation step was 22 - 26 hours. The duration of the serial dual transduction culture process was 44 -52 hours.Attorney Docket No.: 063384-525001WO

[0461] Cell Density during Dual Transduction. Multiple cell seeding density setpoints were shown to be capable of producing Allo CAR T cells in the cell density range of 3 * 106cells / cm2to 30* 106cells / cm2. The transduction volume for these cell cultures remained static at 10 mL per well or 1 mL per square centimeter of culture surface area. Transduction efficiencies for both co-transduction and serial transduction were captured on Day 8 of the process - during the harvest unit operation and summarized in FIG. 10. The transduction efficiencies for Allo CAR T cells across the range of seeding densities under co-transduction and serial transduction are summarized in Tables 26 - Table 29 below.Table 26. Day 8 TriCAR+ Transduction Efficiency of Dual-Transduced T Cells at Titrating Cell DensitiesTable 27. Day 8 TCRa - Transduction Efficiency of Dual-Transduced T Cells at Titrating Cell DensitiesTable 28. Day 8 TriCAR+ / TCRa|J- (Pre-depletion) Transduction Efficiency of Dual-Transduced T Cells at Titrating Cell DensitiesTable 29. Day 8 TriCAR+ / TCRa|J- (Post-Depletion) Transduction Efficiency of Dual-Transduced T Cells at Titrating Cell DensitiesAttorney Docket No.: 063384-525001WO

[0462] Transduction Culture Volume during Dual Transduction. Multiple transduction culture volume setpoints were shown to be capable of producing Allo CAR T cells in the culture volume per square centimeter of culture surface area ranging from 0.25 mL / cm2to 1.0 mL / cm2. The cell density for these cell cultures remained static at 30* 106cells per well or 3.0* 106cells / cm2. Transduction efficiencies for both co-transduction and serial transduction were captured on Day 9 of the process - during the harvest unit operation and summarized in FIG. 11 and FIG. 12. The transduction efficiencies for Allo CAR T cells across the range of transduction volumes are summarized in Table 30 - Table 33 below.Table 30. Day 9 TriCAR+ Transduction Efficiency of Dual-Transduced T Cells atNormalized Transduction VolumesTable 31. Day 9 TCRa - Transduction Efficiency of Dual-Transduced T Cells atNormalized Transduction VolumesTable 32. Day 9 TriCAR+ / TCRa|J- (Pre-depletion) Transduction Efficiency of Dual- Transduced T Cells at Normalized Transduction VolumesAttorney Docket No.: 063384-525001WOTable 33. Day 9 TriCAR+ / TCR«p- (Post-Depletion) Transduction Efficiency of Dual- Transduced T Cells at Normalized Transduction Volumes

[0463] Transduction MOIs during Dual Transduction (co-transduction only). Multiple ALLO vector MOI setpoints were shown to be capable of producing Allo CAR T cells in the ALLO vector MOI range of 0.31 to 10. The cell density for these cell cultures remained static at 30* 106cells per 6M G-Rex well, or 3.0* 106cells / cm2. The transduction culture volume remained static at 10 mL per 6M G-Rex vessel, or 1.0 mL / cm2. Transduction efficiencies for both co-transduction and serial transduction were captured on Day 8-9 of the process - during the harvest unit operation and summarized in FIG. 13. The range of transduction efficiencies are summarized in Table 34 below.Table 34. Day 8-9 Transduction Efficiency of Dual-Transduced T Cells at Titrating ALLO-vector MOIsEXAMPLE 4 - EXPANSION

[0464] Approximately 24-hour post-dual transduced CD4+ and CD8+ T Cells were sampled for enumeration using the NC-200, CRG-023 In-Process Count and Viability - Via2 protocol (internally developed) and the Via-2 Cassette.

[0465] The volume of dual transduced cells required to meet the desired expansion seeding density were calculated and seeded into the appropriate G-Rex vessel(s). The volume of expansion media formulation, Complete T Cell Media (Prime XV CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15), was calculated by subtracting the target “Total Culture Volume” from theAttorney Docket No.: 063384-525001WO“T cell suspension” required to meet the expansion starting cell density target and added to the G-Rex vessel(s). The cells and media were well mixed, then the G-Rex vessel(s) were transferred to an incubator set to 35-39°C, 5.0% CO2 (2 ~ 7%), and 100% humidity. The duration of the expansion unit operation ranged from 6 to 7 days. FIGs. 14-17 and Tables 35-37 below show that Allo CAR T cells growth and production was achieved at a normalized expansion seeding density range of 0.50* 106cells / cm2to 3.0* 106cells / cm2.Table 35. Total Viable Cell (TVC) Counts during Cell Expansion PhaseTable 36. Fold Change during Cell Expansion PhaseTable 37. Cell Viability during Cell Expansion PhaseEXAMPLE 5 - HARVEST ND DEPLETION

[0466] Upon completion of the Allo CAR T Expansion unit operation, cells were harvested from the G-Rex vessels using the GatheRex™ Cell Harvest Pump from ScaleReady™. First,Attorney Docket No.: 063384-525001WOapproximately 80-90% of the supernatant was removed from the G-Rex via the GatheRex™. Then, cells were resuspended in the remaining culture media. If desired, a cell sample aliquot can be obtained to enumerate cells prior to harvest using the NC-200™, CRG-023 In-Process Count and Viability - Via2 protocol, and the Via-2 Cassette™. Finally, cells were harvested via the GatheRex™ into a transfer bag. Additionally, up to 24-hours in advance of harvest, a cell sample aliquot was used for quantification via flow cytometry of TCRaP expression in the population of Allo CAR T cells. This measurement is used as a parameter for the Depletion unit operation.

[0467] Harvested cells may be sampled and enumerated using the NC-200™, CRG-023 In-Process Count and Viability - Via2 protocol, and the Via-2 Cassette™ to determine a postharvest cell count. Harvested cells may then be passed through a filter assembly (Miltenyi Biotec, 600 mL Filtration Bag, 170-076-626) to reduce and remove cellular aggregates. Again, a post-filtration sample may be obtained and enumerated to determine the cell count post-filtration.

[0468] The harvested and / or filtered Allo CAR T cells were then washed, buffer exchanged and concentrated in preparation for the CD3+ Depletion unit operation. The CTS™ Rotea™ Counterflow Centrifugation System from ThermoFisher Scientific or LOVO Automated Cell Processing System from Fresenius-Kabi were used to perform pre-depletion preparation. The Allo CAR T cells were washed and concentrated into Complete T Cell Media (Prime-XV T Cell CDM + 12.5 ng / mL IL-7 + 12.5 ng / mL IL-15) or a solution of Phosphate Buffered Saline (PBS) + 1 mM Ethylenediaminetetraacetic acid (EDTA) + 0.5% Human Serum Albumin (HSA). Additional preparation was then dependent on the instrument to be used for CD3+ Depletion.

[0469] When using the CliniMACS® Plus from Miltenyi Biotec, the CliniMACS® CD3 Reagent CR / GMP (200-070-202) was added to the washed and concentrated Allo CAR T cells per the manufacturer’s recommendation. Cells were then incubated at room temperature for 30 minutes with gentle rocking. The CliniMACS® Depletion Tubing Set (170-076-652) was used with the Depletion 3.1 separation protocol. Incubated Allo CAR T cells were then processed on the CliniMACS® Plus for magnet-assisted cell separation of the CD3+ / TCRaP+ T cells, which are cells that were not successfully transduced with the Allo lentiviral vector. These cells must be removed from the drug product prior to administration to prevent potential Graft-vs-Host Disease (GvHD) in patients receiving the Allo CAR T drug product.Attorney Docket No.: 063384-525001WO

[0470] When using the Akadium Alerion™ for the Depletion unit operation, the T Cell Depletion Kit and BioRise™ were used to perform the bubble assisted cell separation process. In the BioRise™, the washed and concentrated Allo CAR T cells were incubated with the T Cell Depletion Kit’s antibody cocktail per the manufacturer’s recommendation. Then the Microbubbles were added per the manufacturer’s recommendation to the Allo CAR T cells and antibody cocktail, and a second incubation was performed. Finally, the Allo CAR T cells and reagent mixture was gently centrifuged with the Alerion™ and cells that were not successfully transduced with the Allo lentiviral vector were separated from the remaining Allo CAR T drug product cells.

[0471] Following the Depletion unit operation on either the CliniMACS® Plus or Alerion™, the Allo CAR T drug product cells were ready for formulation and filling prior tocryopreservation. FIG. 18 shows representative Depletion unit operation performance in the CliniMACS® Plus or Alerion™. TCRaP frequency was measured via flow cytometry with either the eAllo vl.l method or the ALL-in-One spectral flow cytometry panel. The Allo CAR T drug product must be highly pure, TCRaP-, to ensure the drug product does not cause GvHD upon administration. FIG. 18 shows that both the CliniMACS® Plus or Alerion™ Depletion methods can achieve highly pure Allo CAR T drug product. FIG. 19 shows the same set of representative Depletion runs. Table and Table below show the data for eight representative depletion runs on the Alerion™ and CliniMACS® Plus. Table and FIG. 19 show the TCRaP- cell yield is high and reliable in both Depletion unit operation methods.Table 38 - Summary of pre-depletion data for eight representative Depletion Unit Operation runs. TCRaP- cells are the target cells to be purified during the Depletion Unit Operation. Two depletion instruments (Alerion™ & CliniMACS™) were used for these representative runs. Two different flow panels were used to measure the input and output purity of the Depletion Unit Operation. TCRa - Total Viable Cells is calculated by multiplying the Total Viable Cells by the TCRaP- purity.Attorney Docket No.: 063384-525001WOTable 39 - Summary of post-depletion data for eight representative Depletion Unit Operation runs. TCRa - cells are the target cells to be purified during the Depletion Unit Operation. Two depletion instruments (Alerion™ & CliniMACS™) were used for these representative runs. Two different flow panels were used to measure the input and output purity of the Depletion Unit Operation. TCRa - Total Viable Cells is calculated by multiplying the Total Viable Cells by the TCRa - purity. Depletion yield is calculated as TCRa - Total Viable Cells post-depletion divided by TCRa - Total Viable Cells pre-depletion (seeTable above).EXAMPLE 6 - FORMULATION AND FILL / FINISH

[0472] Formulation and fill / finish for the manufactured allogeneic T cells is expected to be compatible with traditional manual modes of filling or by using commercially available fillers. The rate limiting piece for manual and automated fill is the DMSO exposure time of the allogeneic products while not frozen.Attorney Docket No.: 063384-525001WO

[0473] Manual Fill. For manual fill, the material is formulated in a mixture of Plasma-Lyte A+4% HSA (w / v) that is subsequently diluted 1:1 with Cryostor® CS10. Formulated material is pooled into bulk DP bag at 2x target dose concentration. 2X final formulation buffer is manually added into the bulk DP bag at a flow rate of 10% total volume per minute with constant mixing by massaging the bag. Following addition of the entire final formulation buffer volume, a target of 700e6 well-mixed DP cells is aliquoted into a bulk QC testing bag. The remaining final formulated DP is filled manually into < 20 bags at the target dose volume. The bulk QC testing bag is used to fill each QC testing sample in accordance with sampling requirements. Filled bags are manually “burped” to remove excess air and bubbles before being sealed, labeled, and placed into cryo-cassettes. QC samples are either prepared in bags or vials and labeled appropriately. Both DP cassettes and QC samples are transferred into a CryoMed™ controlled rate freezer (CRF; ThermoFisher) with the baseline CRF profile as shown in Table 40.Table 40. CRF Profile for DP

[0474] After Freeze down, DP cassettes are removed from the CRF and transported on dry ice to long term storage (LN2). The DMSO exposure time should be less than 2 hours in total. Automated Fill. For automated fill, commercially available fillers can be considered for the CRG-Allo DP. Commercially available fillers are capable of automated filling of up to ~60 bags or -150 vials. Again, the time-limiting factor during the filling step is to minimize DMSO exposure time to less than 2 hours in total.

[0475] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the disclosure. It is intended that the following claims define theAttorney Docket No.: 063384-525001WOscope of the disclosure and that method s and structures within the scope of these claims and their equivalents be covered thereby.

Claims

Attorney Docket No.: 063384-525001WOCLAIMS1. A method of manufacturing a population of CAR-expressing immune cells, the method comprising:(a) obtaining a liquid sample comprising an initial population of cells comprising immune cells from a human subject;(b) processing the initial population of cells comprising immune cells;(c) on day 0, enriching the population of cells comprising immune cells for CD4+ and CD8+ T cells to generate an enriched population of cells comprising immune cells;(d) culturing the enriched population of cells in a volume of a medium comprising an activation agent to generate an enriched and activated population of cells comprising immune cells;(e) transducing the enriched and activated population of cells comprising immune cells with one recombinant polynucleotide encoding three CARs and one recombinant polynucleotide encoding a universal allogeneic expression cassette comprising (i) a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, (ii) a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and (iii) a third molecule capable of reducing CD58 expression on the surface of an immune cell and optionally, (iv) a fourth molecule capable of blocking the CD8-MHC class I interaction and (v) one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58, thereby generating an enriched, activated, and transduced population of cells comprising allogeneic CAR-expressing immune cells;(f) expanding the enriched, activated, and transduced population of cells comprising allogeneic CAR-expressing immune cells in media to yield an expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells;Attorney Docket No.: 063384-525001WO(g) harvesting the expanded population of enriched, activated, and transduced cells comprising allogeneic CAR-expressing immune cells on or after Day 6 after the culturing in step (d);(h) depleting CD3 / TCR+ immune cells from the harvested population of cells; and(i) formulating the harvested population of enriched, activated, transduced and CD3 / TCR+ depleted cells comprising allogeneic CAR-expressing immune cells for cryopreservation and administration to patients.

2. The method of claim 1, wherein the liquid sample is a cryopreserved sample.

3. The method of claim 2, wherein the cryopreserved sample is thawed prior to step (b) to generate a thawed population of cells comprising immune cells.

4. The method of any one of claims 1 to 3, wherein the liquid sample including an initial population of cells comprises a leukapheresis product.

5. The method of any one of claims 1 to 4, wherein the processing step (b) comprises diluting the liquid sample comprising the initial population of cells with media to generate a diluted population of cells comprising immune cells.

6. The method of claim 5, wherein the media comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

7. The method of claim 6, wherein the 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

8. The method of any one of claims 1 to 7, wherein the processing step (b) further comprises a step of washing and concentrating the diluted population of cells in media to generate a washed and concentrated population of cells.

9. The method of claim 8, wherein the washing comprises phosphate buffered saline (PBS) and ethylenediaminetetraacetic acid (EDTA)(PBS / EDTA) + 0.5% (w / v) human serum albumin (HSA).

10. The method of any of claims 8 to 9, wherein the processing is performed on a Rotea CounterflowIMCentrifugation System.Attorney Docket No.: 063384-525001WO11. The method of any one of claims 1 to 7, wherein the enriching step (c) comprises positive selection of CD4+ and CD8+ T cells.

12. The method of any one of claims 1 to 10, wherein the enriching step (c) comprises negative selection of CD4+ and CD8+ T cells.

13. The method of claim 11, wherein the positive selection comprises mixing the diluted or thawed and diluted population of cells with magnetic beads derivatized with CD4- specific binding agents and CD8-specific binding agents, washing, and eluting to generate the enriched population of cells.

14. The method of claim 13, wherein the positive selection is performed on a Miltenyi Prodigy®.

15. The method of claim 12, wherein the negative selection comprises mixing the diluted, washed, and concentrated population of cells with anti-CD14, anti-CD16, anti-CD19, anti-CD20, anti-CD36, anti-CD56, anti-CD123, and anti-CD235ab (anti-glycophorin A / glycophorin B) antibodies to generate the enriched population of cells.

16. The method of claim 15, wherein the negative selection is performed on an Akadeum Alerion™.

17. The method of any one of claims 1 to 16, wherein the culturing of the enriched population of cells comprises seeding between at least 30* 106cells and at least 300* 106cells from the enriched population of cells in a vessel.

18. The method of claim 17, wherein the vessel is a G-Rex® vessel.

19. The method of any one of claims 1 to 18, wherein the enriched population of cells is cultured in a volume of media comprising modified T Cell Culture Medium.

20. The method of claim 19, wherein the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

21. The method of claim 20, wherein the 1: 1 mixture of recombinant human cytokines IL- 7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

22. The method of any one of claims 1 to 21, wherein the activation reagent comprises agonists of CD3 and CD28.Attorney Docket No.: 063384-525001WO23. The method of claim 22, wherein the activation reagent comprising CD3 and CD28 agonists comprises the T cell TransActIMreagent.

24. The method of claim 22, wherein the activation reagent comprising CD3 and CD28 agonists comprises CTS™ Detachable Dynabeads™ CD3 / CD28.

25. The method of any one of claims 1 to 24, wherein the one recombinant polynucleotide encoding three CARs comprises a first lentiviral expression vector and the one recombinant polynucleotide encoding a universal allogeneic expression cassette comprises a second lentiviral expression vector.

26. The method of any one of claims 1 to 25, wherein the lentiviral expression vector(s) is / are manufactured using a suspension cell culture method.

27. The method of any one of claims 1 to 26, wherein the transduction in step (e) is performed on Day 1.

28. The method of any one of claims 1 to 27, wherein the transduction in step (e) is performed 22-26 hours after culturing of the enriched and activated population of cells comprising immune cells on Day 0.

29. The method of any of claims 1-28, wherein the amount of vector used to transduce the enriched population of cells comprising immune cells in step (e) is determined based on the infectious titer of the first and second lentiviral vectors and the number of cells used to culture the enriched population of cells comprising immune cells such that the transduction is performed with a multiplicity of infection (MOI) of 1.7 for the first lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs and an MOI of 2.5 for the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette.

30. The method of any one of claims 1 to 29, wherein the transduction is performed with an MOI of at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1.0, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2.0, at least 2.1, at least 2.2, at least 2.3, at least 2.4, at least 2.5, at least 2.6, at least 2.7, at least 2.8, at least 2.9, at least 3.0, at least 3.5, at least 4.0, at least 4.5, at least 5.0, at least 5.5, at least 6.0, at least 6.5, at least 7.0, at least 7.5, at least 8.0, at least 8.5, at least 9.0, at least 9.5, or at least 10.0 for each vector.Attorney Docket No.: 063384-525001WO31. The method of any one of claims 1 to 30, wherein the transduction is a cotransduction.

32. The method of any one of claims 1 to 30, wherein the transduction is a serial transduction.

33. The method of any one of claims 1 to 32, wherein the first lentiviral expression vector comprising one recombinant polynucleotide encoding three CARs and the second lentiviral expression vector comprising one recombinant polynucleotide encoding the universal allogeneic expression cassette are thawed, diluted into modified T Cell Culture Medium, and added to the enriched population of cells comprising immune cells.

34. The method of any one of claims 1 to 33, wherein the modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

35. The method of claim 34, wherein the 1: 1 mixture of recombinant human cytokines IL- 7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

36. The method of any one of claims 1 to 35, wherein the final volume in which the transduction in step (e) is performed comprises 2.5 mL.

37. The method of any one of claims 1 to 35, wherein the final volume in which the transduction in step (e) is performed comprises 5 mL.

38. The method of any one of claims 1 to 35, wherein the final volume in which the transduction in step (e) is performed comprises 7 mL.

39. The method of any one of claims 1 to 35, wherein the final volume in which the transduction in step (e) is performed comprises 10 mL.

40. The method of any one of claims 1 to 39, wherein the expanding step comprises culturing the enriched, activated, and transduced population of cells in modified T Cell Culture Medium comprises Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

41. The method of any one of claims 1 to 40, wherein the 1:1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.Attorney Docket No.: 063384-525001WO42. The method of any one of claims 1 to 41, wherein the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 6.

43. The method of any one of claims 1 to 41, wherein the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 7.

44. The method of any one of claims 1 to 41, wherein the harvesting step comprises harvesting the expanded population of enriched, activated, and transduced population of cells on Day 8.

45. The method of any one of claims 1 to 44, wherein the harvested cells are washed and concentrated prior to the depleting step (h).

46. The method of claim 45, wherein the washing and concentrating of the harvested cells is performed on a CTS™ Rotea™ Counterflow Centrifugation System.

47. The method of any one of claims 1 to 46, wherein the harvested cells are concentrated into Prime XV CDM Medium supplemented with a 1: 1 mixture of recombinant human cytokines IL-7 (hIL-7) and IL-15 (hIL-15).

48. The method of claim 47, wherein the 1: 1 mixture of recombinant human cytokines IL- 7 (hIL-7) and IL-15 (hIL-15) comprises 12.5 ng / mL hIL-7 and 12.5 ng / mL hIL-15.

49. The method of any one of claims 1 to 46, wherein the harvested cells are concentrated into Phosphate Buffered Saline (PBS) + 1 mM Ethylenediaminetetraacetic acid (EDTA) + 0.5% Human Serum Albumin (HSA).

50. The method of any one of claims 1 to 49, wherein depleting CD3 / TCR+ immune cells comprises mixing the harvested population of cells with magnetic beads derivatized with CD3-specific binding agents.

51. The method of claim 50, wherein the magnetic beads derivatized with CD3-specific binding agents comprise CliniMACS® CD3 Reagent.

52. The method of any one of claims 1 to 51, wherein the depleting step is performed on a CliniMACS® Plus.

53. The method of any one of claims 1 to 49, wherein depleting CD3 / TCR+ immune cells comprises bubble assisted cell separation.Attorney Docket No.: 063384-525001WO54. The method of claim 53, wherein the bubble assisted cell separation comprises the Alerion™ Microbubble Cell Separation System.

55. The method of any of claims 1 to 54, wherein the formulation step is automated.

56. The method of any one of claims 1 to 54, wherein the formulation step is manual.

57. The method of any one of claims 1 to 56, wherein the harvested population of cells including CAR-expressing immune cells comprises allogeneic CAR-expressing immune cells that are CD3 / TCR negative.

58. The method of any of claims 1-57, wherein the harvested population of cells including allogeneic CAR-expressing immune cells comprises allogeneic T cells expressing a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a first molecule capable of reducing TCR-CD3 complex expression on the surface of an immune cell, a second molecule capable of reducing MHC class I and / or MHC class II expression on the surface of an immune cell, and a third molecule capable of reducing CD58 expression on the surface of an immune cell.

59. The method of any one of claims 1-58, wherein the recombinant polynucleotide encoding three CARs encodes a CD19-specific CAR, a CD20-specific CAR, and a CD22-specific CAR.

60. The method of any one of claims 1-59, wherein the recombinant polynucleotide encoding three CARs comprises a polynucleotide sequence encoding the CD 19- specific CAR, a polynucleotide sequence encoding the CD20-specific CAR, and a polynucleotide sequence encoding the CD22-specific CAR, wherein each CAR- encoding polynucleotide sequence is separated from the other CAR-encoding polynucleotide sequences by a sequence encoding a viral ribosome skipping peptide selected from the group consisting of a P2A peptide, a T2A peptide, an E2A peptide, and an F2A peptide.

61. The method of any one of claims 1-60, wherein the recombinant polynucleotide encoding three CARs comprises from 5’ to 3’, a sequence encoding the CD22- specific CAR; a sequence encoding a viral P2A ribosome skipping peptide; a sequence encoding the CD19-specific CAR; a sequence encoding a viral T2A ribosome skipping peptide; and a sequence encoding the CD20-specific CAR.Attorney Docket No.: 063384-525001WO62. The method of any one of claims 1-61, wherein the CD22-specific CAR comprises a CD22-specific binding domain, a transmembrane domain, and an intracellular domain.

63. The method of any one of claims 1-62, wherein the CD22-specific CAR comprises a CD22-specific binding domain, a spacer, a hinge domain, a transmembrane domain, a peptide linker, and an intracellular domain.

64. The method of any one of claims 1-63, wherein the CD22-specific binding domain comprises an antibody that binds CD22 or an antigen-binding fragment thereof.

65. The method of any one of claims 1-64, wherein the CD22-specific binding domain comprises an antibody that binds human CD22.

66. The method of any one of claims 1-65, wherein the CD22-specific binding domain comprises an antigen-binding fragment of an antibody that binds human CD22.

67. The method of any one of claims 1-66, wherein the antigen-binding fragment of an antibody that binds human CD22 is a single chain variable fragment (scFv) that binds CD22.

68. The method of any one of claims 1-67, wherein the scFv that binds CD22 has the sequence of QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGR TYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVT GDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQ TIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAE DFATYYCQQSYSIPQTFGQGTKLEIK (SEQ ID NO: 1).

69. The method of any one of claims 1-68, wherein the scFv that binds CD22 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 1.

70. The method of any one of claims 1-69, wherein the CD22-specific CAR comprises a CD8a hinge domain comprising the sequence of TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO:23) and a CD8a transmembrane domain comprising the sequence of IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 24) and optionally a peptide linker having the sequence of LYC.Attorney Docket No.: 063384-525001WO71. The method of any one of claims 1-70, wherein the CD22-specific CAR comprises a CD8a hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 23 and a CD8a transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 24.

72. The method of any one of claims 1-71, wherein the CD8a transmembrane domain further comprises a spacer having the sequence of LYC.

73. The method of any one of claims 1-72, wherein the CD22-specific CAR comprises an intracellular domain comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.

74. The method of any one of claims 1-73, wherein the primary T cell activating domain comprising an ITAM comprises a CD3ζ intracellular signaling domain.

75. The method of any one of claims 1-74, wherein the CD3ζ intracellular signaling domain comprises the sequence of RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR (SEQ ID NO: 26).

76. The method of any one of claims 1-75, wherein the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

77. The method of any one of claims 1-76, wherein the costimulatory signaling domain comprises a 4-1BB / CD137 signaling domain.

78. The method of any one of claims 1-77, wherein the 4-1BB / CD137 signaling domain comprises the sequence of KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 25).

79. The method of any one of claims 1-78, wherein the 4-1BB / CD137 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 25.Attorney Docket No.: 063384-525001WO80. The method of any one of claims 1-79, wherein the CD22-specific CAR comprises the sequence of QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGR TYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVT GDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQ TIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAE DFATYYCQQSYSIPQTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEA CRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYI FKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 29).

81. The method of any one of claims 1-80, wherein the CD22-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 29.

82. The method of any one of claims 1-81, wherein the CD22-specific CAR comprises the sequence of MLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSN SAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSL QLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTMVTVSSGGGGSDIQMTQ SPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVP SRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIKAAATTT PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG VLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR (SEQ ID NO: 30).

83. The method of any one of claims 1-82, wherein the CD22-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 30.Attorney Docket No.: 063384-525001WO84. The method of any one of claims 1-83, wherein the CD19-specific CAR comprises a CD19-specific binding domain, a transmembrane domain, and an intracellular domain.

85. The method of any one of claims 1-84, wherein the CD19-specific CAR comprises a CD19-specific binding domain, a hinge domain, a transmembrane domain, a spacer, and an intracellular domain.

86. The method of any one of claims 1-85, wherein the CD19-specific binding domain comprises an antibody that binds CD 19 or an antigen-binding fragment thereof.

87. The method of any one of claims 1-86, wherein the CD19-specific binding domain comprises an antibody that binds human CD 19.

88. The method of any one of claims 1-87, wherein the CD19-specific binding domain comprises an antigen-binding fragment of an antibody that binds human CD 19.

89. The method of any one of claims 1-88, wherein the antigen-binding fragment of an antibody that binds human CD 19 is a single chain variable fragment (scFv) that binds CD 19.

90. The method of any one of claims 1-89, wherein the scFv capable of binding CD 19 has the sequence of EVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDILTGWAMDVWGQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVS AAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFS GSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVL (SEQ ID NO: 34).

91. The method of any one of claims 1-90, wherein the scFv capable of binding CD19 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 34.

92. The method of any one of claims 1-91, wherein the CD19-specific C AR comprises a CD28 hinge domain comprising the sequence of IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43) and a CD28 transmembrane domain comprising the sequence of FWVLVWGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).Attorney Docket No.: 063384-525001WO93. The method of any one of claims 1-92, wherein the CD19-specific CAR comprises a CD28 hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 43 and a CD28 transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 44.

94. The method of any one of claims 1-93, wherein the CD19-specific CAR comprises an intracellular domain further comprising a primary T cell activating domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.

95. The method of any one of claims 1-94, wherein the primary T cell activating domain comprising an ITAM comprises a CD3ζ intracellular signaling domain.

96. The method of any one of claims 1-95, wherein the CD3ζ intracellular signaling domain comprises the sequence of RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR (SEQ ID NO: 26).

97. The method of any one of claims 1-96, wherein the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

98. The method of any one of claims 1-97, wherein the costimulatory signaling domain comprises a CD28 signaling domain.

99. The method of any one of claims 1-98, wherein the CD28 signaling domain comprises the sequence of RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 45).

100. The method of any one of claims 1-99, wherein the CD28 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 45.

101. The method of any one of claims 1-100, wherein the CD19-specific CAR comprises the sequence ofEVQLVQSGAEVKKPGESLKISCKASGYRFTNYWIAWVRQRPGKGLEWMGRIAttorney Docket No.: 063384-525001WODPSDSYTHYSPSFQGHVTMSTDKSISTAYLQWSSLKASDTAMYYCARPGDIL TGWAMDVWGQGTLVTVSSAAASGGGGSGGGGSGGGGSALQSVLTQPPSVS AAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFS GSKSGTSATLGITGLQAEDEADYYCQSYDSSLSGNYVFGTGTKVTVLIEVMY PPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVK FSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL HMQALPPR (SEQ ID NO: 47).

102. The method of any one of claims 1-101, wherein the CD19-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 47.

103. The method of any one of claims 1-99, wherein the CD19-specific CAR comprises the sequence of MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKASGYRFTN YWIAWVRQRPGKGLEWMGRIDPSDSYTHYSPSFQGHVTMSTDKSISTAYLQ WS SLKASDTAMYYC ARPGDILTGWAMD VWGQGTLVTVS S AAASGGGGSGG GGSGGGGSALQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGT APKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQAEDEADYYCQSYDSSLS GNYVFGTGTKVTVLIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPF WVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRK HYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 48).

104. The method of any one of claims 1-103, wherein the CD19-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 48.

105. The method of any one of claims 1-104, wherein the CD20-specific CAR comprises a CD20-specific binding domain, a transmembrane domain, and an intracellular domain.

106. The method of any one of claims 1-105, wherein the CD20-specific binding domain comprises an antibody that binds CD20 or an antigen-binding fragment thereof.Attorney Docket No.: 063384-525001WO107. The method of any one of claims 1-106, wherein the CD20-specific binding domain comprises an antibody that binds human CD20.

108. The method of any one of claims 1-107, wherein the CD20-specific binding domain comprises an antigen-binding fragment of an antibody that binds human CD20.

109. The method of any one of claims 1-108, wherein the antigen-binding fragment of an antibody that binds human CD20 is a single chain variable fragment (scFv) that binds CD20.

110. The method of any one of claims 1-109, wherein the scFv capable of binding CD20 has the sequence of DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKL LIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFG QGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTF GDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSS (SEQ ID NO: 50).

111. The method of any one of claims 1-110, wherein the scFv capable of binding CD20 comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 50.

112. The method of any one of claims 1-111, wherein the CD20-specific CAR comprises a CD28 hinge domain comprising the sequence of IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 43) and a CD28 transmembrane domain comprising the sequence of FWVLVWGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 44).

113. The method of any one of claims 1-112, wherein the CD20-specific CAR comprises a CD28 hinge domain comprising a sequence comprising 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 43 and a CD28 transmembrane domain comprising a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 44.

114. The method of any one of claims 1-113, wherein the CD20-specific CAR comprises an intracellular domain further comprising a primary T cell activating domainAttorney Docket No.: 063384-525001WOcomprising an immunoreceptor tyrosine-based activation motif (ITAM) and a costimulatory signaling domain.

115. The method of any one of claims 1-114, wherein the primary T cell activating domain comprising an ITAM comprises a CD3ζ intracellular signaling domain.

116. The method of any one of claims 1-115, wherein the CD3ζ intracellular signaling domain comprises the sequence ofRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR (SEQ ID NO: 26).

117. The method of any one of claims 1-116, wherein the CD3ζ intracellular signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 26.

118. The method of any one of claims 1-117, wherein the costimulatory signaling domain comprises a CD2 signaling domain.

119. The method of any one of claims 1-118, wherein the CD2 signaling domain comprises the sequence ofKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGH RSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGA AENSLSPSSN (SEQ ID NO: 59).

120. The method of any one of claims 1-119, wherein the CD2 costimulatory signaling domain comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 59.

121. The method of any one of claims 1-120, wherein the CD20-specific CAR comprises the sequence ofMLLLVTSLLLCELPHPAFLLIPDIVMTQSPDSLAVSLGERATINCKSSQSVLYSS NNKNYL AWYQQKPGQPPKLLIYWASTRESGVPDRF SGSGSGSDFTLTIS SLQ A EDVAVYYCQQYYSFYQTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGG GVVRPGGSLRLSCTASGFTFGDYGMSWVRQAPGKGLEWVSGINWNGGSTG YADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARKSYYGSGSPDVF DIWGQGTMVTVSSIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPF WVLVVVGGVLACYSLLVTVAFIIFWVKRKKQRSRRNDEELETRAHRVATEEAttorney Docket No.: 063384-525001WORGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPA PSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSNRVKFSRSADAPAYKQ GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 64).

122. The method of any one of claims 1-121, wherein the CD20-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 64.

123. The method of any one of claims 1-119, wherein the CD20-specific CAR comprises the sequence ofDIVMTQ SPD SL AVSLGERATINCKS SQ S VL YS SNNKNYL AW YQQKPGQPPKL LIYWASTRESGVPDRFSGSGSGSDFTLTISSLQAEDVAVYYCQQYYSFYQTFG QGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGVVRPGGSLRLSCTASGFTF GDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTALYYCARKSYYGSGSPDVFDIWGQGTMVTVSSIEVMYPP PYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVA FIIFWVKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHP PPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQP KPPHGAAENSLSPSSNRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLD KRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 62).

124. The method of any one of claims 1-123, wherein the CD20-specific CAR comprises a sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to SEQ ID NO: 62.

125. The method of any one of claims 1 to 124, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises at least one or more of an exogenous promoter, a post-transcriptional response element (PRE), and a polyadenylation signal sequence.

126. The method of any one of claims 1 to 125, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette is tricistronic.

127. The method of any one of claims 1 to 125, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette is bicistronic.Attorney Docket No.: 063384-525001WO128. The method of any one of claims 1 to 127, wherein the first molecule of the universal allogeneic expression cassette comprises a dominant negative mutant TCR-CD3 complex component capable of binding an unmutated or wild-type TCR-CD3 complex component.

129. The method of claim 128, wherein the dominant negative mutant TCR-CD3 complex component is a dominant negative mutant TCRalpha, TCRbeta, TCRgamma, TCRdelta, CD3gamma, CD3delta, CD3 epsilon, or CD3zeta.

130. The method of claim 129, wherein the dominant negative mutant TCR-CD3 complex component is a dominant negative mutant CD3epsilon.

131. The method of any one of claims 1 to 130, wherein the second molecule of the universal allogeneic expression cassette comprises a mutated RFX5 polypeptide.

132. The method of claim 131, wherein the mutated RFX5 polypeptide comprises a truncated RFX5 molecule.

133. The method of claim 132, wherein the RFX5 polypeptide comprises a sequence selected from the sequences listed in Table 5.

134. The method of any one of claims 1 to 133, wherein the third molecule of the universal allogeneic expression cassette comprises an anti-CD58 PEBL comprising an scFv capable of binding CD58 (anti-CD58 scFv).

135. The method of claim 134, wherein the anti-CD58 scFv comprises a sequence selected from the sequences listed in Table 7, Table 8, Table 9, or Table 10.

136. The method of any one of claims 134 to 135, wherein the protein localization sequence or tag of the PEBL comprises an ER localization tag.

137. The method of claim 136, wherein the ER localization tag is selected from the group consisting of KKAHKSKTH (SEQ ID NO: 1), KKKKRD (SEQ ID NO: 2), PKNRYKKH (SEQ ID NO: 3), KKYL (SEQ ID NO: 4), LLEALTLASARGPLRKRSVPMAKAKPKFSISPDSLS (SEQ ID NO: 5), LLEALTLASARGPLRKRSVPMAKAKPKFSISPKKYL (SEQ ID NO: 6), CFRKLAKTGKKKKRD (SEQ ID NO: 7), KHILFRRRRRGFRQ (SEQ ID NO: 8), LYKYKSRRSFIDEKKMP (SEQ ID NO: 9) KKMP (SEQ ID NO: 10), and AEKDEL (SEQ ID NO: 11).Attorney Docket No.: 063384-525001WO138. The method of any one of claims 1 to 137, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette further comprises a fourth molecule capable of blocking the CD8-MHC class I interaction.

139. The method of claim 138, wherein the fourth molecule capable of blocking the CD8- MHC class I interaction comprises an MHC class I binder.

140. The method of claim 139, wherein the MHC class I binder comprises a CD8alpha extracellular domain with a cysteine to serine (C to S) mutation at amino acid position 54 and a serine to asparagine (S to N) mutation at amino acid position 74 in SEQ ID NO: 407.

141. The method of claim 140, wherein the MHC class I binder comprises SEQ ID NO:411.

142. The method of claim 140-141, wherein the MHC class I binder additionally comprises a B2M polypeptide or a fragment thereof.

143. The method of any one of claims 1 to 142, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette further encodes one or more shRNAs capable of reducing expression of CD3zeta, FasR, B2M, CIITA, CD3epsilon, TRAC, RFX5, and / or CD58.

144. The method of claim 143, wherein the one or more shRNAs are located in an intron of a promoter.

145. The method of claim 144, wherein the promoter is an EF-lalpha, a MND, MNDU3, an SFFV promoter, a CAG promoter, a CBA promoter, a Gamma Retro 5’ LTR promoter, or a hUbC promoter.

146. The method of any one of claims 143 to 145, wherein the one or more shRNAs further comprises a mirE or mirl55 scaffold.

147. The method of any one of claims 1 to 146, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette is tricistronic and encodes, from 5’ end to 3’ end, a mutated RFX5, a 2A ribosome skipping sequence, a 54mer MHC class I binder fused to B2M, a 2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, a CD3z shRNA located in an EF-lalpha promoter in aAttorney Docket No.: 063384-525001WOmirE scaffold, and an RFX5 shRNA located in an EF-lalpha promoter in a mirl55 scaffold.

148. The method of claim 147, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 440.

149. The method of any one of claims 1 to 137, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette is bicistronic and encodes, 5’ end to 3’ end, a mutated RFX5, a T2A ribosome skipping sequence, a fusion protein comprising a PEBL comprising an scFv capable of binding a CD58 and a dominant negative mutant CD3epsilon, and a CD3z shRNA located in an EF-lalpha promoter in a mirE scaffold.

150. The method of claim 149, wherein the recombinant polynucleotide encoding a universal allogeneic expression cassette comprises the sequence of SEQ ID NO: 441.